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Chapter synopsis 
The overactive bladder (OAB) is a prevalent syndrome of urinary urgency, usually 
accompanied by frequency and nocturia, with or without urgency urinary incontinence. OAB 
significantly affects patient quality of life. This chapter is a prospective evaluation of 
Percutaneous Tibial Nerve Stimulation (PTNS) as a treatment for overactive bladder 
syndrome. This treatment was introduced as a service in the department of Uro-Neurology, 
and this chapter analyses the first 18-months of experience, in a heterogenous group of 
patients that have been referred to a tertiary neurological centre. Within the chapter there is a 
literature review that explores the evidence behind PTNS, and the outcomes of this cohort of 
patients are discussed. The chapter also discusses the challenges with objectively assessing 
patient outcomes. The overactive bladder syndrome is a patient reported symptom profile and 
outcomes are inherently subjective and fully reliant on the accuracy of patient reporting. 
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Tibial nerve stimulation for the management of the neurogenic and idiopathic 
overactive bladder: A safe and effective treatment 
  
Abstract  
Background 
Percutaneous Tibial Nerve Stimulation (PTNS) is a minimally invasive technique of 
neuromodulation for treating overactive bladder (OAB) symptoms. The aim of this study was 
to assess safety and efficacy of PTNS in patients with neurological disease reporting 
overactive bladder symptoms.     
 
Methods 
In this prospective evaluation, patients finding first-line treatments for OAB either ineffective 
or intolerable underwent a standard 12-week course of PTNS (Urgent PC, Uroplasty). 
Urinary symptoms were evaluated using standardised questionnaires (ICIQ-OAB and ICIQ-
LUTSqol) and bladder diaries. Patients opting to continue treatment after 12 weeks returned 
for top-up sessions.  
 
Results  
Seventy-four patients (22 males and 52 females) with mean age of 56.0 (95% CI: 52.2, 59.8) 
years, were included in this cohort. Twenty-five patients (33.8%) had idiopathic OAB, 19 
(25.7%) had multiple sclerosis (MS), and 30 (40.5%) other neurological diagnoses at entry. 
Sixty-four patients (86%) completed 12 weeks of treatment. Significant improvements were 
noted in mean ICIQ-OAB scores of -5.1 (SD: 10.4) (p=0.003), ICIQ-LUTSqol quality of life 
scores -22.4 (SD:44.3) (p=0.001), 24-hour bladder frequency -1.2 (SD: 2.2) (p=0.001), and 
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severity of incontinent episodes -0.2 (SD: 0.4) (p=0.004). Patients found treatment 
comfortable and no adverse effects were reported. Twenty-four out of fifty-three patients 
(45%), who were invited for top-up therapy returned with mean top-up frequency of 44.4 
days (7-155 days). Patients who reported improvements in OAB symptoms, leakage severity 
and quality of life at week 12, as well as patients with MS, were more likely to return for top-
up sessions.   
 
Conclusions  
The safety and efficacy of PTNS for the management of OAB is comparable between patients 
with idiopathic and neuropathic OAB. Significant improvements in overactive bladder 
symptoms and quality of life were observed, with minimal adverse effects.   
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INTRODUCTION 
 
The Overactive Bladder (OAB) syndrome is defined by the International Continence Society 
(ICS) as a syndrome of urinary urgency, usually accompanied by frequency and nocturia, 
with or without urgency urinary incontinence (UUI), in the absence of urinary tract infection 
or other obvious pathology [6]. OAB symptoms affect all age groups with increasing 
prevalence with age, and therefore relavent with an ageing UK population. It has significantly 
negative impacts on quality of life affecting sleep, sexual activity, mental health, work 
productivity and may also increase social isolation [7]. Elderly patients with OAB are 
reported to have increased numbers of falls, fractures, and skin infections. Patients can be 
difficult to screen for, with and although many patients seek treatment it is felt a significant 
proportion of patients do not receive it [8].  
The cost of this condition is difficult to calculate accurately as one must consider the cost of 
treatment, including medications or surgical intervention, cost of continence products such as 
pads and liners, and the treatment of other collateral medical issues it can cause, aswell as the 
loss productivity of work and earnings that the patient is unable to sustain. For individual 
patients, this is a condition which has worse quality of life scores than those with asthma, 
diabetes, hypertension and depression [8].  
In the United States a cost of illness study estimated the national cost of OAB with urgency 
incontinence in 2007 at $65.9 billion, with predicted costs of $76.2 billion in 2015 and $82.6 
billion in 2020 [9]. Prevalence of OAB is underestimated, although the National Overactive 
Bladder Evaluation study have suggested 17% of men and women are affected in the United 
States, and from 12-17% in six European nations [10-12]. The prediction of those affected is 
thought to rise to 20.1% by 2018 [13].  
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Management of OAB 
The first line of treatment for the OAB involves conservative measures such as behavioural 
modifications with fluid and caffeine restriction, pelvic floor exercises and medical therapy 
[14]. Clinicians however frequently face patients who have failed to respond to these initial 
measures. The success of antimuscarinic therapy, although effective for many patients, may 
be misrepresented in clinical trial results which tend to have a short duration of follow-up 
(3months), with intensive follow-up regimes and incentives, which may falsely elevate 
adherence [15]. In longer term follow-up studies only 18.2% of patients continued with 
treatment after six months, due to poor treatment efficacy, cost, adverse effect profiles or 
inadequate follow-up regimes [16].  
 
Other potential treatment options include sacral neuromodulation (SNM), a form of central 
nerve stimulation, which is a clinically effective alternative to drug therapy, being efficacious 
in up to 80% of patients [17]. However important considerations are its cost, need for 
specialist surgery and the associated potential complications. Although less invasive than 
augmentation cystoplasty, implantable devices are susceptible to infections in 5%, pain at 
surgery site in 25%, lead migrations in 16%, haematoma formation, subsequent revision 
surgeries for repositioning in 15%, and wound problems in 7%. These complications include 
a re-operation rate of 33% [17]. SNM may therefore be unsuitable for many elderly patients 
who may be frail and have several co-morbidities or cognitive impairment. Implants are also 
contraindicated in patients who may need MRI scanning, which is a consideration especially 
for patients with Multiple Sclerosis (MS) who may need regular follow up scanning.  
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OnabotulinumtoxinA (BTX-A) is another option, which has recently acquired its licence in 
the UK for its use in patients with idiopathic and neuropathic bladder dysfunction after the 
acquisition of high level evidence for its success [18, 19]. However this is currently not 
offered by many primary care trusts due to costs, and its availability remains limited. Patients 
can also be dissuaded from pursuing this line of management due to its inherent risks of 
voiding dysfunction and the need for subsequent clean intermittent self-catheterisation 
(CISC). Also its effectiveness is only for a limited duration, and patients ultimately require 
repeated injections. This leaves a gap in the available management options between 
antimuscarinic medications and more invasive treatments such as BTX-A, SNM and 
ultimately invasive surgical options to physically increase the bladder storage capacity such 
as clam-ileocystoplasty. Such an alternative treatment should be efficacious whilst combining 
other characteristics such as cost-effectiveness and being minimally invasive with little 
adverse events.  
 
Neuroceuticals 
For what is largely a functional lower urinary tract disorder as opposed to an anatomical one, 
surgery may not be the most suitable solution. The use of ‘Neuroceuticals’ is a form of 
treatment that uses electrical stimulation to target specific nerve fibres to manage a number of 
different conditions. This stimulation modulates neural impulses that control bodily 
functions, and is aiming to repair lost function. Researchers across many disciplines are 
exploring the use of this technique for example to encourage insulin release from cells to treat 
diabetes, to regulate food intake for obesity, and to rebalance vascular smooth muscle tone 
for patients with hypertension or pulmonary diseases [20]. Circuits of action potentials, the 
catalyst for electrical impulses, are essential for the normal functioning and communications 
between all organs. These nerve fibres are all interconnected and organized in bundles 
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allowing for pinpoint localization of therapy. Currently delivery of electrical stimulation is 
initially being harnessed in devices that are being designed for these specific purposes. For 
example pacemakers and defibrillators for cardiac muscle stimulation, deep brain stimulators 
for patients with Parkinson’s Disease and depression, sacral nerve stimulators for patients 
with bladder dysfunction, and vagus nerve stimulators for patients with epilepsy or 
rheumatoid arthritis [20]. However these devices are still at a preliminary stage in that they 
still do not target individual cells within these circuits. Within bundles adjacent individual 
nerve fibres may be carrying signals in opposing directions, or fibres originating from 
different organs leading to side effects by stimulating collateral fibres and dampening the 
clinical efficacy. Devices of today are not as yet producing naturalistic patterns of action 
potentials, and currently only provide simple waveforms that can either block or stimulate 
nerves rather than reproduce dynamic activity on a millisecond scale [20]. 
 
The mechanisms of action for neuromodulation is unclear, but is thought to have a 
combination of a direct effect on the bladder and a central effect on the micturition centres of 
the brain. It has been observed that nerves can change their function and signalling in 
response to disease, injury and repeated electrical stimulation, which is coined in the phrase 
neural plasticity. The aim of electrical nerve stimulation in the lower urinary tract is to 
modulate this plasticity in order to restore bladder dysfunction. Neuromodulation can either 
be targeted at the level of the central or peripheral nerves. Sacral nerve stimulation is an FDA 
approved treatment, applied centrally, to manage OAB and urinary retention.  
 
Peripheral Nerve Stimulation 
Dorsal Penile Nerve Stimulation 
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Peripheral nerve stimulation has been subject to interest and study for some time. 
Experimental animal studies have investigated the use of a range of peripheral nerves to 
target the bladder. Electrical stimulation of the dorsal penile nerve (DPN) in anaesthetised 
cats had clear effects on the micturition reflex [21]. It was observed that stimulation at a 
lower frequency of 5-10Hz, inhibited distension evoked bladder contractions, promoted 
urinary storage, and increased the bladder capacity. Whereas stimulation at 33-40Hz 
augmented the distension-evoked contractions and when the bladder was filled above a 
threshold volume, stimulation at 20-40Hz activated the micturition reflex and elicited 
detrusor contractions increasing voiding efficiency compared to the distension-evoked 
voiding. This ability to promote detrusor contractions through DPN stimulation was 
preserved following acute spinal transection, suggesting the ability of genital afferents in 
modulating the micturition reflex and potential use of restoring bladder control through nerve 
stimulation. The frequency of delivery was also clearly important for the type of effect 
induced. When applied to human patients with detrusor overactivity (DO), dorsal genital 
nerve stimulation has lead to an improvement in bladder capacity, reduction in urgency and 
incontinence episodes [22].  
 
Clitoral Nerve Stimulation 
An early rat study showed that pelvic or hypogastric nerve stimulation, could evoke 
responses in the postganglionic nerves that supply the penis and clitoris [23]. More recently it 
has been shown that in 4 women with spinal cord injury, short duration electrical stimulation 
of the clitoral nerve provided significant improvements in bladder capacities and reduction of 
maximum bladder pressures [24].   
 
Pudendal Nerve Stimulation 
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In the same way, pudendal nerve stimulation (PDNS) has also been explored in patients with 
OAB and DO [25]. One of the early reported studies recruited 29 patients who had failed 
conservative treatments. PDNS was experimented using either intravaginal or intra-anal 
transcutaneous electrodes. Some patients also had additional stimulation through a single 
needle electrode placed directly into the pudendal nerve. Stimulation was administered with 
amplitudes determined by the patient’s pain threshold. Voltage pulses at 10Hz were used, at 
one-week intervals for four weeks in total. All patients showed significant improvements in 
functional bladder capacity and some reduction in the frequency of micturition. Two patients 
who were unaffected by the external electrodes, responded well to the direct needle electrode 
suggesting the mode of delivery may be more effective using direct needle puncture onto the 
nerve for some patients.  
Later another study examined the use of chronic PDNS, in 84 patients who had either 
Interstitial Cystitis (IC), or OAB refractory to sacral neuromodulation (SNM) [26]. Ninety-
three percent of those who had failed SNM responded to PDNS. At median follow up of 24.1 
months, significant improvements were seen in frequency, voided volume, incontinence, 
urgency, and IC Symptom scores. This study shows that chronic PDNS is a potential 
alternative for patients refractory to other therapies. 
  
The safety and efficacy of these forms of peripheral nerve stimulation are yet to be backed by 
evidence from phase 3 clinical trials. It has been noted during OAB drug trials that the 
placebo effect can effect up to 64% of patients for urinary incontinence symptoms [27]. One 
form of peripheral nerve stimulation that has an emerging evidence base is Percutaneous 
Tibial Nerve Stimulation (PTNS). This chapter focuses on the use of PTNS for the OAB. 
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Percutaneous Tibial Nerve Stimulation 
Percutaneous Tibial Nerve Stimulation (PTNS) is another peripheral method of stimulating 
nerves for controlling bladder function. is This less invasive, office based treatment applies 
electrical stimulation in a retrograde manner through the tibial nerve, to indirectly modulate 
the sacral plexus. 
Curently being explored as an alternative for patients, PTNS may have the qualities to fill the 
gap in the treatment armentarium [28]. It is felt that PTNS could offer a suitable alternative 
for patients unable to tolerate side effects of antimuscarinic medications (such as dry mouth, 
dry eyes, constipation and cognitive CNS effects), and those refractory to behavioural 
modifications, and those not willing to consider more invasive options such as the surgical 
implantation of a SNM device, or more complex reconstructive surgery. 
The inherent advantages that PTNS could offer over SNM, are summarised in table 1 below. 
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Table 1: Percutaneous Tibial Nerve Stimulation (PTNS) versus Sacral Nerve 
Stimulation (SNM). 
 PTNS SNS 
Non-invasive; Fine gauge 
needle placed into the medial 
aspect of ankle 
Invasive; tined lead placed 
through S3 foramina 
No anaesthesia required Requires general anaesthesia 
Advantages of PTNS 
 
Side-effect profile minimal, 
include discomfort at needle 
insertion site, one report of 
haematoma formation at the 
ankle 
Side-effects, which may 
require surgical revision:  
• implantable devices 
are susceptible to 
infections in 5%,  
• pain at surgery site in 
25%,  
• lead migrations in 
16%,  
• haematoma 
formation,  
• subsequent revision 
surgeries for 
repositioning in 15%, 
and  
• wound problems in 
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7%.  
• These complications 
include a re-operation 
rate of 33%   
Proven against sham Unproven against sham 
 
PTNS appears significantly 
less costly [29], however 
more health economic studies 
required for accurate cost 
effectiveness  
Health economic studies 
required for cost 
effectiveness 
Requires 12 weekly visits to 
the outpatients 
Fewer visits however follow 
up will be long term 
Long term data not available 5 year data available [30] 
Mechanism of action unclear Mechanism of action unclear 
Not able to cure symptoms, 
possibly less efficacious than 
SNS [31] - however no head 
to head studies 
Possible to cure patient 
symptoms 
Advantages of SNS 
Intermittent stimulation Continuous stimulation 
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PTNS - Mechanism of action 
The location of the posterior tibial nerve for stimulation is behind and above the medial 
malleolus of the ankle.  This point coincides with ‘spleen-6’ the traditional Chinese 
acupuncture site for the treatment of urological complaints, pelvic disorders and 
dysmenorrhoea. 
PTNS involves the stimulation of the posterior tibial nerve, which is a mixed sensory motor 
nerve, formed of axons derived from the L4 to S3 spinal nerve roots, comprising the outflow 
of sacral nerves, which innervate the bladder, urinary sphincter and pelvic floor. These fibres 
provide autonomic and somatic innervation to the lower urinary tract (bladder and urethral 
sphincter), large bowel and pelvic floor. PTNS inhibits bladder activity by depolarizing the 
lumbar afferent and somatic sacral nerves and ultimately rebalancing the inhibitory and 
excitatory impulses that control bladder function. This promotes inhibitory somatic afferent 
signalling, which is largely deficient in the OAB. These afferents project to the pontine 
micturition centre and with chronic stimulation, can lead to changes in the suprapontine 
regions that finally modulate micturition reflexes [32]. Afferent nerve stimulation provides 
central inhibition of the preganglionic bladder motor nerves through a direct route in the 
sacral spinal cord. In animal models, it has been shown that neuromodulation can lead to 
hypertrophy of the external urethral sphincter and consequently greater urethral closure 
pressures and hence promoting the guarding reflex [32]. Figure one below is a schematic of 
the course of the tibial nerve travelling down the lower limb. 
 
 
 
 
 
Figure one: The course of the Tibial nerve as it travels in the lower limb (Grey’s 
Anatomy). 
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Three main pathways have been debated for mechanism of action [33]: 
1. Direct stimulation of the hypogastric nerve through activation of sympathetic fibres at 
low bladder filling volumes 
2. Direct stimulation of the nuclei of the pudendal nerve in the spinal cord at maximal 
bladder filling 
3. Supraspinal inhibition of the detrusor 
 
This treatment therefore requires the existence of uninterrupted spinal inhibitory pathways, 
which are capable of preventing a detrusor contraction.  
It has been shown in an animal model that intravesical acetic acid instillation in the rat, 
resulted in a rise in c-fos expression (a marker of neuronal metabolic activity) in the sacral 
cord, and this was significantly reduced after PTNS treatment of the hind leg [34]. Another 
study in rats demonstrated that after PTNS, the mast cell count in the bladder diminished 
[35]. Tai et al showed in cats that irritation induced bladder overactivity can be suppressed by 
tibial nerve stimulation [36]. A 30 minute stimulation at low and high frequencies (5Hz and 
30Hz) was able to produce prolonged inhibition of bladder activity and increased bladder 
capacity for 2hours or more. 
  
PTNS – Background of Clinical studies 
Despite the lack of clarity about it mechanism of action, PTNS is being adopted as a potential 
treatment for the OAB, and other conditions such as non-obstructive urinary retention, 
neuropathic bladder, paediatric voiding dysfunction, and painful bladder syndrome, although 
it still requires further validation for all of the above. McPherson in 1966 demonstrated that in 
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cats stimulation of the posterior tibial nerve inhibited bladder contractions [37]. Further 
efforts to stimulate this nerve for bladder dysfunction stem back to McGuire in 1983 [38]. In 
his publication, inspired by effects of acupuncture at the tibial and peroneal nerves, McGuire 
described electrical stimulation of the tibial nerve in 22 patients with bladder complaints 
secondary to a variety of conditions including neurological diseases, interstitial and radiation 
cystitis. The results were declared ‘astonishingly good’ when eight of eleven patients with 
DO became ‘dry’ using urodynamic parameters. 
Also in the 1980s, Stoller began studies on pig-tailed monkeys that showed intermittent 
PTNS could inhibit bladder instability and urge incontinence [39]. Over the next decade, at 
the Univerity of California and San Francisco, Stoller reported in a guest lecture that 
intermittent percutaneous stimulation of the tibial nerve in a group of 98 patients proved its 
safety and potential efficacy. PTNS became more recognised after this as Stoller afferent 
nerve stimulation (SANS).  
SANS technique was described using a 34-guage needle, which is placed bilaterally, three 
finger-breadths above the medial malleolus and posterior to the tibia. The location of the 
posterior tibial nerve at the ankle is illustrated in figure two below. A grounding adhesive 
electrode is placed near the medial calcaneus. Electrical stimulation is then administered via a 
9-V battery-powered generator, at an amplitude of 0.5 to 10mA, with a fixed pulse width 
(200µs) and frequency (20Hz). The confirmation that the needle is in the correct place is by 
evoking plantar flexion of the toes or toe fanning once the nerve is being stimulated.  
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Figure two: The course of the posterior tibial nerve at the ankle. 
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Govier et al following this performed another of the earlier multicentre studies on 53 patients 
with OAB in the United States. Patients received weekly treatments for 12 weeks. Seventy-
one patients were classified to have treatment success, with overall reductions of 25%, 21% 
and 35% for mean daytime, night-time voiding frequency, and urge incontinence.  
 
Based on this data, regulatory clearances were achieved for PTNS with FDA-approval in 
2000 for urinary urgency, frequency and urge incontinence. In 2010 this was updated to 
include OAB. A PTNS device received the CE mark for this purpose in 2005, since which 
Uroplasty have marketed the Urgent PC Neuromodulation System, the only device 
commercially available today. This has subsequently been the device used in the pivotal 
phase III study, ‘The Study of Urgent PC vs Sham Effectiveness in Treatment of Overactive 
Bladder Symptoms’ (SUmiT) [40]. PTNS has also acquired approval from the National 
Institute of Clinical Excellence (NICE) within the guidance for the management of urinary 
incontinence in women. Although approved, the data concerning the patient selection criteria 
and the longevity of treatment is still limited.  
 
A published systematic review examining PTNS for adults with OAB, identified four 
randomized controlled trials and six prospective observational cohort studies investigating 
this treatment. PTNS was found to be efficacious compared to control groups for reducing 
urinary frequency and urge incontinence episodes [41]. Most studies include a follow-up 
period of 12 weeks.  
 
A published multicentre, randomized study known as the OrBIT (Overactive Bladder 
Innovative Therapy) trial, examined the head to head use of PTNS versus extended release 
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tolterodine [42]. This was conducted over 11 centres in the United States, and the primary 
endpoint was the frequency of urination per 24-hour period, after 12 weeks of treatment. 
Secondary endpoints included the mean change in the number of urge incontinence episodes, 
number of voids causing waking, volume voided, and number of urgency episodes using the 
Indevus Urgency Severity Scale. This information was captured using voiding diaries, OAB-
q questionnaires and a Global Response Assessment (GRA) scale. The results reported 100 
patients randomized, with 50 patients in each of the two arms. The GRA showed that 79.5% 
of patients from the PTNS arm and 54.8% in the tolterodine arm self-reported to have been 
either cured or improved. Significant improvements were seen in all OAB symptom subset 
scores after 12-weeks treatment for both groups, and there was no significant difference 
between groups. The lack of a placebo arm in this study leaves uncertainty about how much 
the elevated improvements noted in the GRA from the PTNS group is related to placebo 
effect.  
 
Another randomized study comparing PTNS to solifenacin has also recently been published 
[43]. This was a randomized crossover study of 40 patients who had four weeks of therapy 
with 5mg oral solifenacin followed by a 3-month washout period before having a 6-week 
regime of PTNS treatment, which entailed twice weekly 30-minute sessions. The results of 
this study suggest that both PTNS and solifenacin provide improvements in all subscores of 
OAB, however PTNS was shown to be superior to solifenacin in particular with regards to 
the number of episodes of daily micturition and quality of life improvements. The dosing of 
10mg of solifenacin was not used in this study, and the effect of an increased dosage may 
have influenced the results. 
 
 
The same group that conducted the OrBIT study went on to develop a validated sham and 
published the results of the first multicentre, double-blind, placebo-controlled randomised 
trial involving 220 patients with idiopathic OAB [40]. This is known as the SUmiT Trial and 
compared the efficacy of 12 weekly, 30 minute stimulations of PTNS against a sham 
treatment [40].  Quality of life questionnaires and voiding diaries were completed at baseline 
and after 12-weeks of treatment. A responder was defined by the reporting of a moderate or 
marked improvement of bladder symptoms on a 7-level GRA. The GRA is a subjective 
outcome that considers patient perceived improvement. Secondary endpoints included any 
change in a specific subset of symptom scores (either urgency, frequency, and urge 
incontinence), voiding diary parameters measured over 3-days, OABq scores and quality of 
life scores using the SF-36 [40]. To blind the treatment, patients were seated in a recliner, and 
their feet were draped, away from view. In the sham group, a dummy needle was placed, 
where the needle retracted into the sheath but also gave the sensation of a pin-prick, with no 
skin puncture taking place, and therefore the tibial nerve could not be stimulated.  
The results at 13-weeks, for the primary end point, shows that 54.5% and 20.9% of patients 
from the treatment and sham group respectively achieved a moderate or marked improvement 
in the GRA, which was statistically significant (p<0.001). For secondary end points of 
individual subset symptom scores for urinary urgency, frequency and urge incontinence, 
there were significant improvements in the PTNS arm compared to sham. Interestingly with 
the three-day voiding diary parameters for mean daytime and night-time urinary frequency, 
there were significant improvements from baseline to 13 weeks in both the PTNS and sham 
arms. The change in OAB-q symptom scores and quality of life scores from baseline to 13-
weeks, suggested significant improvements in the PTNS group compared to sham. The 
authors concluded this study, which is the first to include a realistic sham arm, provides level-
one evidence that PTNS is a safe and effective treatment for OAB.  
 
 
A smaller randomized placebo controlled, double-blind study of 35 female patients with 
proven DO has also been reported [44]. Seventeen patients completed the treatment arm of 
PTNS, and fifteen received a placebo treatment of having a needle placed into the medial 
aspect of the gastrocnemius muscle. The stimulator was switched on for 30 seconds in the 
sham group so patients could feel a minor electrical sensation in the skin, but this was then 
turned off for the remainder of the 30-minute treatment. Patients in both arms received three 
30-minute treatments per week, with 12 sessions in total. The number of patients who had a 
50% or greater reduction of incontinence episodes was 12 (71%) in the treatment arm and 0 
(0%) in the sham arm. Significant improvements were also seen in the treatment arm for the 
number of micturitions, voided volumes and I-QOL scores, with no improvements noted at 
all in the sham arm.  
Table two summarises all of the clinical studies evaluating PTNS for the OAB. 
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Table two: A summary of all clinical studies investigating PTNS in patients with 
idiopathic and neuropathic OAB. 
Study Population and 
Number of 
patients 
Study design and 
Treatment 
Regime 
Criteria for success Results 
1. Peters et 
al, 2010. 
SUmiT 
study [40]. 
Patients with 
idiopathic OAB 
(220) 
randomized 
between PTNS 
versus a sham 
treatment. 
Multicentre, 
double blind, 
placebo controlled 
RCT. 
Once weekly for 12 
weekly x 30minute 
sessions.  
Current level of 0.5 
to 9mA at 20Hz. 
 
 
 
Primary Endpoint: 
Responder defined as 
reporting symptoms to 
moderately or markedly 
improve on a 7-level 
global response 
assessment (GRA). 
Secondary Endpoints: 
GRA subset symptom 
components, 
Voiding diary 
parameters, OAB-q 
symptom severity score, 
SF-36 general health 
quality of life score 
54.5% PTNS arm and 
20.9% of sham arm 
reporting moderate or 
marked improvement. 
Significant voiding diary 
parameter improvements 
compared with sham. 
 
2. Finazzi-
Agro et al, 
2010 [44]. 
Female patients 
with DO (35) 
randomized 
between PTNS 
versus a sham 
treatment.  
Double blind, 
Placebo controlled 
RCT  
12 x 30minute 
sessions, performed 
three times a week 
Low voltage 
stimulator (9V), 
Primary outcome: 
Percentage of responders 
in the two groups. 
(Patients with 50% or 
greater reduction in urge 
incontinence episodes). 
Secondary outcome: 
number of incontinence 
71% of the PTNS arm and 
0% of the sham arm were 
considered responders. 
Statistically significant 
improvements were seen in 
the bladder diary and 
quality of life scores in the 
PTNS arm but not in the 
 
using a stimulation 
current of 0-10 mA 
and a pulse width 
of 200 mseconds 
increased until toe 
flexion/fanning was 
noticeable. 
 
episodes, micturitions, 
mean voided volume 
(from voiding diary) and 
I-QOL score. 
placebo arm. 
3. Peters et 
al, 2009. 
OrBIT 
study [42]. 
OrBIT 
(Overactive 
Bladder 
Innovative 
Therapy) trial.  
100 adults with 
urinary 
frequency were 
randomised to 
12 weeks of 
PTNS or 4mg 
tolterodine 
daily. 
Multicentre, non-
blinded, non-
placebo controlled 
RCT 
12 weekly 30-
minute sessions of 
PTNS delivered. 
 
Primary objective: 
Compare efficacy of 
PTNS to tolterodine in 
reducing the 24 hour 
urinary frequency (from 
voiding diaries). 
Secondary endpoints: 
mean change in urinary 
urge incontinence 
episodes over 24 hours, 
nocturia, volume 
voiding per day, urgency 
from Indevus Urgency 
Severity Scale, 
improvement in OAB-q 
scale and using a GRA 
scale. 
Global response assessment 
(a subjective asessment) 
demonstrated 79.5% of 
patients in the PTNS arm 
reporting cure or 
improvement compared to 
54.8% of patients on 
tolterodine arm. 
Objective assessments 
showed significant 
improvements in both arms 
that were comparable. 
4. 
Vecchioli-
Scaldazza 
et al, 2013 
[43]. 
Women with 
OAB (40) 
crossover 
between 
Solifenacin 
Non-placebo, 
randomised 
controlled 
crossover study 
30-minutes of 
Primary endpoint: 
Reduction in the number 
of voids/24hours. 
Secondary endpoints: 
reduction in number of 
Reduction in bladder diary 
parameter of daily 
micturitions, nocturia, and 
urge incontinence in both 
groups. However PTNS 
 
Succinate (SS) 
5mg (4 weeks) 
and 6 weeks of 
twice weekly 
PTNS with 3 
months washout 
in-between. 
PTNS twice a week 
for 6-weeks.  
Crossover study, 
randomised.  
episodes of urge 
incontinence, nocturia, 
changes in voided 
volume, patient 
perception of intensity 
of urgency and quality 
of life using OAB 
Questionnaire Short 
Form. 
showed greater 
effectiveness in patient 
perception of urgency and 
quality of life. 
5. 
Karademir 
et al, 2005 
[45].  
Patients with 
DO (43) 
randomized 
between SANS 
alone (Group 1), 
8 weekly 60 
minute sessions, 
vs SANS, 8 
weekly 60 
minute sessions 
plus oxybutynin 
5mg daily 
(Group 2)  
Non-placebo 
controlled RCT 
(combination 
study) 
SANS was applied 
at 0.2ms at a 
frequency of 20Hz, 
with adjustable 
amplitude within 
the range of 0.5-
10mA. 
Patients were evaluated 
with the Bristol Urinary 
Questionnaire and a 
voiding diary. 
Improvements in 
symptoms >70%, 35-
70% and <35% were 
considered as complete, 
partial and non-
responses respectively. 
Treatment response rate of 
61% and 83.2% for groups 
1 and 2 respectively.  
36.7% and 46.1% reduction 
of frequency and urgency 
in Group 1 whilst 44.2% 
and 61.1% reduction in 
Group 2.  
However no statistically 
significant difference 
between the two groups. 
6. Klinger 
et al, 2000 
[46]. 
15 patients with 
DO  
(11 women and 
4 men) 
Open label  
urodynamic study 
12 x 30 minute 
stimulations, at a 
rate of 4 
stimulations per 
week, with a 9V 
monopolar 
Complete response: Day 
voids 8, nocturia 2, 
pad test 0-1g, DO 
improved. 
Partial response: Day 
voids 8-10, nocturia >2, 
pad test 2-10g, DO 
improved. 
Seven (47%) showed a 
complete response and 
considered cured. 
Three (20%) had 
significant improvement. 
Five (33%) were classified 
as non-responders. 
Urodynamic DO was 
 
generator. 
Stimulation was 
selected with a 
range of 0.5-10mA, 
fixed pulse width 
of 200ms and a 
frequency of 20Hz. 
Mean follow up 
was 10.9 months. 
Non-response: Day 
voids >10, nocturia >2, 
pad test >10g, DO 
unchanged. 
eliminated in 77% of 
patients. Significant 
increases were seen in 
urodynamic parameters 
such as bladder capacity, 
volume at first bladder 
sensation, and bladder 
volume at normal desire to 
void. 
Mean reduction in day and 
night voids from 16.1 to 8.3 
and 4.4 to 1.4 respectively. 
7. 
Vandoninck 
et al, 2003 
[47]. 
90 Patients with 
OAB  
Urodynamic 
Study, open 
labelled, non-
placebo 
12 sessions of 
PTNS. 
Primary outcome: 
reduction in number of 
leakage episodes of 
50% per 24 hours. 
Secondary outcomes: 
Patient’s request for 
continuation of 
treatment was subjective 
assessment (considered 
positive responders). 
Bladder diary 
parameters 
Incontinence specific 
QOL 
Short Form-36 for 
general wellbeing. 
Urodynamic data after 
12 PTNS sessions – 
Objective success rate at 
56% achieving primary 
outcome. 
Subjective success rate was 
64%. 
Voiding diary and quality 
of life scores improved 
significantly. 
DO could only be 
diminished in a few cases. 
Increases in bladder 
capacity were significant. 
Patients without DO at 
baseline were 1.7 times 
more likely to respond. 
 
 
volume at which DO 
occurred. (DO defined 
as an increase of more 
than 15cm H20 or lower 
amplitude if 
accompanied with 
distinct sensation of 
urgency). 
8. 
Vandoninck 
et al, 2003 
[48].  
35 patients with 
urge 
incontinence 
(10 male, 25 
female) 
Multicentre, open 
label 
12 weekly sessions 
of PTNS 
Needle and 
electrode connected 
to a low voltage 
(9V) electrical 
stimulator 
Current 0-10mA 
applied with a fixed 
frequency of 20Hz 
and a pulse width 
of 
200microseconds. 
The former was 
increased until 
curling of the big 
toe or fanning of all 
toes were seen, at a 
well tolerable level. 
Frequency/Volume 
charts were completed, 
Incontinence-QOL 
questionnaire, and SF-36 
at 0 and 12 weeks. 
Subjective success was 
willingness to continue 
treatment. 
Objective success was 
defined as a decrease (to 
< 50%) in total number 
of leakage episodes. 
22 patients (63%) reported 
subjective success 
24 (70%) showed a 50% 
reduction in total number 
of leakage episides, 
QOL parameters improved 
significantly. 
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9. Van 
Balken et 
al, 2001 
[49]. 
37 patients with 
OAB (10 male 
and 27 female) 
12 patients with 
non-obstructive 
urinary 
retention (5 men 
and 7 women) 
 
Multicentre, open 
label study 
12 weekly sessions 
of PTNS 
performed, each for 
30 minutes. 
Low voltage 
stimulator (9V), 
adjustable pulse 
intensity of 0 to 10 
mA, a fixed pulse 
width of 
200microseconds 
and a frequency of 
20Hz. Amplitude is 
slowly increased 
until large toe curls 
or toes fan. 
Success was defined as 
patient request for 
further treatment. 
Voiding diaries were 
collected, SF-36 used to 
assess quality of life. 
OAB patients: Significant 
reduction in leakage 
episodes, number of pads, 
voiding frequency and 
nocturia, increase in mean 
voided volume. 
Retention patients: 
Reduction in number of 
catheterisations, increased 
mean volume voided. 
 
10. Govier 
et al, 2001 
[50] 
52 patients with 
OAB 
Multicentre, open 
label, non-
randomised 
12 weekly sessions 
of PTNS for 
30minutes. 
Stimulation was 
titrated from 0-
10mA, with a fixed 
pulse width pf 200 
microseconds at a 
frequency of 20Hz. 
Primary objective to 
demonstrate safety and 
efficacy (using 3-day 
bladder diaries) 
Secondary objectives 
were assessed using 
impact of incontinence 
on health related quality 
of life outcomes (SF-36, 
Short form McGill Pain 
Questionnaire). 
71% were classified as a 
treatment success and 
started on long-term 
treatment. 
25% and 21% reduction in 
mean day and night time 
voids. 
Urge incontinence episodes 
were reduced by 35%. 
Significant improvements 
in QOL indices. 
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11. 
Amarenco 
et al, 2003 
[51] 
44 patients with 
OAB (29 
women and 15 
men).  
13 patients had 
DO secondary 
to  Multiple 
Sclerosis, 15 
with spinal cord 
injury, 9 with 
Parkinson’s 
disease, and 7 
with idiopathic 
DO. 
Prospective study 
Examination of the 
acute urodynamic 
effect of PTNS. 
Stimulation 
delivered in 
continuous mode at 
10Hz frequency 
and 200 
milliseconds wide.  
Intensity was 
chosed under the 
threshold 
determining motor 
contraction. 
Volume comparisons 
were made at first 
involuntary detrusor 
contraction (IDC) and at 
maximum cystometric 
capacity (MCC). 
Test was considered 
positive if first IDC 
and/or MCC increased 
100ml or 50% during 
stimulation. 
Mean volume at first IDC 
was 162.9mls pre-
stimulation and 232.1 
during PTNS. Mean MCC 
was 221mls pre-stimulation 
and 277.4 during PTNS.  
Significant improvements 
in first IDC volume and 
MCC were seen with 
PTNS. The test was 
considered positive in 
22/44 patients.  
12. Van der 
Pal et al, 
2006 [52] 
30 patients with 
urge 
incontinence (4 
men and 26 
women). 
Prospective study 
Low voltage 
stimulator (Urgent 
PC) 
Adjustable 
stimulation 
intensity 0-10mA 
and fixed 
stimulation 
parameters e.g 
pulse width of 
200ms and 
frequency of 20Hz. 
Amplitude was 
slowly increased to 
Bladder diaries, SF-36 
and incontinence 
specific QOL were 
recorded at baseline and 
after PTNS. 
Significant improvements 
were seen with reduction of 
SF-36 domain, which 
correlated with a significant 
reduction in the number of 
pads required. 
 
achieve motor signs 
with big toe flexion 
or toe fanning. 
PTNS was 
performed for 30 
minutes for 12 
sessions, three 
times a week for 
four weeks. 
13. Van 
Balken et 
al, 2006 
[53].  
132 patients (51 
men and 81 
women). 
83 with OAB, 
16 with non-
obstructive 
urinary 
retention, and 
33 with chronic 
pelvic pain. 
Multicentre, non-
randomised 
Stimulation had an 
adjustable pulse 
intensity from 0-
10mA, a fixed 
pulse width of 
200microseconds 
and a frequency of 
20Hz. The 
stimulator 
contained a 9V 
battery (Urgent 
PC), and motor 
response in the feet 
were sought for an 
adequate response. 
PTNS was 
delivered weekly 
for 12 weeks, in 30 
minute sessions. 
Subjective response was 
the patients request for 
further chronic 
treatment. 
 
Objective success was a 
decrease in symptoms of 
over 50% for number of 
voids/24 hours, number 
of incontinence 
episodes, visual 
analogue score for pain, 
number of 
catheterisations/24hours) 
Objective success seen in 
32.6% and subjective 
success in 51.5%.  
 
A total low score at 
baseline in the SF-36 
questionnaire, especially 
the mental component 
showing poor mental 
health, proved to be 
predictive for not obtaining 
objective or subjective 
success.  
 
Mental health should be 
considered when selecting 
patients for this therapy.  
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14. Van der 
Pal et al, 
2006 [52].  
11 patients with 
OAB 
Prospective study 
All patients had 
been successfully 
treated with PTNS 
having 50% fewer 
incontinence 
episodes and 50% 
lower voiding 
frequency at the 
end of the treament 
regime (noted as 
T1).  
All patients then 
stopped treatment 
for 6 weeks and 
completed the 
bladder diaries and 
QOL 
questionnaires after 
this T2.   
After this they 
restarted PTNS 
treatment and were 
re-assessed (T3). 
The first objective was 
defined as 50% 
increase in incontinence 
episodes and /or voiding 
frequency at T2. 
The second objective 
was 50% fewer 
incontinence episodes 
and/or voiding 
frequency at T3.  
At T2, 7/11 patients had 
50% increase in 
incontinence episodes and 
/or voiding frequency. 
Performance had 
signficantly deteriorated 
once PTNS was stopped. 
At T3, nine patients had 
50% fewer incontinence 
episodes and/or voiding 
frequency. Other bladder 
diary parameters had 
improved significantly 
once back on PTNS. 
It was concluded that 
continuous therapy is 
required for OAB patients, 
and that efficacy can be 
reproduced in patients 
previously treated 
successfully.  
15. 
Nuhoglu et 
al, 2006 
[54]. 
35 patients with 
OAB refractory 
to oxybutynin 
therapy. 
Prospective study 
SANS weekly for 
10 weeks, 30 
minutes a session. 
Utitlised Urosurge 
SANS device, 
Three-day voiding 
diaries were recorded 
and urodynamics was 
performed at baseline, 
after treatment and at 
one year. 
19 (54%) of patients had 
complete recovery after 
treatment. Significant 
improvements were noted 
in the QOL and urgency 
core, with increased voided 
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monopolar 
generator, working 
at 20Hz frequency, 
with 200msn pulse 
width and 0-10mA 
adjustable pulse 
intensity, using a 
9V battery. 
volumes. 
Eight out of 19 subjects 
maintained complete 
recovery at one year follow 
up. 
Significant improvements 
were observed in 
urodynamic parameters 
after treatment such as 
volume and pressure at 
IDC, and MCC. 
However uninhibited IDC 
disappeared in no patients. 
16. Kabay 
et al, 2009 
[55]. 
19 patients with 
MS and NDO (6 
men and 13 
women). 
Prospective study 
Urodynamics were 
performed at 
baseline and after 
12 weeks of weekly 
PTNS.  
Stimulation was 
delivered at 
200µsecond pulses 
at a pulse rate of 
20Hz. 
Urodynamic data, 
voiding diaries, and pad 
tests were performed. 
Complete response was 
considered as a 50% 
decrease in urgency, 
urinary incontinence, 
daytime frequency, 
nocturia and pad test. 
A decrease between 
25% and 50% was 
considered a partial 
response. 
A decrease below 25% 
was considered as non-
response. 
Significant increases in 
mean volume and 
maximum pressure at first 
IDC, and MCC were 
observed.  
Improvements were also 
seen with mean maximum 
pressure at MCC, maximal 
flow rate. Detrusor pressure 
at maximal flow improved 
in 3 out of 5 patients with 
detrusor sphincter 
dyssynergia (DSD). 
 
Clinical complete response 
was seen in 33.3%, 40%, 
57.9%, 75% and 90% for 
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urgency, urinary 
incontinence, daytime 
frequency, nocturia and pad 
test respectively. 
Use of PTNS in MS 
patients with NDO is 
promising from this study. 
17. Gobbi 
et al, 2011 
[56].  
21 patients with 
MS and LUTS, 
unresponsive to 
anticholinergics. 
Open label, 
prospective study 
12 weekly sessions 
of PTNS, for 30 
minutes, at a 
current level of 0.5-
9mA, at 200µs 
pulses, with a pulse 
rate of 20Hz, based 
on motor sensory 
responses in the 
foot. 
3 day bladder diaries 
were collected, 
symptoms were assessed 
with patient perception 
urgency scale, and 
King’s Health QOL 
questionnaire before, 
during and after 
treatment. A visual 
analogue scale (VAS) 
was used (indicated no 
improvement to 10 
indicating complete 
cure). 
Treatment satisfaction 
was defined as a VAS 
score greater than 5, or a 
reduction of LUTS 
50%. 
Significant reduction of 
daytime frequency, 
nocturia and mean post 
void residual. 89% of 
patients reported 70% 
satisfaction with the 
treatment. Significant QOL 
improvements were seen in 
the King’s Health QOL 
domains. 
18. Kabay 
et al, 2009 
[57].  
29 patients with 
MS and NDO. 
(12 men and 17 
women). 
Prospective study 
PTNS delivered at 
a pulse rate of 
20Hz, at 200µs 
Acute effects of PTNS 
were assessed with 
urodynamics.  
There were significant 
increases in mean volume 
at first IDC, and mean 
MCC.  
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pulses.   
19. 
Fjorback et 
al, 2007 
[58].  
8 patients with 
MS and DO. 
Prospective study 
20Hz, at 200µs 
pulses, PTNS was 
applied bilaterally. 
Urodynamic study 
assessing acute effects 
of PTNS on DO. 
PTNS failed to suppress 
DO in all patients. 
20. Zecca et 
al, 2014 
[59],  
83 patients with 
MS and LUTS. 
Prospective study 
30 minutes 
stimulation weekly 
for 12 weeks. 
Current level of 
0.5-9mA using 
charge-
compensated 200µs 
pulses and a pulse 
rate of 20Hz.  
Assessment of sensory 
and motor response in 
the feet and correlation 
with clinical outcome.  
Objective parameters 
included 3 day voiding 
diary, Kings Health 
Questionnaire and 
treatment satisfaction 
VAS scale. 
51 out of 83 (61%) patients 
reported an improvement in 
LUTS of 50%. All 
patients showed a motor 
and or sensory response. 
64%, 6% and 30% 
exhibited a sensory only, 
motor only and a combined 
sensory-motor response 
respectively.  
The presence of either was 
not associated with sensory 
or motor impairment or 
spasticity. 
Those with a sensory only 
and combined sensory 
motor response were 
associated with a 
significantly better 
outcome than a motor 
response alone. Over 90% 
of responders showed a 
sensory response. 
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21. Zecca et 
al, 2014 
[60]. 
84 patients with 
Multiple 
Sclerosis and 
mixed LUTS 
(voiding and 
storage 
symptoms) 
Open label, 
Multicenter, 
Prospective Study. 
12 weekly sessions 
of PTNS 
Responders defined 
as having (50%) 
improvement of 
LUTS entered a 
maintenance phase. 
Greatest frequency 
was every two 
weeks. 
Assessed with 3-day 
bladder diary and patient 
perception of bladder 
condition (PPBC) 
questionnaire before and 
after 12 weeks. 
Treatment satisfaction 
was assessed using a 7-
level GRA scale. 
Urodynamics were 
perfomed before the 
start and after 24 months 
of PTNS. 
89% of patients responded 
to the initial 12-week 
therapy. Prolonged PTNS 
lead to persistent 
improvement of LUTS in 
patients with MS. 
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PTNS in neurological patients 
The majority of publications regarding PTNS relate to idiopathic OAB. Fjorback investigated 
the acute effects of bilateral PTNS in a group of eight patients with MS and NDO. Bilateral 
stimulation was used to maximize the number of depolarized afferent tibial nerve fibres. Slow 
fill cystometry was performed in these patients to confirm DO, and this was then repeated 
during stimulation with PTNS. The second cystometry during PTNS however failed to 
demonstrate suppression of either phasic or terminal DO in these patients [58]. 
Kabay et al. studied PTNS in neurological patients [55, 57, 61]. In one study of 29 patients 
with MS and proven DO, the acute effects of PTNS were investigated. A 50% increase in the 
bladder volume at first involuntary detrusor contraction (1st IDCV) was seen in 18 patients 
during PTNS, from a mean of 138 to 230mls. A 50% improvement in the MCC was also seen 
in 14 patients with a mean increase from 194 to 286mls during stimulation [57]. Stimulation 
was applied in 200 microsecond pulses at a pulse rate of 20 Hz. Kabay et al went on further 
to study the effects before and after 12 weeks of PTNS, again in patients with MS. Nineteen 
patients were recruited, and PTNS was delivered in the same manner as the previous study. 
The intensity setting was chosen as the intensity immediately under the threshold for 
determining motor contraction. The stimulation amplitude was set at the maximum tolerable 
level according to the individual subject. It was again shown that there were significant 
increases in the mean volume at 1st IDCV from 124 to 218mls after PTNS, and MCC 
improved from 200mls to 267mls after PTNS. There were also significant improvements in 
the PdetQmax (cmH20) from baseline at 36mls to 25mls after PTNS.  
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Kabay et al also examined the acute urodynamic effects of PTNS in a group of 32 patients 
with Parkinson’s disease with DO. Again electrical stimulation at 200µs pulses at a rate of 
20Hz were applied, at the amplitude that was most tolerable for evoking toe flexion or 
fanning. During stimulation the mean volume at first intradetrusor contraction (IDCV) 
increased from 145ml to 245ml, whilst the mean MCC increased from 205ml to 301ml.   
 
As mentioned above out of the few PTNS studies reporting on patients with neuropathic 
bladder dysfunction, seven have included patients with Multiple Sclerosis (MS) [51, 55-60]. 
It has been reported that between 50% to 100% of all patients with MS will complain of 
LUTS and poor QOL [62] [63]. As the neurological pathology progresses, voiding 
dysfunction may worsen and more resistant to treatment. This can lead to more severe DO, 
poor bladder emptying, voiding difficulties, recurrent urinary tract infections, which can 
ultimately trigger further relapses causing spasticity, immobility, and cognitive impairment 
[57].  
 
As with idiopathic OAB, the treatment options are limited. Neurological patients also often 
fail to respond to drug therapy. In addition the evidence for SNM for patients with MS is 
weak and is not recommended [64]. It is thought that surgical implantation of such a device 
may also be futile as patients are prone to neurological relapses at which stage the device 
loses its efficacy.  
 
The availability of a non-invasive, easily applicable, low risk treatment such as PTNS for 
patients with MS would be significantly beneficial. The experience of PTNS in these patients 
needs further study and is the focus of this study. 
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Aims and objectives 
The aim of this study was to assess safety and efficacy of PTNS in patients with reporting 
OAB symptoms attending a tertiary neurological referral centre.   
The objectives of the study were to prospectively evaluate the efficacy, safety and impact on 
quality of life of PTNS in patients with a heterogenous cohort of neurological disease 
including MS and idiopathic OAB with LUTS refractory to other therapies such as 
antimuscarinic therapy. Idiopathic and neuropathic groups of patients were also compared for 
any difference in response to PTNS.  
 
The patient population included those that were attending the outpatients in the Department 
of Uro-Neurology, which serves a heterogenous group of neurological patients. In June 2012, 
the department began offering PTNS as a service. This service prospectively collected data 
through an audit and there were two patient groups within this study;  
1. Patients with idiopathic OAB, or  
2. Patients with neuropathic OAB secondary to Multiple Sclerosis or other neurological 
diseases.  
 
This study followed up patients who were treated with PTNS and compared the clinical 
response to this treatment between these groups. Factors that predict whether patients return 
for top-up treatments were also analysed.  
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MATERIALS AND METHODS 
The National Hospital for Neurology and Neurosurgery is a tertiary referral centre for 
patients with all neurological conditions. Patients seen in the Department of Uro-Neurology 
are offered a range of therapeutic options including medications, intradetrusor injections of 
BTX-A and SNM. A nurse led clinical service offering PTNS was introduced in June 2012.   
 
PTNS was conducted in an outpatients setting in a single centre over the period of 18 months 
(June 2012 to December 2013). Consecutive patients with refractory OAB, regardless of 
primary pathology, were offered PTNS after appropriate counselling with department 
information leaflets. Patients were excluded if they were unable to attend weekly 
appointments, or diagnosed to have a urinary tract infection with urine dipstick testing.   
Patients were reviewed and assessed by a clinician in the outpatients, and suitable patients for 
PTNS were selected. Patients attended weekly for their treatments, and completed bladder 
diaries and symptom questionnaires at baseline and end of study. 
 
The procedure consists of introducing a 34 gauge needle inserted at 60 degree angle 
approximately 5 cm cephalad to the medial malleolus and slightly posterior to the tibia. 
PTNS lead connected to the Urgent PC stimulator (Urgent PC, Uroplasty, Minnetonka, USA 
Surface electrode is placed on the ipsilateral calcaneus, 20 Hz) and a current strength ranging 
from 0.5 to 9 mA is delivered based on an individual subject’s motor (flexion of the big toe 
or fanning of the toes) and sensory responses across the sole of the foot. Patients were only 
included into the study if they had a positive sensory and/or motor response to the stimulation 
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in the feet. This is important as a previous study has demonstrated that efficacy is associated 
with an appropriate presence sensory/motor response [59]. 
The standard protocol consists of once weekly, 30-minute sessions of stimulation over a 
twelve-week period.  .  
 
Questionnaires 
Many questionnaire tools exist to evaluate the severity of the different aspects of LUTS. 
Some are designed to assess OAB symptoms, others are more focused on urinary 
incontinence and its impact on QOL [65]. Questionnaire tools that are highly recommended 
by the International Continence Society (ICS) at the third consultation receive a Grade A 
rating [65]. This rating suggests that evidence has demonstrated the validity, reliability and 
responsiveness to change following standard psychometric testing. The questionnaire tools 
chosen for this study are the ICIQ-OAB (which is based on the ICSmale and BFLUTS) and 
the ICIQ-LUTSqol which is based on the King’s Health Questionnaire, both of which have 
received grade A rating. The different types of ICIQ modular questionnaires that have 
received grade A rating are listed in the figure three below [65, 66]: 
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Figure three: Enlists the questionnaire tools that have received grade A 
recommendation from the third ICI. 
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Study timeline 
The duration of treatment varied in previous published studies, from between 4 to 12-weeks. 
This study design included a 12-week treatment regime to be comparative with the SUmiT 
study, which is the largest placebo controlled study to date. 
The first 20 patients completed questionnaires and bladder diaries at baseline, week 4, 8 and 
12. After an initial analysis, it was evident that patients were experiencing benefit beyond 8 
weeks upto 12-weeks, and so the remainder of patients continued to complete 12-weeks of 
treatment as art of the study design. Questionnaire tools and bladder diary collection was 
performed at baseline and end of study (week-12). The study timeline is illustrated in figure 
four below. 
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Figure four: Study timeline. 
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Primary Outcome 
The change in the ICIQ-OAB and ICIQ-LUTSqol questionnaire scores, and the 3-day bladder 
diary parameters over twelve weeks of treatment was the primary outcome. Outcomes were 
the change in OAB symptoms, LUTS-related quality of life, and individual symptoms 
(urinary urgency, 24-hour frequency, daytime frequency, night-time frequency, leakage 
episodes and severity) as assessed on the bladder diary at week-12.  
 
Secondary Outcome 
Secondary outcomes were patient satisfaction and request to continue with the treatment, as 
measured by a more subjective Satisfaction Survey administered at the end of treatment at 
week-12. Sub-analyses were performed to identify the factors that could predict which 
patients would opt for top-up treatment after the study. Idiopathic and neuropathic groups of 
patients were also compared for any difference in response to PTNS.  
 
Reviewing the literature, various studies use completely different definitions of a successful 
response. Some studies suggest the use of 50% improvement in OAB symptom scores, 
whilst others make use of the patient reported GRA. Some discussion focuses on whether a 
mean improvement in scores of 50% actually correlates with patient satisfaction. Therefore 
we included the use of a satisfaction survey, which included a question of whether the patient 
would be interested to continue the treatment by attending for further top-up treatments. This 
would allow us to identify those who responded to therapy. 
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Subjects reporting benefit at 12-weeks were invited to return for top up PTNS sessions based 
upon self-reported recurrence of OAB symptoms. Subjective reporting using patient reported 
outcomes (PRO) has been recommended in the evaluation of treatments for OAB, as this is a 
symptom syndrome [67]. The diagnosis and management almost entirely judged by patient’s 
self reporting on symptoms and their impact on their QOL and well-being. 
 
Paired t-tests were used to see whether baseline levels in each factor differed from 12-week 
measurements. Count data was compared using chi-squared tests or Fisher’s exact test as 
appropriate. The distribution of continuous variables was examined and Students t-
tests/ANOVAs or Kruskal Wallis tests/Mann Whitney U tests were applied as appropriate. 
Linear regression was used to explore the relationship between baseline factors and the 
change in OAB symptoms and logistic regression analysis was used to identify the 
relationship between pre-specified variables and coming for a top-up. Data analysis was done 
using Stata 13.1. All statistical tests are two-sided and a p-value<0.05 was considered to be 
significant. 
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RESULTS 
Of 74 consecutive patients (22 male, 52 female; mean (95% CI) age 56.0 (52.2, 59.8) years) 
25 (33.8%) had idiopathic OAB and 49 had neuropathic OAB. Of the neuropathic group, 19 
(25.7%) had multiple sclerosis (MS) and 30 (40.5%) had other neurological conditions 
enlisted in table 3 below. As can be seen from the flow chart below, sixty-four (86%) patients 
completed 12-weeks of treatment. There were no statistically significant differences between 
the diagnosis groups in age, gender or baseline questionnaires scores (see table four).   
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Figure five: Flow chart illustrating the patient pathway for the study. 
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Table three: The spread of diagnoses in patients receiving PTNS.  
 
Diagnosis Number of patients 
Idiopathic 25 
Multiple sclerosis (MS) 19 
Parkinson’s disease 6 
Fowlers syndrome 4 
Parkinsonian syndrome  1 
Transverse myelitis 1 
Adrenomyeloneuropathy 2 
Adrenomyeloneuropathy carrier 1 
Carnitine palmitoyltransferase II (CPT II) 
deficiency  
1 
Limbic encephalitis and subdural haematoma 1 
Poliomyelitis 1 
Cauda equina, lumbar decompression 1 
Cervical and lumbar stenosis 1 
Peripheral neuropathy, lumbar canal stenosis 1 
Pure autonomic failure 1 
Familial dysautonomia, central sleep apnoea 1 
Friedrichs ataxia 1 
 
Spinal cerebellar ataxia type 3 1 
Alpha-actin deficiency 1 
Myasthenia gravis 1 
Systemic lupus erythematosus with cerebral 
involvement 
1 
Epilepsy 1 
Post-traumatic epilepsy, migraine 1 
Total 74 
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Table four: Baseline demographics according to the disease group of patients 
attending PTNS (n=74). 
 
Variable Overall 
N=74 
Idiopaths 
N=25 
Neuropathic 
OAB N=49 
P-value 
Gender; n male (%) 22 (29.7%) 6 (24.0%) 16 (32.7%) 0.74 
Age; mean (SD) 56.0 (16.1) 58.3 (17.1) 53.7 (15.1) 0.65 
ICIQ-OAB total score;  
mean (SD) 
40.4 (9.8) 41.1 (11.6) 40.2 (8.9) 0.91 
ICIQ-LUTSqol total 
score;  
Mean (SD) 
187.3 (51.3) 186.9 (53.0) 187.6 (49.5) 0.97 
24h bladder freq (BD) 
score;  
Mean (SD) 
11.7 (3.9) 12.6 (4.1) 10.8 (3.8) 0.39 
Mean bladder urge (BD) 
score;  
Mean (SD) 
2.5 (1.0) 2.6 (1.3) 2.3 (0.9) 0.30 
Mean no. leakages (BD);  
mean (SD) 
3.3 (4.9) 3.5 (5.9) 3 (3.8) 0.57 
Bladder leakage severity 
(BD);  
mean (SD) 
0.9 (0.9) 0.8 (0.9) 1.0 (0.8) 0.72 
 
MS: Multiple Sclerosis 
BD: Bladder diary 
Values expressed as mean (SD) 
Mean bladder urge: 0; nil, 1;mild, 2; moderate, 3; severe urge 
Bladder leakage severity; 0; mild, 1; moderate, 2; severe leakage severity 
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The table above shows no significant differences for the baseline parameters between the 
three patient groups. P-values compare the symptom scores at baseline for each disease 
group. 
 
 
Table five: Shows the comparison of the mean sub-scores for individual domains on the 
ICIQ-OAB and ICIQ-LUTSqol at baseline. 
  
Parameter Overall Idiopathic OAB Neuropathic 
OAB 
Range 
Mean Urge 
(ICIQ-OAB 
subscore) (SD) 
2.7 (0.9) 2.8 (0.9) 2.7 (0.9) 0: never 
1: occasionally 
2: sometimes 
3: most of the time 
4: all of the time 
Mean Urge 
leakage (ICIQ-
OAB) (SD) 
2.3 (1.1) 2.5 (1.3) 2.3 (1.0) 
 
0: never 
1: occasionally 
2: sometimes 
3: most of the time 
4: all of the time 
Mean Frequency 
(ICIQ-OAB) 
(SD) 
1.9 (1.2) 1.8 (1.2) 2.0 (1.3) 0: 1 to 6 times 
1: 7 to 8 times 
2: 9 to 10 times 
3: 11 to 12 times 
4: 13 or more times 
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Mean Nocturia 
(ICIQ-OAB) 
(SD) 
2.6 (1.1) 2.8 (1.1) 2.5 (1.1) 0: none 
1: one 
2: two 
3: three 
4: four or more 
ICIQ-OAB A; 
mean (SD) 
9.6 (2.5) 10.1 (2.9) 9.3 (2.3) 0-16 
ICIQ-OAB B; 
mean (SD) 
30.6 (8.2) 30.9 (9.4) 30.5 (7.8) 0-40 
OAB Symptoms 
(ICIQ-OAB 
total A+B); 
mean (SD) 
40.4 (9.8) 41.1 (11.6) 40.1 (9.0) 0-56 
ICIQ-LUTSqol 
A; mean (SD) 
56.6 (11.0) 56.6 (11.1) 56.6 (11.1) 0-76 
ICIQ-LUTSqol 
B; mean (SD) 
130.2 (41.8) 130.3 (43.2) 130.2 (41.8) 0-200 
ICIQ-LUTSqol 
total (A+B); 
mean (SD) 
186.9 (48.5) 186.9 (53.0) 186.9 (47.1) 0-276 
 
ICIQ question format [66] 
A: assesses the presence or absence of a symptom and its severity 
B: is a separate scale to assess associated bother 
BD: bladder diary  
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SD: Standard deviation 
 
 
 
For all patients combined, significant improvements were noted after 12 weeks of treatment 
with mean decrease in total ICIQ-OAB scores of -5.1 (SD: 10.4) (p=0.003), total ICIQ-
LUTSqol scores -22.4 (SD: 44.3) (p=0.001), and reduced bladder diary parameters of 24-
hour urinary frequency -1.2 (SD: 2.2) (p=0.001), number of incontinence episodes -0.4 (SD: 
1.9) (p=0.16) and severity -0.2 (SD: 0.4) (p=0.004) of incontinent episodes. P values have 
been calculated using paired ttests. This is shown in table six below. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table six: The mean change in the measured parameters from baseline to 12 weeks for 
all patients. 
 
Variable N Mean baseline 
level (SD)* 
Mean week 12 
level (SD) 
Mean change 
from baseline to 
week 12 (SD) 
P-value 
OAB symptoms (ICIQ-OAB)  
Quality of life (ICIQ-LUTSqoL) 
24h frequency (BD) 
Urge (BD) 
Number of incontinent episodes 
(BD) 
Incontinence severity (BD) 
43 
46 
39 
40 
37 
38 
40 (9.7) 
188.5 (47.9) 
11.6 (3.8) 
2.5 (1.0) 
3.3 (4.6) 
0.9 (0.8) 
34.9 (13.2) 
166.1 (58.9) 
10.3 (3.7) 
2.3 (1.0) 
2.9 (4.5) 
0.7 (0.8) 
-5.1 (10.4) 
-22.4 (44.3) 
-1.2 (2.2) 
-0.2 (0.8) 
-0.4 (1.9) 
-0.2 (0.4) 
0.003 
0.001 
0.001 
0.16 
0.16 
0.004 
* Only including individuals with follow up values available 
 
BD: Bladder Diary 
ICIQ: International consultation on incontinence questionnaire 
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Table seven: Absolute changes in key factors: overall and according to disease 
group. 
 
Variable Overall 
N=74 
Idiopaths 
N=25 
All 
neuropathic 
OAB 
N=49 
MS 
N=19 
Other 
Neurological 
conditions 
N=30 
P-value 
ICIQ-OAB total 
difference; median 
(IQR) 
-4.8 (-14.2, 3) 
 
-5.5 (-19, 
3.5) 
-4 (-9.3, 2.5)  -7 (-11, -1) -1 (-7.5, 6) 0.19 
ICIQ-LUTSqol total 
difference; median 
(IQR) 
-25 (-57, 11.4) 
 
-16 (-62, 18) -34 (-53, 4.8) -57 (-79, 3) -11 (-27, 6.5) 0.35 
24h bladder freq 
Difference (BD); 
median (IQR) 
-1.3 (-3.3, 0.4) 
 
-1.7 (-3.7, 
0.3) 
-0.85 (-2.8, 
0.4) 
-1.7 (-3, 0) 0 (-2.5, 0.7) 0.50 
Mean bladder urge 
difference (BD); median 
(IQR) 
-0.2 (-0.8, 0.2) 
 
-0.3 (-1.1, 
0.1) 
0 (-0.4, 0.2) 0 (-0.5, 
0.1) 
0 (-0.3, 0.3) 0.35 
Mean no. leakages 
difference; median 
(IQR) 
-0.5 (-2, 0.1) 
 
-0.7 (-3, 0) -0.2 (-1, 0.2) 0 (-0.7, 0) -0.3 (-1.3, 
0.3) 
0.36 
Bladder leakage 
severity difference; 
median (IQR) 
-0.1 (-0.3, 0.1) 0 (-0.2, 0) -0.2 (-5.5, 
0.1) 
-0.4 (-0.8, 
0) 
0 (-0.3, 0.1) 0.09 
 
BD: Bladder diary 
IQR: Inter-quartile range 
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Table seven above shows the absolute changes for the ICIQ questionnaires or bladder diary 
parameters. The improvement in symptoms were not significantly different between the three 
individual groups by 12 weeks suggesting the treatment was as efficacious in each patient 
group. There was a trend for the MS group to improve more than the other neuropathic 
patients, from the change in ICIQ-OAB and ICIQ-LUTSqol scores. 
For percentage improvements, all patients combined (both idiopathic and neuropathic OAB), 
regarding the ICIQ-OAB subscores, there was a 27 % improvement in urgency and frequency 
at 12 weeks compared to baseline, 20.8 % improvement in nocturia, and 24 % improvement 
in the total ICIQ-OAB, whilst there was a 21.5 % improvement in the total ICIQ-LUTSqol 
score.  
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Continuation of treatment with top-ups 
After the first twenty patients had completed 12-weeks of treatment, we included the patient 
satisfaction survey, which included the question whether patients would opt to continue for 
top-up therapy. Thirty-five out of fifty three patients (66 %), opted to continue treatment after 
completing 12-weeks. Twenty-four out of fifty-three patients actually returned (45%) and 
eight had idiopathic OAB, and 16 neuropathic OAB.  The mean top-up interval was 44.4 days 
(7-155 days), with a mean top up frequency of 1.1top ups/month. It has been described in the 
literature that once PTNS treatment has stopped, symptoms regress. It is not clear when they 
regress and but some studies have reported recurrence at 6-weeks to 3-months post end of 
treatment [52, 54]. This study correlates with the literature and maintenance treatment is 
clearly necessary for continued benefit.  
 
Patients reporting less of an improvement in ICIQ-LUTSqol, ICIQ-OAB, and less 
improvement in leakage severity had significantly lower odds of returning for top-up therapy. 
MS patients were 2.92 (95% CI: 0.85, 10.09) times more likely to return back for top ups 
(p=0.01) compared to those with other neurological diagnoses. 
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Table eight: Logistic regression analysis investigating the relationship between baseline 
factors and changes in key variables and returning for top-ups.  
 
There were a total of 24/53 (45%) people who came back for topups. An Odds ratio of >1 
suggests a patient is more likely to return for a top-up with an improvement in this parameter. 
Any factor with a value of <1 means they are less likely to return for a top-up. 
 
 Unadjusted Analysis Adjusted Analysis 
Variable Odds ratio 
(95% CI) 
P-value Odds ratio 
(95% CI) 
P-value 
Diagnosis; 
Idiopathic 
MS 
Other Neuro 
 
Ref 
2.92 (0.85, 10.09) 
0.43 (0.12, 1.52) 
0.01  
Ref 
10.90 (0.43, 274.63) 
0.19 (0.03, 1.18) 
0.04 
Age;  
(per 5 year increase) 
0.91 (0.78, 1.06) 0.22 - - 
Gender;  
(female versus male) 
1.04 (0.36, 3.03) 0.94 - - 
Baseline ICIQ-OAB;  
(per 1 unit increase) 
1.00 (0.99, 1.01) 0.95 - - 
Baseline ICIQ-LUTSqol;  
(per 1 unit increase) 
0.86 (0.73, 1.02) 0.09 - - 
Baseline 24h bladder freq;  
(per 1 unit increase) 
1.03 (0.76, 1.40) 0.83 - - 
Baseline mean bladder urge; 
(per 1 unit increase) 
1.00 (0.56, 1.79) 0.99 - - 
Baseline mean no leakages; 
(per 1 unit increase) 
0.93 (0.80, 1.09) 0.38 - - 
Baseline leakage severity;  
(per 1 unit increase) 
1.22 (0.57, 2.57) 0.61 - - 
ICIQ-OAB change;  
(per 1 unit increase) 
0.93 (0.87, 0.99) 0.03 1.01 (0.90, 1.12) 0.86 
ICIQ-LUTSqol change;  
(per 1 unit increase) 
0.98 (0.96, 0.99) 0.007 0.96 (0.94, 0.99) 0.02 
24h bladder freq change;  
(per 1 unit increase) 
0.95 (0.71, 1.28) 0.75 - - 
Mean bladder urge change; 
(per 1 unit increase) 
0.38 (0.13, 1.10) 0.07 - - 
Mean no leakages change; (per 0.81 (0.54, 1.21) 0.30 - - 
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1 unit increase) 
Leakage severity change;  
(per 1 unit increase) 
0.93 (0.87, 0.99) 0.03 - - 
 
Satisfaction survey 
Fifty three patients completed the PTNS satisfaction-survey, patients found treatment 
comfortable on a 7-point Likert scale (1-poor 7- high), the mean comfort score was 
5.98±1.15, mean symptom improvement was 3.96± 2.15, mean treatment satisfaction was 
4.36±2.45, mean recommendation to a friend score of 5.71±1.69).   
 
Table nine: Results of the patient satisfaction survey. 
Parameter Satisfaction Score (7-point Likert scale (1-
poor, 7- high)) 
Comfortability of treatment 6.0 
Recommend treatment to a friend 5.7 
Mean symptom improvement 4.0 
 
Adverse effects 
No significant adverse effects were reported. Five patients experienced mild discomfort at the 
site of needle insertion, however this did not affect the compliance to the treatment. 
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DISCUSSION 
PTNS is one of the few neuromodulative techniques that has been studied through a placebo 
controlled, randomised phase III multicentre study. The literature suggests that once the 
stimulation is discontinued, symptoms tend to recur, and that OAB is a chronic syndrome that 
requires long-term or lifelong therapy [68]. Therefore the use of a minimally invasive, cost-
effective form of intermittent stimulation, with efficacious outcomes is highly desirable. 
Compared to the use of BTX-A, the efficacy of which has been proven in numerous high 
volume, multicentre, double blind, placebo controlled, randomised trials, demonstrating the 
level I evidence for its use, the data on PTNS is significantly lacking. The evidence is lacking 
for patients with neuropathic OAB, in particular patients with MS, where there may be 
disease specific factors that make the OAB symptoms more aggressive and resistant to 
treatment.  
OAB symptoms in these patients themselves can also exacerbate fatigue, spasticity, disability 
and mental health that possibly increases the impact of OAB and incontinence on QOL, that 
justifies considering these patients as a separate entity to those with idiopathic OAB.   
 
This is one of the few studies to examine the use of PTNS in patients with neurological 
diseases, with only four previous studies reporting results in patients with MS [51, 55-57], 
and the first to compare response with patients with idiopathic OAB. At baseline this patient 
cohort was comparable to those patients included in the SuMIT Study, with moderate OAB, 
with a 24 hour urinary frequency at 12.6 and 12.4, number of daily incontinence episodes at 
3.2 and 3 respectively.  
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For all patients in this study grouped together, significant improvements were seen for 
daytime frequency and the ICIQ-OAB and ICIQ-LUTSqol scores, of -1.2 (p=0.001), -5.1 
(p=0.003) and -22.4 (p=0.001) respectively.  
 
Using a subjective question at the end of 12-weeks of treatment, patients were asked if they 
would like to continue with treatment. Thirty-five out of fifty three patients (66%) answered 
they would be keen to continue with treatment, however only 24 (45%) of the patients 
actually returned for further top up treatments. The reason for this is unknown, however 
many patients were travelling far distances to reach the hospital and this is especially difficult 
for those with poor mobility, and reliant on patient transport to attend appointments. 
 
Although these are small numbers, it appears that there was a trend for the absolute 
improvements in ICIQ-OAB and ICIQ-LUTSqol to be more evident in the patients with MS 
compared to the other neuropathic or idiopathic group, however this was not to significance. 
Furthermore patients with MS were significantly more likely to request further top-up 
treatment. This requires further investigation in a larger study with a higher volume of 
patients. This may reflect the difference in the underlying disease process between these two 
groups. Perhaps the interrupted neural pathways that occur in MS may be more responsive to 
the sacral afferent remodeling that occurs with PTNS. It is also possible that patients with 
idiopathic OAB have a more severe or alternative pathology that is less correctable through 
the mode of action of PTNS. Furthermore it may be that MS patients have less treatment 
expectation, due to the numerous co-morbidities that they face with their condition [69].  
Baseline clinical scores were not able to predict from this cohort which patients were more 
likely to attend for top-up therapy. However patient performance and the response to the first 
12-weeks of treatment can predict those who will return for continuation treatment. 
 
 
 
 
Study Limitations 
Ten patients (13.5%) were lost to follow up and did not complete the 12-weeks of PTNS 
treatment. It is unknown whether this was due to lack of efficacy or adverse effects of the 
treatment. 
BD parameters did not change significantly such as the mean and maximum voided volume. 
There is a lack of evidence for the precision of bladder diaries and they continue to be used as 
an outcome measure in clinical studies of incontinence. They can be difficult to complete for 
patients due to the inconvenience of having to measure every single void and record every 
urge, leakage and volume of fluid that is consumed. From patient feedback some found the 
BD particularly difficult to adhere to during weekdays due to the lack of discretion available 
at the workplace and having to carry a measuring jug for frequent toilet visits, leading to poor 
diary compliance. Other patients have difficulties with memory and as a result forget to 
complete voiding episodes, especially at night. Those who reserve capturing BD visits for the 
weekend only, also have inherent inaccuracies as patients when at home on weekend have 
different drinking habits to when they have to leave the house during the working week, and 
may therefore not be a true reflection of the working week when symptoms are more 
problematic. For future studies, portable electronic bladder diaries have been shown to 
potentially be superior to paper diaries, as patients are able to input data in real-time and 
found these easy to use [70]. Although this still requires further investigation, it may provide 
a superior alternative to accurately witness to the daily bladder behaviour.  
 
 
The evaluation is limited to the 12-weeks of therapy, and therefore follow up was not studied.   
For a true representation of clinical efficacy, patients will be followed up for another 12-
months to capture the top up process. Very little information is known about the long-term 
efficacy of repeated treatments. Macdiarmid reported on thirty-three patients from the 
Overactive Bladder Innovative Therapy Trial who were offered to complete 12-months worth 
of PTNS [68]. Subjects received a mean of 12.1 treatments each, with a mean of 21-days 
between treatments. This showed that 94 and 96% of responders had sustained benefit at 6 
and 12-months respectively. At end of study, 12-months, there were reported mean 
improvements in bladder diary parameters, increased voided volumes compared to baseline 
assessments, and a significantly improved OAB symptom severity score compared to 
baseline, 12-weeks and 6-months. This suggests that PTNS can sustain its durability through 
a 12-month period. 
The STEP study identified that at least 75% of the patients who had a positive response to the 
first 12-weeks of therapy, went on to have sustained symptom improvements for up to three 
years with an average top up treatment of one per month [71].  
 
The assessment tools used were largely subjective and focused on PRO measures. From the 
literature, the definitions of successful PTNS treatment have differed amongst the various 
authors, and therefore more difficult to compare studies. There currently is a lack of formal 
guidance to judge OAB treatment response. A systematic-review examined 75 clinical trials 
that evaluated behavioural, medical or neural stimulation treatments for OAB [72]. 
Considerable heterogeneity was evident between these studies. Some authors used percentage 
improvements regarding a threshold of 50-100% as a response, whilst others used absolute 
changes in symptom frequency, or PROs that measured general satisfaction or symptom 
bother. There was also heterogeneity among patients for what constitutes a treatment success 
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or failure. PROs are important however as they can demonstrate whether an observed change 
is clinically meaningful to the patient. 
 
Cystometry was not performed on patients after starting treatment to ascertain objective 
changes objective in urodynamic parameters, however the experience from the literature is 
that whether DO appears to diminish or not, urodynamic parameters may not necessarily 
correlate with clinical findings. The role of urodynamics prior to recruitment for this 
treatment is unclear, however it has been shown that patients not showing DO at baseline 
seem to be more likely to respond to treatment [47]. Clinical and quality of life parameters 
are arguably the more relevant endpoints to study. Without urodynamic data, it is also harder 
therefore to describe the severity of the pathology and whether patients had high pressure DO 
or DSD, which may make their condition more refractory to treatment. 
 
Since there was no sham treatment offered, positive results could be argued to be from 
placebo effect. The study design was a prospective clinical evaluation of PTNS for a series of 
patients with heterogenous pathology, all suffering from refractory OAB symptoms. Attempts 
were made to exclude the synchronous effects of other adjunct treatments such as 
physiotherapy and antimuscarinics, which were not used during the study due to potential 
confounding. In the placebo controlled studies, the response rate of the placebo arm of 20.9% 
[40] is much lower than this response rate of 66%. Also with the chronicity of the symptoms 
experienced by these patients, who had all failed previous therapies before trying PTNS, it is 
possibly less likely that they would have a profound placebo effect. However to validate this 
data properly with this group of patients a placebo controlled study is warranted.  
 
 
One of the disadvantages of PTNS is the need for repeated insertion of the stimulation 
electrode and regular outpatient visits, which will have to involve long-term compliance for 
sustained clinical efficacy. This may affect patient suitability as some patients may find the 
weekly trips very difficult, especially if they have poor mobility and need to travel long 
distances.  
Despite these limitations, these results are in line with previous studies examining the 
efficacy of PTNS in non-neuropathic patients. Although there were still relatively small 
numbers of patients in this study, the use of a validated questionnaire should allow 
comparison of these results with others. Compared to the SUmiT trial, from which 54.5% of 
patients self-reported moderate to markedly improved symtoms, this study has shown 45% of 
patients who felt that improvement was significant enough to warrant attendance for further 
continuation therapy.  
Results from a systematic review evaluating PTNS for the OAB suggested that 54-79% of 
patients are ‘successfully treated’ [73]. Once again the definition of success varied among 
these studies from the use of urodynamic data to clinical and QOL measures. 
 
Compared to the adherence to antimuscarinic therapy, which has been estimated to be at 
40%-58%, and 17%-35% at 6 and 12 months respectively [74], this study shows that PTNS 
may perform favourably, with 45% of patients willing to continue with therapy at 3 months. 
The efficacy of PTNS compared with antimuscarinic therapy has already been demonstrated 
to be equivalent from the OrBIT Study [42]. 
 
There was a minimal adverse effect profile in this study with five patients complaining of 
mild discomfort at the needle insertion site, however this did not affect their compliance to 
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therapy. This correlates with the previous literature where no major complications have been 
reported [73].  
 
These results re-confirm the safety of PTNS as a treatment option, and this may represent a 
reliable form of 2nd line management for patients who fail to respond to OAB medications. 
There were no serious adverse events with this treatment, and only mild discomfort with the 
treatment, with most patients regarding this as a highly comfortable and convenient 
treatment. With regards to cost-effectiveness, a report by Martinson et al disclosed that the 
projected three-year costs for the following treatments are $7,565 for PTNS, $11,748 for 
onabotulinumtoxinA, $16,830 for augmentation cystoplasty and $24,681 for SNS [29]. This 
is another reason why PTNS should be studied further to judge its efficacy, as it may perform 
more favourably in a National Health Service model for care provision. There is evidence to 
suggest that combination treatment of the use of anticholinergics concomitantly with PTNS 
offers even further efficacy in patients with idiopathic DO [45]. This also needs to be studied 
in a neuropathic population.   
 
As with other medical therapies, it is recognised that for sustained symptom benefit, the 
treatment needs to be continued. There is no one-off definitive treatment or cure for the OAB. 
Behavioural modifications, antimuscarinic therapies, SNM, onabotulinumtoxinA all need 
require repeated treatments, and PTNS is no exception. It seems appropriate to allow patients 
to recognize any deterioration in their symptoms to guide them when to plan the next top-up 
treatment. No standardized long-term protocol has been established as yet, and currently it is 
being personalized and tailored to the needs of each individual patient.  
 
Future studies 
 
There is clearly a place for PTNS in the management ladder for OAB, although investigation 
does need to take such as how to best define a responder or a treatment success with this 
treatment.  
Is there a role for combination therapies alongside antimuscarinic agents or the emerging 
beta-agonist medications? It could be argued that PTNS could be offered to patients before 
antimuscarinic use due to the unwanted side effects of these medications. Head to head 
studies of PTNS versus SNS could be conducted, as PTNS is emerging to be the more 
economical and least invasive form of therapy.  
Other forms of Tibial Nerve Stimulation are also being developed, such as transcutaneous 
tibial nerve stimulation. The evidence for this is in its infancy and the European Urology 
Guidelines on incontinence report the evidence for this is lacking and is required. This would 
address the few disadvantages that PTNS entails, such as the need for repeated visits, and the 
discomfort with the needle placement, and if its efficacy is proven, it could offer an even 
more convenient management option [31, 75]. 
The role of a prognostic marker would be of use to identify patients who are most likely to do 
well from this treatment before starting a 12-week course of therapy. PTNS may be more 
suited to those patients with mild to moderate symptoms, compared to those with a moderate 
to severe burden. This requires further investigation, along with a prolonged period of follow 
up of patients to assess the long-term clinical efficacy. 
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CONCLUSION 
Objective and subjective findings suggest that PTNS was effective for patients with 
neuropathic OAB and comaparable to idiopatic OAB.  Thirty-five out of fifty-three patients, 
after 12-weeks of therapy, were keen to pursue further top up treatments. The patients with 
neuropathic OAB secondary to MS were significantly more likely to attend for top-up 
therapy. This confirms the efficacy of this form of treatment in a diverse group of patients 
with a heterogenous mix of disease aetiology. 
PTNS is a promising treatment alternative for neuropathic patients with OAB, especially MS, 
and as time goes on, efforts could be to optimise the efficiency of electrical delivery to 
further improve efficacy.  
Further multicentre study is required in a larger volume of patients to also investigate 
prognostic predictors of success, and the role of combination therapies. 
PTNS is a well-tolerated, minimally invasive, readily applicable therapy with a minimal 
adverse profile compared to the alternatives of antimuscarinic therapy, BTX-A and SNM. 
This prospective study supports the data that was reported in the SUmiT study. This would 
therefore make it a much more acceptable treatment to patients. 
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CHAPTER TWO 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter Synopsis 
Chapter two explores further the challenge raised in Chapter one regarding the need for an 
objective assessment tool for the OAB, especially for patients with neurological conditions 
who may have significant lower urinary tract dysfunction, with altered bladder sensation and 
motor function. Patient reporting outcomes (PRO) are an important part of the assessment, 
however there are inherent inaccuracies using this form of evaluation alone. Patient 
symptoms may not reflect the true severity of the disease process, and may also be influenced 
by placebo effect. An accurate urinary biomarker for the OAB would be easy to collect and 
greatly beneficial for patients: 
• to assist diagnosis, to guide treatment choice  
• to objectively monitor and quantify responses to treatment (to help define a treatment 
responder)  
• to research and evaluate the mechanism of action of various treatments (especially 
new treatments such as PTNS)  
• to identify any placebo effect with new treatments 
• to predict response to treatment 
• to inform clinician and patient regarding the disease prognosis  
• to highlight the patients at higher risk of poor bladder compliance and unsafe detrusor 
pressures.  
The urinary biomarkers that are currently being evaluated in practice are the neurotrophins. 
These have been explored by numerous studies recently with growing interest, and the aim of 
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this chapter is to perform a literature review of the two main urinary neurotrophins, known as 
Nerve Growth Factor and Brain Derived Neurotrophic Factor (NGF and BDNF) as 
biomarkers for the OAB. 
 
A review of Urinary Neurotrophins as a biomarker for Overactive Bladder 
 
INTRODUCTION 
Subjective and Objective markers for assessment of the Overactive Bladder 
The European Association of Urology guidelines recommend that accurate assessment of 
patient’s symptoms require subjective and objective quantification of LUTS [31]. As 
discussed in the previous chapters, objective assessment tools can also be of use to evaluate 
the efficacy of a particular treatment, and to compare therapies with each other. 
The well known phrase ‘the bladder is an unreliable witness’ still rings true today [76, 77]. 
Whilst the range of urodynamic dysfunction is large, the types of bladder symptom that can 
manifest are limited, to either storage or voiding LUTS. Therefore it remains difficult to 
assign symptoms to a particular disease process. For example, poor detrusor contractility may 
manifest with the same symptoms as bladder outlet obstruction such as hesitancy, urinary 
frequency, reduced urinary flow and sensations of incomplete bladder emptying. Despite a 
careful history, patients may interpret their own experiences differently and clinician’s may 
be biased with interpreting their answers [78].  
 
Questionnaires – Patient Reported Outcomes  
The questionnaires used to assess symptoms and the impact on QOL, are a form of patient 
reported outcome (PRO), as the outcome originates directly from the patient, without 
interpretation by clinicians or anyone else. The aim of the PRO is to accurately assess how a 
 
patient feels in relation to a disease or treatment.  It was considered that subjective 
assessments can provide valuable information on aspects of disease that impact most on the 
patient’s life and are most bothersome. Health related QOL outcomes area particularly 
valuable for chronic conditions, where the bother and distress can affect daily function [79]. 
PRO measures are therefore promoted for clinical trials and clinical practice. In addition, the 
more objective measures such as bladder diary variables and urodynamic parameters may not 
be so strongly associated with improvements in subjective measures such as treatment 
benefit, symptom bother and patient satisfaction [80]. If a treatment provides reductions in 
frequency, urgency and urge incontinence, yet these do not improve the health related QOL, 
whether the treatment can be considered clinically effective remains questioned. Patients 
must be able to perceive an improvement in well-being and daily functioning using a valid 
PRO measure.  
Up until the development of the ICIQ modular questionnaires, there was a lack of 
standardisation of the multiple PRO assessments available [81]. Many of the PRO 
instruments were for patients with urinary incontinence, and few designed for those with 
OAB [82]. The decision to construct the modular ICIQ questionnaire took place after the first 
ICI meeting in 1998. 
 
Questionnaires have been used for some time to attempt quantification of disease severity, 
assess symptoms, document response to therapy, and to compare effectiveness of various 
interventions. However these are not perfect tools, and LUTS have been notoriously difficult 
to accurately capture with them.  
Symptoms including urinary incontinence, may be interpreted as severe by a questionnaire, 
however the tool may not clearly extract the extent to which it can impair an individuals 
quality of life. For example the QOL implications for a groups of patients scoring the sample 
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symptom questionnaire score may widely differ. Patient understanding may also affect the 
way they interpret questions, each in an individual manner, and their answers can also be 
affected by recall bias. Perceptions of urinary urgency especially can be difficult to 
standardize, and yet this is a pivotal symptom that underpins the OAB [82].  
A questionnaire that is comprehensive, yet not lengthy is an issue that developers are often 
faced with [83]. However on the other hand, simplicity and brevity can risk lack of sensitivity 
and loss of qualitative description.   
Likewise questionnaires such as the International Prostate Symptom Score, designed for a 
particular group of patients may not necessarily transfer for a similar situation in a different 
population, such as assessing men and women, or evaluating patients with idiopathic OAB 
and neurogenic OAB [84]. The former group of patients being distinct from the latter who 
may have a deficit of afferent nerve function and hence altered bladder sensations or may 
even be self-catheterising.  
 
Responses to various treatments should be captured with a PRO, and represent not only a 
measurable change, but also one that is meaningful to the patient. This is known as the 
minimal important difference. Changes can be statistically significant, but this may not imply 
a meaningful difference to the patient [82]. 
 
Patient perceptions are another consideration as these are shaped by a number of factors such 
as age, sex, ethnicity, their family or caregiver’s perceptions and these can in turn affect 
treatment expectations and consequently impact treatment outcomes [79]. Their experience 
with previous illnesses such as multiple sclerosis can influence their perception of symptom 
impact on QOL and treatment expectations. Expectation can affect treatment outcomes, and 
are therefore thought to be the basis for the placebo effect. This can motivate and 
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psychologically condition a patient to observe certain symptoms and ignore others [85]. Little 
is known about the expectation of OAB treatment and PRO measures, but evidence suggests 
realistic expectations are important for treatment satisfaction. 
 
Bladder diaries 
Bladder diaries (BD) are an integral aspect of the assessment with OAB, and their use 
recommended by the EAU [31]. They can record the day and night frequency of urinary 
episodes, the volumes voided, note the frequency and severity of urgency and incontinence 
episodes, and provide information about fluid intake.   
However BDs are not as yet validated for use in the clinical or research setting, as with PRO 
symptom questionnaires. Only most recently has a validated format has been reported [86]. 
BDs can have inaccuracies and although valuable, do not represent a tool that is flawless. 
Bladder diaries can miss the more infrequent symptoms such as urge incontinence if it did not 
occur within that particular three-day period. During the three-day diary collection patients 
are aware that their behaviour is being monitored by a medical team, and may adopt their 
behaviour and habits to prevent the occurrence of incontinence, such as fluid modification, 
and voiding more frequently to prevent the bladder reaching higher capacities. 
Patients may complete these diaries at the end of the day, as it is inconvenient to keep a real-
time record due to work commitments and the practicality of carrying around a measuring 
jug, from which the record may be fraught with inaccuracies due to poor patient recall.  
Measures such as pad usage can be difficult to interpret as a marker of severity of 
incontinence, which is a very subjective symptom. Some patients may change pads when 
only slightly damp, whilst others tolerate a higher volume of leakage.  
Patients may misinterpret nocturia, and wake up at night due to leg cramps or pain or a 
plethora of other reasons and take that opportunity to void and record it, rather than it being 
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the sensation of urgency urinary that wakes them from sleep. 
Due to the inaccuracies of these assessment tools, effort has been invested to develop and 
validate the bladder diary instrument [86] .  
 
Urodynamic Study 
Traditionally it has been recommended that pressure flow studies, are a more objective 
measure, and are important in the evaluation of LUTS if any surgical interventions are being 
considered. The physiological assessment of the lower urinary tract to assess function and 
dysfunction has been used for many years. The different types of urodynamic studies are 
defined in the ICS terminology report [87]. The earlier descriptions of simultaneous pressure 
flow studies with a specific reference to urge incontinence was made in 1971 [88], however 
the earliest descriptions of this technique being simulated leads back to 1882 using a smoked-
drum and a water manometer [89]. 
This study is an essential adjunct for patient assessment and especially for patients with 
neurological disease where this can be a part of ongoing urological evaluation. It is the only 
way to objectively assess lower urinary tract function in patients with incontinence. There are 
well-documented methods to standardize how this test is performed to ensure reliability and 
reproducibility [90].  
However questions remain regarding its role, predictive value, and effect on treatment 
outcomes [90]. Studies have shown that urodynamic studies do not perfectly predict the 
outcome of relevant treatment in all patients such as those with DO. The ICS recommends 
that large multicentre prospective research is performed to also evaluate its cost effectiveness.  
It has been shown in a study that urodynamic evaluation of symptom free adults showed a 
wide range of all urodynamic parameters, some of which could be interpreted to be 
pathological signs. It was concluded that urodynamics are not physiological, but they are the 
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best tests available thus far, and that interpretations should be made with caution [91]. 
The American Urological Association recommend that prior to proceeding with an invasive 
urodynamic study, the clinician must have a clear question and indication for performing the 
test [92]. The invasive nature of urodynamic testing can subject the patient to risks of urinary 
catheterization such as urethral trauma, pain and infection. 
The standard urodynamic study does not replicate real life for the patient. The bladder filling 
is not at a physiological rate, provoking inaccuracies, and the inhibited patient may become 
anxious by being exposed and with the task of voiding amongst medical staff. As a result the 
urodynamic trace is unable to represent real life for the patient, and it may fail to reproduce 
symptoms such as incontinence if the patient is trying to inhibit voiding. The process of 
urethral catherisation can be uncomfortable and the catheter itself can trigger off urgency that 
is not usually experienced by the patient. 
Its invasiveness is not without risk of infection and bleeding for the patient and the cost of the 
study is also a limitation. Furthermore the lack of its availability means not all patients or 
clinicians can access this test. 
 
The need for a biomarker 
Because the OAB is a symptom-defined condition, patients are directly required to evaluate 
treatment response. This should be assessed using validated and reliable PRO instruments. 
However patient’s responses can be influenced by their treatment expectations. Assessing the 
true efficacy of a treatment, does require PRO measures, but accuracy may be even stronger 
if combined with an objective, biological marker that can demonstrate the pathophysiology of 
disease activity. 
Considering the limitations of the above mentioned assessment tools currently used to 
evaluate the LUT, it can be argued there is a clear need for a biomarker. A molecule that is 
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physiologically relevant to the urinary tract, and that upregulates in pathological states could 
be used as a marker for disease activity. This could offer an objective assessment for 
clinicians and patients with diagnosis, prognosis and monitoring response to treatment and 
assist with research into pathophysiology. Such a marker that is easy and non-invasive to 
collect, such as a sample of urine, is highly desirable.  
 
Study Aim  
To review the evidence, and discuss the prospect of the urinary neurotrophins Nerve Growth 
Factor (NGF) and Brain Derived Neurotrophic Factor (BDNF) as potential urinary 
biomarkers for the overactive bladder (OAB).  
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METHODS 
A pubmed literature search was carried out of published peer-reviewed studies that measured 
urinary Nerve Growth Factor or Brain Derived Neurotrophic Factor in patients.  
 
Background 
Biomarkers for OAB – Nerve Growth Factor and Brain Derived Neurotrophic Factor 
In 1950, Nobel prize winners Stanley Cohen and Rita Levi-Montalcini, first discovered and 
explored the role of nerve growth factor (NGF), in the regulation of the developing 
neurological system [93]. Their early work showed that the transfer of mice tumour cells into 
chick embryos, promoted the development of the nervous system, particularly the sensory 
and sympathetic neurones. It was concluded that a growth-promoting substance was being 
released from the tumour cells, which had a selective influence on certain nerves. This 
substance was identified as NGF, which is a small signalling protein, which in the bladder, is 
produced by detrusor smooth muscle cells and by urothelial cells. NGF is now known to be 
necessary to promote the growth and survival of sympathetic fibres and sensory nerves, 
which are both vital for normal bladder functioning [94].  
 
Overactive Bladder pathophysiology 
The overactive bladder (OAB) is a clinical syndrome consisting of urinary urgency, 
frequency with or without urinary incontinence (UI) [95]. The diagnosis of OAB is a clinical 
one, which can be assessed, somewhat subjectively by patient reported symptoms. The 
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symptoms can be severely bothersome and negatively impact health-related quality of life. 
Symptoms of OAB, and in particular those with urgency UI, are also associated with DO, a 
urodynamic diagnosis, which may also be related to raised NGF levels in the lower urinary 
tract [96]. In the healthy bladder, sensory C-fibre activity maintains a quiescent role in the 
sensation of physiological bladder filling, except nearing functional bladder capacity, only 
being activated by distension that is greater than that required to stimulate A fibres [97].  
However, in an OAB, neuronal and non-neuronal release of neurotransmitter substances, 
from the urothelium and suburothelium, have a stimulatory effect on C-fibre activity.  
 
The pathological mechanisms that lead to the OAB and DO are yet to be fully elucidated, 
although increasing evidence supports a central role for the increased excitability and activity 
of the sensory as well as motor bladder pathways [98]. The role of the urothelium is also 
thought to be crucial in the development of OAB [2]. The urothelium and suburothelium are 
innervated by a complex network of sensory afferent nerve endings which serve to initiate the 
micturition reflex and to reinforce the drive that maintains bladder contractions [1]. The 
afferent nerves consist of myelinated A fibres and unmyelinated C-fibres (see figure one) 
[1]. The location of A fibres is largely within the detrusor smooth muscle, which responds to 
detrusor stretch during bladder filling, and provides the sensation of fullness [97]. 
Unmyelinated sensory C-fibres are more widespread, and are found in the suburothelium and 
urothelial mucosa. These have a higher mechanical threshold, and are activated by and 
sensitive to heat, chemical and noxious stimuli [1]. C-fibres are less important in the 
sensation of physiological bladder filling, and may become primarily involved in pathological 
situations [97]. This makes them a stronger candidate to be involved in the pathological 
sensation of urgency [97]. A variety of neural receptors expressed within the superficial 
bladder layers have been identified such as the capsaicin receptor TRPV1, purinergic receptor 
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P2X3, and TrKA [2]. It is thought that the stimulation of urothelium by stretch, inflammation, 
acidity and temperature causes local release of a variety of neuropeptides, including NGF, 
BDNF ATP, substance P (SP), neurokinin A (NKA) and calcitonin gene related peptide 
(CGRP). Some of these have paracrine actions through these receptors, and modulate the 
expression of these receptors and afferent signaling [2]. The proposed urothelial complex of 
sensory signaling pathways are illustrated in figure seven [2]. After a neurological or 
inflammatory insult, it is thought that the C-fibre activity becomes the predominant route 
through which afferent impulses leave the bladder to the spinal tract to initiate the micturition 
reflex [1]. The increased amount of neurotransmitter substance being released by the 
urothelium, results in increased bladder excitability, hypersensitivity and ultimately OAB 
symptoms [1].  
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Figure six [1]: The afferent fibres leave the bladder and travel to the spinal cord with 
the neurotransmitter substances. 
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Figure seven [2]: The proposed complex interaction of afferent receptors and the 
different acting neurotransmitter substances. P2X3/P2Y (purinergic receptors) 
activated by ATP; Suburothelially released SP acts on NK1 (neurokinin receptors) on 
myofibroblasts; Acetylcholine (ACh) acts on M2/M3 (muscarinic receptor on smooth 
detrusor fibres); NGF is thought to affect the expression of urothelial and/or 
suburothelial TRPV1 (transient vanilloid receptor potential 1). 
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Figure eight below shows the close proximity and intimate relationship between the urothelial 
cells, myofibroblasts, and the afferent and efferent nerves [3]. This forms the basic 
mechanosensory unit, which may become overactive with up regulated neural receptors and 
neurotransmitter substances with OAB, NDO, IDO and conditions such as interstitial cystitis.  
 
 
Figure eight [3]: A model illustrating possible chemical interactions between urothelial 
cells, afferent nerves, efferent nerves and myofibroblasts in the urinary bladder. 
Activation of receptors and ion channels in urothelial cells by bladder distension or 
chemical stimuli can release mediators, such as ATP, nitric oxide (NO), neurokinin A 
(NKA), acetylcholine (ACh) and nerve growth factor (NGF), that target adjacent nerves 
or myofibroblasts and might also act in an autocrine or paracrine manner on urothelial 
cells. NGF released from muscle or the urothelium can exert an acute and chronic 
influence on the excitability of sensory nerves through an action on tyrosine kinase A 
(TrkA) receptors. 
 
Role of NGF in OAB pathophysiology 
It is thought that NGF, which is expressed in excess in pathological bladder states, is one of 
these stimulatory substances, and has a knock on affect to sensitise afferent C-fibres, leading 
to sensory urgency, and ultimately reflex bladder hyperactivity, causing urinary frequency 
and urgency UI. The overexpression of NGF has led to the interest in this secretory protein as 
a potential urinary biomarker for the OAB, which represents a considerable health and 
economic burden.  
The proposed role of NGF in the development of LUTD is illustrated in figure nine [4].  
 
 
 
 
 
 
 
 
Figure nine [4]: Provoked NGF release from target cells occurs under certain 
circumstances, which sensitizes afferent nerves, enhances synaptic transmission and 
produces OAB symptoms. 
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Tissue NGF: Animal and Human Studies  
Evidence has been accumulated from numerous animals studies, discussed below, to show 
the importance of NGF in the pathological bladder [99]. A study in cats examining a naturally 
occurring model of feline interstitial cystitis (IC), found an increase in the levels of NGF and 
Substance P in the urothelium, along with an increase in the cell body size of the dorsal root 
ganglia (DRG) when compared with controls. This suggests that the inflamed urothelium may 
be an important source of increased NGF, and also act as a transducer of physical and 
chemical stimuli, by undergoing retrograde transport to DRGs [100]. In rat models of spinal 
cord injury causing neurogenic DO (NDO) or cyclophosphamide-induced cystitis and 
overactivity, levels of NGF have also been found to be increased in the bladder, the DRG and 
the lumbosacral spinal cord [101]. Systemic treatment of rats with this experimental cystitis 
model, with an NGF sequestering molecule, has been shown to reduce the development of 
bladder overactivity [102]. Another study that reported a significant increase in NGF 
production, after cyclophosphamide -induced cystitis in female rats, showed this was also 
associated with a decreased intercontraction interval [103]. Once hyaluronic acid was 
administered intravesically, this significantly reduced the urinary NGF (uNGF) levels and 
increased the intercontraction interval. Furthermore, the application of hyaluronidase, which 
counteracts the action of hyaluronic acid, eliminated the suppressive effect of hyaluronic acid 
on NGF levels [103].  
 
Chronic administration of NGF into the bladder or spinal cord of rats has been shown to 
induce bladder hyperactivity [104]. One study explored the role of NGF by generating 
transgenic mice, and inducing chronic overexpression of NGF in the urothelium. Certain 
characteristics were examined in comparison to wild-type littermate controls [105]. In these 
mice, the overexpression of NGF led to a reduced bladder capacity that exhibited an increase 
 
in the number and amplitude of non-voiding reflex bladder contractions, when compared with 
the controls. There was also marked nerve fibre hyperplasia in the lamina propria and 
detrusor smooth muscle, along with causing elevated numbers of inflammatory cells, e.g. 
tissue mast cells.  
 
Sensory afferent nerves also showed increased density of calcitonin gene-related peptide and 
Substance P containing nerve fibres [105]. These neuropeptides are released in inflammatory 
states, and through their release, NGF may also be implicated in visceral nociception by 
producing hyperalgesia. It is thought that NGF can also modulate the expression of 
membrane ion channels, e.g. P2X3 (purine-receptor), TRPV1 (transient receptor potential 
vanilloid-1), and voltage-gated sodium channels in the bladder, which are thought to play a 
major role in inflammation, tissue-induced pain and hypersensitivity [105].  
 
Another study showed that raised NGF levels can also be related to DO secondary to Bladder 
outflow obstruction (BOO). In this study, 40 rats had a BOO created by partial ligation of the 
urethral outlet, and were shown to develop DO by cystometry. Urine was collected before 
ligation, during the obstructed period and after relief of the obstruction. NGF levels were 
reported to be significantly raised from baseline levels during the period with DO, which then 
decreased back to baseline levels after the DO disappeared after the relief of the BOO.  
In the rats with persistent DO, despite removal of the urethral obstruction, the uNGF levels 
remained significantly raised from baseline and compared with the control rats [106]. 
Another study reported increased mRNA expression of NGF in the bladder in BOO rat 
models associated with DO, and in continued DO after BOO relief [107]. More recently, a 
study reported raised tissue NGF levels, quantified by immunofluorescence staining and 
Western blotting in an unstable BOO rat model, which were then significantly reduced after 
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detrusor onabotulinumtoxinA (BTX-A) injection [108]. It has been shown that once this 
excess quantity of expressed NGF is sequestered, it can reduce the observed bladder 
dysfunction. After spinal cord injury in rats, the resulting DO and detrusor-sphincter 
dyssynergia can be suppressed by intrathecal application of NGF antibodies, which 
neutralises the NGF in the spinal cord [109, 110]. This sequestration of NGF produces effects 
similar to treatments, e.g. resiniferatoxin or capsaicin, which desensitise C-fibre afferents.  
 
Similarly to the studies in animals, which prove that NGF plays an important role in bladder 
dysfunction, human studies have corroborated this. One study that quantified human bladder 
tissue levels of NGF using tissue enzyme-linked immunosorbent assay (ELISA) techniques, 
collected bladder biopsies before and at one and three months after detrusor BTX-A injection 
in patients with NDO [111]. As the urodynamic parameters improved over this time frame, 
the tissue NGF levels were also noted to decrease significantly. This suggests that BTX-A 
may decrease the levels of neurotransmitters, which may otherwise stimulate NGF production 
and release. In bladder biopsies from patients with IC/painful bladder syndrome (IC/PBS), an 
increased expression of NGF mRNA has been reported, which falls 2 weeks after successful 
intravesical injection with BTX-A. This corresponded with a decrease in pain scores [112, 
113]. However, NGF mRNA levels were not reduced in non-responders with persistent pain 
after BTX-A. Interestingly, decreased NGF mRNA levels correlated with decreases in pain 
scores, but not with changes in maximum bladder capacity, which suggests NGF may 
contribute more to pain perception, and increased afferent excitability. This is supported by 
the action of NGF on TrkA (neurotrophic tyrosine kinase receptor type A) receptors, via 
which it further mediates the release of Substance P, which is implicated in inflammatory 
responses and nociception [114].  
 
 
Urinary NGF a Potential Biomarker for OAB/DO?  
The accumulation of the above findings have led to the evaluation of urinary levels of NGF as 
a potential biomarker and as a simple, cost-effective method to objectively diagnose, and 
assess therapeutic outcomes in patients with OAB [4]. Such a tool may also be of use as a 
prognostic indicator and provide information about which patients may respond better to 
certain treatments.  
A biomarker should be ‘a characteristic that is objectively measured and evaluated as an 
indicator of normal biological or pathogenic processes, or pharmacological responses to a 
therapeutic intervention’. A suitable biomarker needs to be easily accessible, reliable, and as 
a test repeatable, whilst offering high specificity and sensitivity to diagnose and monitor 
OAB. There should be a relationship with the severity of OAB. Furthermore it must provide 
information that is not already available from the clinical assessment, improve the outcome of 
the disease, and predict responses to specific therapies. The cost and time aspect of the test 
should be acceptable, and ultimately save costs by avoiding unnecessary therapies [115].  
The levels of NGF in the urine can be quantified using an ELISA system, with most studies 
reporting results from the same kit (Emax, Promega, Madison, WI, USA) for reproducibility. 
The antibodies that come within this kit have not specifically been developed or marketed for 
measurement in the urine, and are only being used within a research domain. The technique 
uses a sandwich ELISA assay, using a polyclonal antibody to NGF to initially coat a well, 
and after incubation with the patient sample, a second monoclonal antibody is then used to 
sandwich the molecule, between the two antibodies. A tertiary species-specific antibody is 
then used, which is conjugated with horseradish peroxidase, which is then incubated with a 
chromogen, to induce a colour change, the intensity of which is proportional to the 
concentration of the substrate within the well. The total uNGF level is normalised to the 
concentration of urinary creatinine (Cr), to overcome the differing dilutions of urine between 
 
patients. Other NGF ELISA kits are available and a validation and standardisation between 
these different kits needs to be performed to check reproducibility.  
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Table ten: Summary of all the published studies that have measured urinary NGF 
(uNGF) levels in patients with various bladder dysfunctions.  
 
Author and 
Year 
Conditions investigated 
and sample sizes  
Conclusions 
Chan et al, 2014 
[116] 
10 females with bladder 
outflow obstruction 
(BOO), with a peak flow 
of 12ml/s, and a history 
of pelvic organ prolapse 
or previous incontinence 
surgery. Control group of 
10 asymptomatic women. 
uNGF/Cr levels were significantly higher in the 
patients with BOO (mean [SE] 20.8 [4.31] pg/mg) 
compared to age-matched control group (5.6 [0.65] 
pg/mg). After treatment, the urinary NGF/Cr level 
significantly decreased to 6.50 (0.57) pg/mg (P = 
0.01).  
Liss et al, 2014 
[117] 
Urine collected from 115 
men before radical 
prostatectomy. 
Increasing Log10 uNGF/Cr was associated with a 
higher gleason score 8, p=0.003. Perineural 
invasion was more prevalent in this higher grade 
disease group. This study concluded that uNGF 
could be a marker for higher grade prostate cancers. 
Aydogmus et al, 
2014 [118] 
90 female patients with 
OAB-dry, randomized 
into either acupuncture, 
solifenacin or placebo 
arms. The number of 
patients that completed 
each arm of therapy were 
Significant clinical QOL improvement with medical 
and acupuncture arms compared with placebo. 
Mean uNGF/Cr levels significantly improved with 
acupuncture and solifenacin arms after treatment 
compared with placebo. 
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28, 30 and 24 
respectively. 
Shalom et al 
(2014) [119] 
23 patients with 
refractory OAB and DO 
before and 5 days after a 
trial of peripheral nerve 
evaluation (PNE) for 
sacral nerve stimulation 
and 22 controls. 
Subjects with DO had significantly higher baseline 
uNGF/Cr levels compared with controls (19.8pg/mg 
vs 7.88 pg/mg, p<0.002). 17 patients had PNE and 
significant improvement in symptom questionnaires 
were seen with this and uNGF/Cr levels were also 
demonstrated to significantly decrease (17.23 
pg/mg to 9.2 pg/mg, p<0.02). 
Antunes-Lopes et 
al (2013) [120] 
Females with OAB (37) 
and healthy controls (40) 
uNGF/Cr and uBDNF/Cr (Brain-derived 
Neurotrophic Factor) were significantly higher in 
OAB than healthy controls. These levels decreased 
after anti-muscarinic treatment. No significantly 
raised urinary glial cell-line derived neurotrophic 
factor/Cr in OAB compared with controls. 
Reduction in number of urgency episodes per week 
correlated with BDNF/Cr but not with NGF/Cr. 
There was no circadian variation to uNGF/Cr 
levels. 
Liu et al (2012) 
[121] 
Interstitial cystitis (IC) 
(30) and healthy controls 
(28) 
Increased mean uNGF/Cr and serum NGF levels in 
patients with IC compared with controls.  
Liu et al (2011) 
[122] 
Serum and uNGF levels 
in OAB (34), wet (17) 
and dry (17) 
Serum NGF and uNGF/Cr levels were significantly 
raised in patients with OAB when compared with 
healthy asymptomatic controls. Serum NGF 
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correlated with uNGF levels. No significant 
differences in serum NGF were detected between 
the OAB dry and wet groups. Serum and urinary 
levels remain unchanged before and after 
solifenacin treatment. 
Liu et al (2011) 
[123] 
OAB dry (113), OAB 
wet (104), controls (84) 
uNGF levels were significantly higher in OAB dry 
and even higher in OAB wet patients. Urinary NGF 
levels were not associated with menopause, ageing 
or higher body mass index. 
Pinto et al (2010) 
[124] 
26 women with painful 
bladder syndrome who 
were treated with trigonal 
injection of 100U of 
BTX-A. Urinary 
neurotrophin levels were 
measured at baseline, and 
month 1, 3 and 6 post 
injection. 
uNGF and uBDNF (brain derived neurotrophic 
factor) levels were measured at baseline, 1, 3 and 6 
months after injection. uNGF and BDNF levels 
were significantly reduced after the injection at one 
month, which corresponded with the improvement 
in pain intensity on a visual analogue scale. At three 
months, levels remain reduced however not as low 
as at one month. At six months levels have risen 
back up to baseline levels. 
Liu et al (2009) 
[125] 
Interstitial cystitis/painful 
bladder syndrome 
(IC/PBS) (122) and 
normal controls (28). 
uNGF /Cr levels were significantly greater in 
patients with IC/PBS than in controls. uNGF/Cr 
levels were very significantly higher when the 
bladder was distended in patients with IC/PBS. 
Patients who responded to treatment with an 
improvement in visual analogue scores of >2 had 
significantly lower uNGF/Cr levels than non-
responders who had improvements of <2. 
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Kuo et al (2010) 
[126] 
Urinary NGF versus 
Bladder wall thickness 
(DWT) as a biomarker 
for OAB (81) 
DWT was not significantly greater in OAB patients 
compared to controls. uNGF/Cr levels were 
significantly increased in patients with incontinence 
and OAB and those with DO. 
Liu et al (2010) 
[127] 
Interstitial cystitis 
IC/bladder pain 
syndrome (40), OAB 
(54) mixture of DO or 
increased bladder 
sensation (IBS), controls 
(27)   
uNGF/Cr levels were raised in the 40 patients with 
IC, and 23 with DO, but not in the 31 with IBS or 
controls. uNGF/Cr levels were not significantly 
different between the IC or DO groups. 
Liu et al (2009) 
[128] 
OAB (70) all treated with 
antimuscarinics, 50 
responders, 20 non-
responders, controls (38) 
uNGF/Cr levels were significantly higher in 
patients with OAB taking and responding to 
antimuscarinics compared with non-responders and 
controls. 
Liu et al (2009) 
[129] 
Cerebrovascular accident 
(CVA) (93) 
uNGF/Cr levels correlated with severity of 
neurological impairment after CVA. 
Liu et al (2009) 
[130] 
Urine collection at OAB 
(39) at first sensation of 
bladder filling (FSF), 
urge sensation (US) and 
controls at FSF and US 
(35) 
uNGF/Cr levels were significantly higher in OAB 
patients than controls. In controls uNGF/Cr levels 
were very low at first sensation of bladder filling 
(FSF), but significantly higher at urge sensation 
(US). In OAB patients there was no significant 
difference in uNGF/Cr levels at FSF and US. 
Liu et al (2008) 
[131] 
Mixed urinary 
incontinence (urinary 
uNGF/Cr levels were significantly higher in women 
with mixed urinary stress incontinence and DO than 
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stress incontinence (USI) 
and OAB) (38), DO 
alone (26), persistent USI 
after anti-incontinence 
surgery (21), de novo DO 
(15), control (31). 
those with pure stress incontinence or controls. 
uNGF/Cr levels were undetectable in women with 
persistent USI, but significantly higher in those with 
de novo DO after anti-incontinence surgery. 
Liu et al (2009) 
[96] 
IDO (143), NDO (100). 
Mixture of untreated, 
well treated and failed 
treatment with 
antimuscarinics. BoNT/A 
was given to IDO (24) 
and NDO (19), Controls 
(38). 
uNGF/Cr levels were significantly higher in 66 
patients with IDO and 59 with NDO compared to 
controls. Patients with well-treated IDO or NDO 
had reduced NGF/Cr levels, whereas those with 
failed-treated IDO or NDO did not. Patients who 
responded to BoNT-A treatment had significantly 
reduced uNGF/Cr levels in both the IDO and NDO 
groups compared to baseline levels. However, the 
NGF levels remained significantly higher at 3 
months in 7 IDO and 5 NDO patients who failed 
BoNT-A treatment.  
Yokoyama et al 
(2008) [132] 
OAB total (51) due to 
IDO (13), sensory 
urgency (6), BOO (16), 
and NDO (16) due to 
spinal cord injury (SCI) 
or CVA. 
The uNGF levels were significantly raised in 
patients with NDO due to SCI, BOO and sensory 
urgency when compared with controls. There was 
no significant difference in urinary levels between 
those with IDO, NDO due to CVA and controls. 
Jacobs et al 
(2010) [133] 
Neurogenic overactive 
bladder (NOAB) (13), 
idiopathic overactive 
bladder (17), interstitial 
uNGF/Cr levels were significantly raised in NOAB 
and IC/PBS groups when compared with controls. 
Raised levels approached significance in the 
patients with nephrolithiasis. 
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cystitis/painful bladder 
syndrome (IC/PBS) (8), 
prostate cancer (7), active 
bladder cancer (4), and 
nephrolithiasis (4). 
Liu et al (2008) 
[134] 
BOO (153): BOO non 
OAB (21), BOO and 
OAB (25), BOO and DO 
(47), BOO on successful 
medical treatment (60), 
Controls (38). 
The uNGF/Cr levels were very low in the control 
group and in patients with BOO/non-OAB and 
significantly greater in patients with BOO/OAB and 
BOO/DO. The uNGF/Cr levels returned to normal 
levels after successful relief of OAB symptoms with 
medical treatment. 
 
Liu et al (2008) 
[135] 
Normal controls (40), 
patients with increased 
bladder sensation (23), 
OAB dry (54), OAB wet 
(80). 
uNGF/Cr levels were low in controls and patients 
with increased bladder sensation. Levels in patients 
with OAB dry were significantly higher than 
controls. Patients with OAB wet had significantly 
higher levels than those with OAB dry. 
Kim et al (2006) 
[136] 
OAB (65) controls (20). uNGF levels were significantly higher in OAB 
patients than controls. 
Kim et al (2005) 
[137] 
OAB (75) and controls 
(20). 
 
Urinary NGF levels and PGE2 (prostaglandin E2) 
were significantly higher in OAB patients than 
controls. 
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Baseline uNGF/Cr levels have been repeatedly demonstrated to be highly expressed in 
patients with OAB when compared with controls. This increase is even more significant in 
patients with OAB and urgency UI (termed OAB-wet), compared with those without (OAB-
dry) [4]. It has been postulated that the difference between the OAB-dry and OAB-wet 
groups, may be due to the higher percentage of DO in the OAB-wet patients, which may 
suggest that higher levels of uNGF may predispose the occurrence of DO [99]. However, 
uNGF levels were not raised in patients with bladder oversensitivity alone [126]. Patients 
with mixed UI, with co-existing DO, were also shown to have higher NGF levels than 
patients with pure stress UI alone. However, in the latter group, urinary levels were raised in 
those patients who developed de novo DO after anti-UI surgery, which resulted from BOO 
[131]. In antimuscarinic-refractory patients with OAB, serum levels of NGF were also 
assayed, and correlated with urinary findings, by being raised compared with controls.  
 
These patients were treated with 3 months solifenacin, after which serum and urinary levels 
remained raised. The complex pathophysiology of OAB, may therefore be multimodal, 
involving several neurotransmitter and inflammatory pathways [122]. NGF urine levels also 
improve in those patients who have responded to medical therapy, with antimuscarinics and 
BTX-A [4, 128, 129]. However, these levels do not fall in patients who have not responded to 
treatment with either of these methods. It was also evident that once patients discontinue 
antimuscarinic treatment for 1 month, the levels re-elevated in almost half of the responders. 
This suggests that uNGF levels could have potential use as an objective tool for assessing the 
response of DO to therapy, as the levels appear to fall as DO is treated. As both of these 
treatment methods either inhibit the release or action of acetylcholine, it may be inferred that 
acetylcholine, which also acts at muscarinic receptors on urothelial and suburothelial cells 
[138], is a required substance for the release of NGF.  
 
Most recently a study has examined the effects after 5 days of peripheral nerve evaluation 
(PNE) in 17 patients, on uNGF levels [119]. All subjects showed a >50% improvement in 
voiding diary parameters such as number of daily voids, and/or leakage episodes, and 
significant improvements in urinary distress inventory scores and QOL scores. The mean post 
void residual also significantly decreased in this time, and concordantly uNGF/Cr levels were 
seen to significantly decrease from 17.23 pg/mg to 9.24 pg/mg after PNE. The authors 
conclude that since NGF induces OAB and DO through sensitization of afferent C-fibres, 
somehow through increasing the expression of sodium or potassium channels in the afferent 
nerves, that SNM may modulate afferent nerve activity from the bladder. They raise the 
prospect that uNGF/Cr could be an evaluation tool for patients undergoing SNM, as it 
correlated with symptoms and PVR. There was a lack of non-responders in this study 
however to comment on the behaviour of uNGF/Cr levels for patients with no clinical 
response as an internal control.  
Another interesting study evaluates the use of acupuncture for the treatment of OAB-dry 
patients [118]. Acupuncture patients received treatment twice weekly for eight weeks and 
were placed by an accredited specialist. These needles were placed at four acupuncture points 
(including the SP6 point which is commonly used for PTNS), and also placed bilaterally. The 
placebo group received a sham acupuncture treatment using needles of the same size, 
however these were not skin penetrating but the patient still experiences a pricking sensation. 
Significant reductions in mean uNGF/Cr were also seen in both the treatment arms at end of 
therapy. It was reported that eight out of twenty eight patients receiving acupuncture did not 
respond to therapy and no decrease in uNGF/Cr level was noted for these patients. There was 
no reduction of these levels in the sham arm. 
 
Some investigations have focused on the relationship between bladder stretch and NGF 
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release, as it is thought that the secretion of NGF from the bladder depends on stretch and 
duration of distension [126]. Detrusor smooth muscle stretch stimulates increased NGF 
production and hyperactive voiding in a rat model [139]. Urinary urgency that occurs with 
fast filling and distension during a cystometric investigation can also induce sensory urgency 
or provoke DO. Urinary NGF/Cr levels in OAB-wet patients are significantly raised, and less 
so with OAB-dry, with natural filling (by drinking water), when compared with levels from 
artificial stretch obtained with catheter filling [126]. This could be because natural filling 
allows more time for NGF to be released from the bladder. In control patients it has been 
shown that NGF levels are higher when volunteers wait to void at strong urge sensation, 
rather than sooner at the first sensation of bladder filling. However, as NGF levels are 
pathologically raised in OAB at small bladder volumes, it does not significantly elevate at 
sensory urgency sensation [130].  
 
OAB is also associated with BOO, and in men with BOO and OAB, and BOO and DO, 
uNGF/Cr levels are significantly higher than in those with BOO and no OAB [134]. These 
levels are lower in treated patients after relief of the OAB associated with BOO. Chronic 
stretching of the urothelium, as with BPH, can stimulate NGF production, among other 
transmitters, and chronically sensitise afferent pathways and DRG constituency, which causes 
increased excitability. In rat BOO models, immunity to NGF prevented obstruction-induced 
hypertrophy of DRG neurones, less retrograde sacral afferent activity, and eliminated the 
spinal micturition reflex [140].  
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BDNF: Animal and human studies  
NGF is most studied and better understood neurotrophin in LUTD. More recently BDNF has 
also received some attention as a potential biomarker in studies with results showing promise. 
BDNF is an abundant neurotrophin, and like NGF is vital for the survival and normal 
function of sensory nerves and has a role in nociception. BDNF, produced by the urothelium 
and spinal cord, has its expression regulated by NGF. It has been shown in animal models 
that after NGF instillation, either into the intrathecal or intraperitoneal compartment, both 
BDNF mRNA and protein are upregulated in the cells of sensory afferents [141].  
Other animal models of cystitis or BOO, have shown an increase in the levels of BDNF and 
its receptor TrkB expressed in the urothelium and bladder sensory afferents. In spinal cord 
injured rats with resultant NDO, BDNF levels also appear to upregulate in the bladder and in 
the spinal cord segments. A recent study has shown that in CYP-induced cystitis in rats, 
BDNF sequestration resulted in a significant decrease in the frequency of bladder reflex 
activity and improved bladder function [142]. However BDNF did not have any impact on 
bladder reflex activity in intact animals that suggests that its role is more relevant to 
pathological conditions. 
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Urinary BDNF studies 
There are a handful of studies that have measured the urinary BDNF levels in patients with 
LUT pathophysiology. These are summarized in Table eleven below: 
Table eleven: Summary of studies evaluating urinary BDNF in patients. 
Author and Year Conditions investigated 
and sample sizes  
Conclusions 
Pinto et al, 2010 [124] See table above  
Antunes-Lopes et al, 2011 
[143] 
Urine samples were 
collected from healthy 
controls, 20 men and 20 
women in the morning, 
afternoon and evening. 
Seventeen female patients 
with naïve OAB were also 
included. This was 
repeated after three 
months.  
Urinary BDNF levels were 
very low in the healthy 
volunteers, despite time of 
collection. There were no 
significant differences 
between male or female. 
BDNF/Cr was 
significantly higher in 
OAB patients compared to 
healthy volunteers. After 
three months of non-
pharmacological 
interventions, OAB scores 
improved and correlated 
with a decrease in 
uBDNF/Cr levels. A 
significant correlation 
between uBDNF/Cr level 
 
and OAB symptom score 
was found (r=0.684, 
p<0.01). 
Wang et al, 2014 [144] 90 women with OAB and 
45 normal controls.  
uBDNF levels were 
elevated in OAB groups 
compared to controls. 
ROC curves suggest a 
sensitivity of 93.33% and 
specificity of 88.9% for 
assessing uBDNF/Cr in 
OAB groups. 
Koven et al, 2014 [145] Urine samples were 
collected from 52 healthy 
adults undergoing 
executive functioning 
tests, and levels of uBDNF 
were measured. 
BDNF concentration was 
positively related with 
cognitive flexibility but 
not with memory or 
reasoning.  
Collins et al, 2014 [146] 52 young adults were 
assessed for aerobic fitness 
and urinary samples 
collected. 
BDNF/Cr levels correlated 
with enhanced level of 
fitness reflecting exercise 
mediated changes in 
peripheral BDNF. 
Circulating levels of 
BDNF were affected by 
aerobic exercise. 
 
 Raised urinary BDNF levels have clearly been shown in patients with OAB [144] compared 
with controls with promising sensitivity. However as with NGF a similar concern is the 
specificity. Urinary BDNF levels have also been demonstrated in patients with interstitial 
cystitis and shown to reduce after successful treatment with BTX-A, following a reduction in 
bladder pain levels [124]. In OAB, uBDNF levels were also found to be raised compared to 
healthy controls, and reduced after behavioural modifications such as bladder training, 
limited fluid intake, and avoidance of caffeine [147]. BDNF is much less explored than NGF, 
however emerging studies suggest that this may be more sensitive and specific.  
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Pitfalls with NGF and BDNF as a Biomarker  
Many proteins are involved in the complex pathophysiology of the OAB, of which NGF is 
only one. It seems to play a role in LUT dysfunction (LUTD), and is closely associated with 
inflammation in the bladder. However, due to the numerous sensory neurotransmitters and 
inflammatory substances that are likely to also play an important role, e.g. Substance P, ATP, 
calcitonin gene-related peptide, other neurotrophins and inflammatory markers, NGF alone 
may be insufficient to act as a urinary marker for OAB.  
Not all patients with OAB have raised uNGF values at baseline, which was up to 30% in 
some cohorts [125]. In a cross-sectional study in 143 patients with IDO, uNGF levels were 
seen to be raised in 66 of these patients [128]. These findings suggest that there may be other 
causes of OAB pathophysiology, some which do not involve inflammatory or NGF pathways. 
Thus, as a potential biomarker, there will therefore be significant proportions of patients with 
OAB or DO, who do not have raised uNGF levels, which lowers its sensitivity.  
Also, it was noticed that in responders to antimuscarinics, who had significantly improved 
urinary symptom scores, and a corresponding fall in uNGF levels after 3 months of therapy, 
that these levels although reduced were still significantly higher than those of controls. This 
may be due to incomplete resolution of the underlying OAB pathophysiology, and that 
overactivity of the cholinergic system is not the sole cause of OAB. 
 
An issue that presents itself for the potential use of this protein as an OAB marker is its 
specificity, as raised levels are not limited to OAB. Links have also been reported for raised 
uNGF levels in patients with painful inflammatory conditions of the urinary tract, e.g. 
IC/PBS, BOO (in men and women), chronic prostatitis, renal stone disease, UTI, and most 
recently prostate and bladder cancer (see table above) [133, 148]. A common trend for 
patients with raised uNGF levels appears to be the presence of inflammation or neural injury, 
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which is an increasingly recognised process in the development of OAB. It has been shown 
that at least half of biopsy samples from patients with NDO and idiopathic DO (IDO) have 
histological evidence of chronic inflammation [149]. This would be consistent with the 
finding that uNGF levels are raised with bacterial cystitis, when compared with controls, and 
that once the infection has been treated with antibiotics for a week, these levels significantly 
decrease [99]. Furthermore, in patients with concurrent UTI and OAB, despite treatment with 
antibiotics, uNGF levels remain significantly raised. Patients with IC/PBS, who responded to 
treatment with hydrodistension with an improved visual analogue scale pain score, also had a 
corresponding reduction in uNGF/Cr level. This reduction in levels was not seen in those 
who did not respond to treatment, which is a further suggestion of the potential use of NGF in 
monitoring the response to treatment.  
 
The presence of NGF in the urine has been affiliated with the raised NGF level expression in 
the urothelium. However, it is not entirely clear if this is the sole source of uNGF. The 
circulating serum NGF levels may also represent some of the sourcing of uNGF, via renal 
excretion, the proportion to which is unknown. Urinary NGF levels have also been identified 
to correlate with the severity of neurological impairment after cerebrovascular accident [129]. 
It is thought that after the brain injury in an acute phase of a stroke, levels of circulating 
neurotrophins are raised, which may have a knock-on effect on urinary levels. Furthermore 
increased serum NGF levels have been identified in numerous other medical conditions, e.g. 
asthma, allergy, Alzheimer’s [150, 151]. Therefore, as a potential biomarker for OAB, this 
raises the possibility that in certain neurological conditions, or other medical conditions, 
when patients do not have any lower urinary tract (LUT) complaints, uNGF levels could be 
silently raised, causing false positives.  
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Neuropsychology and emotional state also may have a role in urinary levels. As these 
neurotrophins are so ubiquitous, it is unlikely that there presence in the urine can be attributed 
to LUT pathology alone. BDNF has a high gene expression in the prefrontal cortex and is 
though to be important with regulation of cognitive reserves and frontal lobe function, and 
urinary levels have been shown to be correlated with cognitive ability [145]. Furthermore it 
has been shown that circulating and uBDNF levels are also related with aerobic fitness, and 
that higher urinary levels indicate a level of higher fitness reflecting the exercise-mediated 
changes in peripheral BDNF [146]. Therefore its role as an indicator of the OAB, is limited 
by the numerous other physiological and pathological states that can influence its levels. The 
molecular weight of neurotrophins are low at approximately 13kDa. The molecular weight 
cut-off for kidney glomerular filtration is classically assumed to be around 30-50kDa, posing 
the possibility that excessive circulating neurotrophins could be removed by kidney filtration 
and hence urinary levels may subsequently rise. 
 
Unresolved Questions  
Diagnostic accuracy has been the subject of much attention, and applies to all medical tests. 
This refers to the ability of a test to identify the condition of interest. This involves 
comparing a test with the reference or ‘gold’ standard in a group of patients suspected of 
having the condition of interest. Accuracy refers to the degree of agreement between the new 
test and the gold standard [152]. Recent development of Standards for Reporting Diagnostic 
Accuracy (STARD) guidelines, which was a multidisciplinary effort of clinicians and 
scientists, have been created to provide a checklist for reporting the accuracy of a diagnostic 
test [153]. This checklist addresses several quality related issues, and an official assessment 
of this proposed biomarker would need to be performed in accordance with STARD 
guidance. To date neither of these potential biomarkers have been validated through this 
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process. 
 
As a potential biomarker it is a non-invasive investigation, as urine is relatively easy to 
collect from the patient. The expression of this abundant protein can change with underlying 
pathological processes. As patients subjectively respond to successful pharmacological 
intervention, NGF levels also reduce, which may be of use as an objective tool to monitor the 
response to a treatment. However, a biomarker should also have a high level of specificity 
and sensitivity, add new information to the clinical assessment, and have a clear association 
with the severity of OAB and improve the outcome of the disease, which uNGF does not do. 
For the latter, not all of patients with symptomatic OAB will have significantly raised uNGF 
levels, and this suggests the possible variation in pathophysiology that exists in this 
condition. As a result, the consideration of NGF as a sole biomarker for this condition may be 
limited. 
 
Clearly, as NGF levels may be raised in numerous conditions, an exclusion criteria needs to 
be established to highlight patient suitability, and avoid performing measurements in patients 
who may have false positive results for OAB. Other groups that may also require exclusion 
are those with active or recent UTIs, and those with indwelling catheters or performing clean 
intermittent self-catheterisation, which may be a significant proportion of the neurogenic 
population, as the minor trauma may theoretically exacerbate urothelial release; however, this 
is yet to be investigated. The exact source of the NGF and BDNF in the urine is also unclear, 
with regards to the proportion that is attributed to the urothelium, and the proportion that may 
be from systemically circulating neurotrophins, which may undergo renal excretion.  
  
More study is also required within a control population, to assess within-person biological 
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variation; levels may change throughout the day. Variables such as the time of sample 
collection, whether the first morning void, or a later sample and bladder volume or degree of 
bladder stretch when providing a sample, may also influence urinary levels. These variables 
may have an impact on the end result and also need to be standardised for collection. Current 
recommendation is to collect samples and immediately placing on ice, followed by rapid 
transfer to the laboratory for processing. If processing is delayed this may risk NGF 
degradation, and hence levels may be affected. Further studies are required on assessing the 
stability of this protein in urine, to help standardise methods of collection in an outpatient 
setting. The costs of the detection techniques may also need to be considered, to gather 
information for cost-effectiveness calculations.  
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CONCLUSION 
 
Whilst the evidence for an increased uNGF and uBDNF in OAB appears convincing, many 
questions about its validity remain including specificity, sensitivity, cost- and time-
eectiveness. As a monitor for the response to treatment, it shows promise for certain patient 
groups who clinically respond to BTX-A, antimuscarinic therapy, PNE for SNS, and even 
acupuncture, and this response needs to be evaluated for other treatment options including 
Tibial nerve stimulation. If a role as a biomarker is not proven, it may still have some ability 
to indicate possible response to a particular treatment or to predict the natural history or 
aetiology of the disease. 
Many criteria for what constitutes a biomarker still need to be evaluated and met before this 
molecule can be considered for this role. However, exploring the role of NGF in these 
conditions has elucidated more information about the complex urothelial signalling 
mechanisms that exist, the pathophysiology of OAB, and the role of the neurotrophins in 
particular. Other promising biomarkers are also being explored, both within the neurotrophin 
family, and in the inflammatory cascade, which may identify some more reliable biomarker 
candidates. It may well be that the ideal urinary biomarker for any particular type of LUTD 
may be the presence of a combination of proteins, the levels of which may differ between 
conditions and patients. Used together, their sensitivities and specificities may be combined, 
to make it a stronger investigation.  
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CHAPTER THREE 
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Chapter Synopsis 
 
Chapter two reviewed the literature of urinary neurotrophins as biomarkers for the OAB. The 
vast majority of these studies have explored urine from patients with idiopathic OAB. Only a 
handful of studies of examined patients with neuropathic bladder dysfunction, and extremely 
few have focused on patients with Multiple Sclerosis (MS). At the National Hospital for 
Neurology and Neurosurgery, there are large numbers of patients with MS, and OAB. The 
aim of this study was to measure the urinary neurotrophin levels from patients with MS and 
healthy controls. As an internal control group, MS patients with no OAB symptoms were 
recruited to examine whether any raised urinary neurotrophin levels specifically correlate 
with OAB symptoms or the underlying neurological disease process. Ethical approval was 
granted for the study. 
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Measurement of Urinary Nerve Growth Factor and Brain Derived Neurotrophic Factor 
in patients with Multiple Sclerosis and Overactive Bladder 
 
Abstract 
Introduction 
Studies examining the role of urinary neurotrophins as a biomarker for the OAB are 
emerging. Only a few have investigated this in patients with neurological disease and even 
fewer in patients specifically with Multiple Sclerosis (MS). OAB symptoms are prevalent in 
patients with MS and a urinary biomarker would be highly desirable to monitor disease 
activity, and monitor response to treatment. MS is also a condition known to have higher 
baseline circulating neurotrophin levels. It is unknown whether urinary neurotrophin levels 
will be related to OAB symptom score only, or whether they will also be influenced by 
neurological disease activity.  
 
Materials and Methods 
Patients with MS attending the outpatients at the National Hospital for Neurology and 
Neurosurgery were recruited. Three main groups were invited into the study, those with MS 
and OAB, MS and no OAB as an internal control, and healthy volunteers. Patients completed 
the Urinary Symptom Profile to objectively assess symptom severity, and urine was collected 
and neurotrophin levels were measured by enzyme-linked immunosorbent assay (ELISA) 
method and normalised by urinary creatinine levels (NGF/Cr).  
 
Results 
Sixty-seven patients with MS-OAB, ten with no OAB and twenty healthy controls were 
recruited.  There are differences between groups in NGF levels with the highest levels seen in 
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MS-OAB patients (median 10.8 (IQR: 3.0, 27.0)) and the lowest levels seen in Controls 
(median 4.8 (IQR: 1.0, 9.5)), Kruskal Wallis p-value=0.04. Similarly larger differences are 
observed between groups in BDNF with the highest levels seen in MS-OAB patients (median 
53.3 (IQR: 13.6, 127.5)) and the lowest levels seen in Controls (median 9.0 (IQR: 6.1, 38.5)), 
Kruskal Wallis p-value=0.002. 
There is no significant difference in NGF/Cr or BDNF/Cr level between the MS and no OAB 
and the control group. MS-OAB patients have a significantly higher NGF/Cr and BDNF/Cr 
level compared to controls. Confidence intervals overlap between the MS no OAB and the 
MS-OAB, and hence they are unlikely to be significantly different, however the sample size 
is insufficiently powered to do pairwise comparisons. 
 
Conclusions 
This study is the first to analyse the levels of urinary neurotrophins NGF and BDNF in MS 
patients with mild to moderate OAB symptoms and without OAB symptoms compared to 
healthy controls. The results obtained confirm that urinary neurotrophin levels are 
significantly raised in patients with MS compared to healthy controls. This was more marked 
for patients with MS and OAB than for those with no OAB symptoms. Since the group with 
no OAB symptoms was small in number, no comment can be made with statistical 
significance, however there is a trend for the levels to be higher than healthy controls. This 
may reflect the pathophysiology of MS, patients of which have observed higher baseline 
circulating neurotrophin levels. This may be influencing urinary levels and therefore render 
these potential OAB markers less reliable in patients with MS. 
 
 
 
 
INTRODUCTION 
 
Multiple Sclerosis is an inflammatory condition affecting the white matter of the central 
nervous system (CNS) resulting in demyelination and, in advanced stages, axonal 
degeneration.  The presence of plaques is the hallmark characteristic of this condition, which 
may be located in the white matter subcortically, brainstem and cerebellum and spinal cord 
and visible in MR (magnetic resonance) imaging. The aetiology of the condition is thought to 
be autoimmune, and involves T cell activation and cell mediated inflammation with targeted 
destruction of myelin.   
In the developed world, MS is the most common progressive neurological condition of young 
adults, with a median estimated global prevalence of 112 per 100,000 person years [154], 
with a predominance for females of 3:1 [155]. Relapsing remitting MS (RRMS) is the most 
common type (85 % of patients), but nearly half of these patients convert to secondary 
progressive MS (SPMS) over a median time period of 11 years [156]. About 10% of patients 
may have progressive symptoms from the onset (primary progressive MS) and a minority 
have progressive relapsing MS [156].  
The Expanded Disability Status Scale (EDSS) is a method of quantifying disability in MS. 
This scale ranges from 0 to 10 in 0.5 increments that represent higher levels of disability. An 
EDSS level of 4 (at which patients can walk some 500 m without aid or rest), is thought to 
the herald the onset of secondary progressive MS. The mean time from disability level EDSS 
4 to 6 (when there is intermittent or constant assistance required to walk 100 m) has been 
estimated to be 6 to 8.4 years. It is during this period of progression that management of the 
lower urinary tract dysfunction (LUTD) may become particularly difficult.  
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Lower Urinary tract dysfunction in MS 
LUTD is common in MS, with up to ninety percent of patients complaining of lower urinary 
tract symptoms (LUTS) at some point [62]. The severity of LUTS is related to the degree of 
pyramidal impairment in the lower limbs [157]. Urinary incontinence is considered to be one 
of the worst aspects of the disease, with 70 % of a group of patients with MS responding to a 
questionnaire classifying the impact bladder symptoms had on their life as “high” or 
“moderate” [158]. Whether patients suffer from an overactive or a poorly emptying bladder 
or a combination of both disorders, the bladder dysfunction experienced can greatly reduce 
the overall QoL due to the functional and psychosocial burden [63]. Effective treatments 
significantly enhance measures of QoL [159]. However, the severity of symptoms may differ 
in the degree of distress and bother they cause, as threatened urinary leakage in someone still 
ambulant may cause greater or less distress than regular episodes of incontinence in a 
permanent wheelchair user. As the disease progresses, patients may also become prone to 
developing urinary tract infections (UTIs) that can lead to progressive neurological 
deterioration [160]. However, as the disease worsens, with pyramidal symptoms affecting the 
lower limbs causing a decline in mobility and increased disability, the bladder dysfunction 
becomes more difficult to manage. It is thought that almost 100% of patients have LUTS 
once they experience walking difficulties [161].  
The pattern of LUTS experienced can be either storage or voiding symptoms, or a 
combination of both. Voiding symptoms due to insufficient detrusor contractility include 
hesitancy, poor urinary stream, dribbling of urine, and incomplete bladder emptying. This 
itself can provoke involuntary contractions and result in urinary stasis with subsequent risk of 
infection.  Both of these sets of OAB and voiding symptoms need to be tackled for effective 
management. 
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Objective evaluation of LUTD in MS 
The current method of assessing patients complaining of this OAB symptom complex is 
through questionnaire scores, which rely on subjecting patient reporting of urgency.  The 
assessment of symptoms is in itself fraught with limitations considering the vague nature of 
LUTS and difficulties patients experience in understanding the term “urgency” and providing 
information about the different severities of the condition. It can be difficult for patients to 
differentiate between the sensation of urge, a normal bladder sensation, and urgency. One 
way to overcome this would be with the availability of an objective test for the diagnosis of 
OAB and to judge its severity. 
The measurement of the postvoid residual (PVR) is a critical part of the investigation in the 
management of LUTS in a patient with MS. One of the cornerstone investigations of patients 
with OAB symptoms is the use of a frequency/volume chart [162]. However the only 
objective evaluation tool to assess the storage function of the bladder whilst filling is to 
perform a urodynamic study. However this test can only identify whether DO is present and 
not itself diagnose OAB [87]. 
A urodynamic study of 100 patients with MS with LUTS showed that 78 % had dynamic 
evidence of LUTD [163]. A regression analysis showed that the likelihood of a urodynamic 
abnormality in MS was higher in patients who had an EDSS greater than 6.5, who were using 
more than one continence pad daily, and if the MS was not of the relapsing-remitting type 
[163].  
DO is the commonest pattern of LUTD seen in MS reporting LUTS and in a review of 22 
studies on MS populations combining a total of 1882 patients, DO was reported in 62 % of 
patients undergoing urodynamic investigations [164]. Other abnormalities responsible for 
bladder symptoms include detrusor underactivity (occurring in 0%-40%, mean 25% of 
patients) and dyssynergia between the detrusor and external urethral sphincter (detrusor 
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sphincter dyssynergia, DSD) occurring in 5%-83% (mean 35%) patients with MS [165]. 
LUTS can be related to the duration of the disease, however 10% of patients can have them at 
initial manifestation. 
It is possible that this functionally disordered co-ordination can change over time, and 
progress in severity. It is also well known that the bladder symptoms that occur with the 
various forms of dysfunction are non-specific, coined in the well known phrase ‘the bladder 
is an unreliable witness’ [76, 77]. Whilst the range of urodynamic dysfunction is large, the 
types of bladder symptoms that can manifest are limited, to either storage or voiding LUTS. 
Therefore it remains difficult to assign symptoms to a particular disease process. For 
example, poor detrusor contractility may manifest with the same symptoms as bladder outlet 
obstruction such as hesitancy, urinary frequency, reduced urinary flow and sensations of 
incomplete bladder emptying. Despite a careful history, patients may interpret their own 
experiences differently and clinicians may be biased with interpreting their answers [78].  
This lack of correlation can be yet more unclear in patients with MS who may have altered 
bladder sensations, and less able to predict poor or incomplete bladder emptying [157]. The 
role of urodynamics for the assessment of LUTS in this group of patients remains under some 
debate with suggested use limited to situations when invasive treatments are being planned, 
although guidelines from a French expert group recommend its use in all MS patients with 
symptomatic LUTS [63, 165]. The benefits and limitations of invasive urodynamics are 
enlisted in table twelve below [166]. 
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Table twelve: Advantages and limitations of urodynamic testing 
Advantages Limitations 
Objective evaluation of bladder function 
during filling and voiding 
Invasive test  
• Discomfort during the procedure  
• Transient bleeding following procedure  
• Theoretical risk of infection: 2-4% risk 
of UTI  
• Important to exclude UTI as this may 
falsely result in increased bladder 
sensation and poor compliance  
• Prophylactic antibiotics may play a role 
in patients with recurrent UTIs 
To identify or to rule out factors and 
mechanisms contributing to incontinence 
and their relative importance in complex 
cases 
Failure to always provide a diagnosis 
To obtain information about other aspects 
of LUTD such as urethral closing 
pressures and competence 
Unable to reproduce patient’s symptoms 
To predict consequences of dysfunction 
for the upper urinary tract 
Inaccuracies can occur due to 
• Poor subtraction which may lead to 
errors 
• Air bubbles in the system or leaks 
may lead to errors of measurement 
• Rectal contractions may be 
misinterpreted as DO 
(These artifacts should be identified 
and eliminated when possible) 
To predict the outcome and side effects 
of a proposed treatment and understand 
Interchangeability of study results 
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its mechanism of action 
To understand reasons for failure of 
previous treatments for incontinence 
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Urinary neurotrophins: An objective marker for OAB in patients with neurological disease? 
The role for a biomarker for OAB in patients with MS 
The previous chapter has discussed the need for an accurate evaluation tool for patients with 
MS that could be used to assess physiological function, disease severity, reveal the 
underlying pathology, monitor the response to treatment, and predict prognosis [167]. 
Validated questionnaire tools are vital for patient assessment yet remain completely 
subjective, whilst urodynamics, the most objective tool available, is not without its 
limitations as mentioned above in table Twelve. A urinary biomarker would therefore be of 
potential use as sample collection is easy and non-invasive. In this way urinary neurotrophins 
are being evaluated as a biomarker for overactive bladder symptoms and more specifically 
DO.  
 
Most of the literature examines urinary neurotrophin levels in patients with idiopathic OAB, 
with very few studies investigating neurological patients [96, 111, 129, 132, 133]. As for 
patients with idiopathic OAB, neurological patients would also benefit from such a 
biomarker. These patients may have more severe bladder dysfunction and symptoms with 
potentially progressive disease pathology, may not have the mobility to sustain the nature of 
the OAB symptoms of urinary frequency and urgency, and hence a significant detriment to 
QoL. Furthermore these patients are at risk of upper urinary tract complications and a 
biomarker that could identify those particularly at high risk would be highly desirable. 
 
A recent meta-analysis of 8 studies measuring urinary NGF in patients with idiopathic OAB, 
showed that patients with OAB symptoms had a higher level of uNGF than healthy people 
[168]. Whether this applies to neurological patients is far less explored and needs further 
evaluation. 
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Most of the reports measuring uNGF in patients with neurological disease emanate from a 
single centre studying limited patient groups. These authors have shown that uNGF levels 
were significantly higher in 93 patients who have had a cerebrovascular accident(CVA) 
compared to healthy controls [129]. This increase in level correlated with the severity of 
neurological impairment. It was suggested that the elevated levels may be directly due to the 
neurological injury rather than secondary to any LUTD that followed. Levels did not 
correlate however with the site of the lesion, duration of the stroke, or urinary symptoms in 
these patients, suggesting that in these patients the uNGF levels were a marker for the 
severity of brain injury after CVA. It was also observed, albeit in the small number of 
patients that had urodynamic evaluation, that uNGF levels were comparable in the patients 
with DO and detrusor underactivity (DUA), also suggesting that in patients with profound 
neurological impairment, uNGF levels can still be raised despite low detrusor contractility. 
Serum BDNF levels have also been suggested to increase after stroke [169]. Although the 
link between NGF and BDNF is unclear, it may be that after brain injury, there is some 
neurotrophin leakage through the blood brain barrier causing systemic levels of circulating 
neurotrophins to be raised and therefore more detectable in the urine, rather than a response 
confined to the bladder. Alternatively there may be a systemic response to neural injury that 
leads to higher circulating levels. The potential origin of neurotrophins detected in the urine 
cannot however be distinguished between that released from an injured CNS or those from 
nerve endings within an overactive bladder. 
 
In addition to this, the evolution of uBDNF as an additional proposed OAB biomarker [144], 
alongside NGF, also needs to be assessed in patients with MS. BDNF is a ubiquitous 
neurotrophin in the human body and is produced in sensory neurons in dorsal root ganglia 
[170]. It is also synthesized by non-neuronal cells in the inflammed bladder, taken up by 
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bladder afferent nerves and undergoes retrograde migration to the spinal cord where it 
modulates neuronal function via its TrkB receptors, which are located in the afferent nerves 
themselves and dorsal root ganglia. It is not fully known how BDNF is involved in the 
pathogenesis of OAB, but it is recognised to be up-regulated in the dorsal root ganglion in a 
neuropathic pain model, by overproduction of prostaglandins (PGE2) by injured nerves. NGF 
is also thought to increase BDNF expression and activate nociceptors [171]. 
 
Urinary NGF levels in patients with MS in particular, or other demyelinating disorders, have 
not been fully evaluated. There is very little evidence and few studies examining the levels of 
uNGF in patients with MS. Since the prevalence of OAB in MS patients is high, it is 
pertinent to assess the performance of this increasingly popular potential biomarker in this 
patient population. Patients with MS have been shown to have a significantly higher basal 
level of serum NGF, due to the inflammatory CNS pathology compared to healthy controls 
[172]. Whether this can affect the urinary levels of NGF and whether uNGF can be 
considered as a biomarker for OAB alone in these patients is unknown. This could be 
investigated by examining urine from patients with MS and no OAB symptoms as a control 
population.  
 
 
 
 
 
 
 
 
 
Study Aims 
The aim of this study was to determine whether urinary NGF and BDNF levels were elevated 
in patients with MS and OAB symptoms compared to patients with MS and no OAB 
symptoms or healthy controls. The MS patients targeted were those with mild to moderate 
OAB symptoms. The results of this study may help to clarify whether urinary neurotrophin 
levels can be used to diagnose OAB in patients with MS and whether urinary baseline levels 
are raised in MS patients with no OAB symptoms. Furthermore any relationships between 
urinary neurotrophin levels and self-reported OAB scores and EDSS scores can be observed. 
The primary and secondary objectives of this study are stated below.  
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Primary objectives 
To measure urinary NGF/Cr and BDNF/Cr levels in three patient groups:  
o Group One: Healthy volunteers with no OAB symptoms (hospital staff). 
o Group Two: Patients with MS who have no OAB symptoms. 
o Group Three: Patients with MS with OAB symptoms.  
 
Secondary end point 
To evaluate any relation between uNGF and uBDNF levels and the severity of OAB assessed 
using a subjective patient reported OAB subset of the Urinary Symptom Profile questionnaire 
(USP) [173] (See appendix). Any relation with between urinary neurotrophin levels and 
EDSS scores can also be observed. 
 
Study Hypothesis 
The levels of urinary neurotrophins, specifically NGF and BDNF are raised in the urine of 
patients with MS who are suffering from OAB symptoms compared to both:  
1) Patients with MS not reporting OAB symptoms  
2) Healthy controls.  
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MATERIALS AND METHODS 
 
Study design 
Roughly 3000 patients with MS visit the National Hospital for Neurology and Neurosurgery 
(NHNN) annually. Therefore the hospital is well suited to recruit patients for this study, who 
were counselled, provided with the patient information leaflet, consented and recruited during 
their clinic visit.  
The close proximity of the Neurometabolic Unit to the OP at the Department of Uro-
Neurology allows for efficient sample collection and storage. Negative control samples were 
taken from members of staff representing the healthy volunteers group with no OAB 
symptoms.   
 
Inclusion Criteria 
Patients and healthy volunteers who were able to and willing to provide written consent to 
enrol into the study were included. 
Participants had to demonstrate the ability to understand and complete the self-reported 
urinary symptom profile (USP) to assess symptom severity. 
 
Exclusion Criteria 
The conditions which excluded participants from being recruited, as these may influence the 
urinary NGF result, either causing a false positive (FP) or a false negative (FN): 
• Evidence of a urinary tract infection on urine dipstick testing which may cause a FP 
• Patients with a history of bladder outflow obstruction due to benign prostate 
enlargement as this may cause a raised urinary NGF level causing a FP [134]. 
• Patient having received intradetrusor injections of Botulinum toxin over the previous 6 
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months with continuing improvement in symptoms, which may reduce NGF levels 
causing a FN [112].  
• Patients with any known history of urological disease such as malignancy or stones 
may cause a FP [174]. 
• Patients with long-term indwelling urinary catheters or carrying out CISC as the 
urothelial trauma induced may cause a FP in urinary NGF. 
• Renal disease 
 
Patients on antimuscarinics were not excluded, however, their use was noted.  This is 
important as it has been shown in previous studies that patients with OAB, who are 
responders to antimuscarinic therapy have reduced levels of urinary NGF [128]. 
 
Urinary Symptom Profile (USP) 
Patients completed the USP to assess their OAB symptoms (See Appendices). The USP is a 
questionnaire developed by the MAPI research trust. It has been standardised and validated 
and had its clinical validity demonstrated against bladder diary parameters in a large study 
that assessed data from OAB patients and healthy controls [173]. It is a straightforward and 
brief questionnaire that enables symptom screening and evaluation of symptom severity.  The 
USP has been recommended by the International Consultation on Incontinence (ICI) that 
reports its development and validation has followed rigorous and thorough methodology.  
Patients self-assess symptoms through a series of questions and total a final aggregate score. 
The final score ranges from 0-21, with 21 representing highest symptom severity and 0 
representing absence of symptoms. MS patients with no OAB, and healthy controls were 
determined with a score of zero on the USP.  
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Collection and Urinary Enzyme-Linked Immunosorbent Assay (ELISA) 
Once consented, participants were asked to provide a urine sample when they had a strong 
desire to void. Voided urine was immediately dipstick tested for traces of a UTI. If an 
infection was detected, patients were excluded from the study and the UTI was treated. 
Voided urine was then immediately placed on ice and transferred to the laboratory for 
preparation for NGF measurement. The urine samples were centrifuged at 3000g for 10 
minutes at 4°C. The supernatant was separated into five 1.5ml aliquots in polypropylene 
eppendorf tubes and preserved in a freezer at -70°C. Because freeze-thaw cycles decrease 
protein stability, the samples for frozen storage at -70°C were dispensed and prepared in 
numerous single-use aliquots so that, once thawed, the urine sample would not be refrozen. 
At the same time, 3mL of urine was taken to measure the urinary creatinine (Cr) level.  
Urinary NGF concentration was determined using an immunoassay system (Emax®, 
Promega, Madison, WI, USA) with a specific and highly sensitive ELISA kit, which had a 
minimum sensitivity of 7.8 pg/mL. Assays were conducted according to the manufacturer’s 
instructions. Generally, urine samples were not diluted in the ELISA assay. When the urinary 
NGF concentration was higher than the upper detection limit (250 pg/mL) the urine samples 
were diluted to fit the detection limit. All samples were run in duplicate and the values were 
averaged.  
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Security: Data Handling and Record Keeping 
The investigators permit study-related monitoring, audits, REC review, and regulatory 
inspection(s), providing direct access to source data/documents. Patient consent to this is 
specifically sought in the Consent Form. Participants enrolled into the study were given a 
study number, and completed questionnaires were identifiable by the hospital number. These 
documents will be stored in a case report file (CRF). Results were stored in a secure 
password protected database, only accessible by a member of the research team.  
Patient details were anonymised and study data could not be linked to individual patients 
other than by those authorised to have access and not in any publication of results. All 
records were maintained in accordance with the Data Protection Act 1998 and Caldicott 
committee.  
Ethics 
To acquire the necessary approvals, a study protocol, participant study information leaflet 
(PIL), participant consent form, and letter to the general practitioner was produced. An NHS 
research ethics committee (REC) form and site-specific (SSI) application forms were 
completed on the integrated research application systems (IRAS) website. These documents 
were compiled and reviewed by the relevant authorities.  
 
Approvals (See Appedices) 
This study was reviewed and a certificate of approval acquired from: 
• UCLH Biomedical Research and Development department.  
• East London Central REC1 Research NHS Ethics Committee at the Royal Free 
Hospital approved the study with REC reference number: 10/H0721/33. Informed 
consent was obtained from all participants.  
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Signed, informed consent was obtained from all participants before recruitment into the 
study. Participants were given time to read the study patient information leaflets, and the 
opportunity to ask questions about the study.  
These approvals are provided in the appendices. Approval for the use of the Urinary 
Symptom Profile was also acquired from the MAPI research trust. 
The study was conducted in compliance with the protocol, good clinical practice (GCP) and 
the applicable regulatory requirement(s). 
 
The study represents the collaboration between the department of Uro-Neurology and the 
Neurometabolic unit where regular delivery of samples were being received from the 
outpatients department. Freezer space and use of centrifuge equipment, bench space was 
provided under their supervision and experience with running the laboratory experiments. 
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MATERIALS 
Patient recruitment and sample collection 
Urinary symptom profile  
Urine dipsticks  
Box of ice 
Polypropylene 25ml urine collection tube  
Refrigerated centrifuge (for spin at 300g at 4°C),  and -70°C freezer 
 
The urinary ELISA 
96-well plate (falcon-polystyrene) 
Anti-NGF pAb 
Anti-NGF mAb 
Anti-Rat IgG-HRP conjugate                                        
NGF standard                                                  
Block and sample buffer 1X 
TMB One solution 
 
The constituents of the necessary reagants for this assay are described below: 
1. Carbonate coating buffer: 
100mls deionised water 
1.59g of Na2CO3 powder 
2.93g of Na HCO3 powder 
Adjust pH to 9.7 using 1N HCL or 1N NaOH 
2. TBST wash buffer 
500mls deionised water 
These items are provided by 
PROMEGA in the NGF Emax 
ImmunoAssay System Kit 
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1.2114g of Tris-HCL 
4.383g of NaCl 
0.05% Tween 20 (500l for 1L) 
3. Block and sample buffer 1X 
  5mls of block and sample 5X 
  20mls of deionised water 
1N Hydrochloric acid 
Multichannel pipettor 
Pipettors capable of accurately delivering volumes of 1l to 1ml 
Plate shaker 
Microplate reader capable of monitoring absorbance at 450nm 
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The ELISA 
An ELISA is a basic application of antibodies to analyse soluble antigens by passive binding 
[175]. This allows the simultaneous processing of many small samples. It requires at least 
two antigen specific antibodies which will capture the antigen in a sandwich format [175]. 
The capture antibody is used to coat a solid substrate, in this case a plate well. This captures 
and immobilizes the antigen from the sample, which is then applied.  
Having the reactants of the ELISA immobilized to the microplate surface makes it easy to 
separate bound from non-bound material during the assay by washing [176]. This ability to 
wash away non-specifically bound materials makes the ELISA a powerful tool for measuring 
specific analytes within a crude preparation [176]. 
An unlabelled primary antibody is then added, which also specifically binds the antigen. The 
capture and primary antibodies must be different isotypes, so that the secondary, when added 
only detects the presence of the primary antibody to correctly indicate that the antigen has 
been captured. A second antibody is then used which is usually conjugated with an enzyme, 
in this case, horse radish peroxidase for detection [175]. Figure ten illustrates the capture 
sandwich assay.    
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Figure ten: The sandwich assay. The capture antibody is coated on to the plate. The antigen 
is then applied. Non-specific binding is minimized by washing in between each step. 
Unlabelled primary followed by conjugated secondary antibodies are then used. After the 
addition of a chromogenic substrate, a direct light reaction can be directly visualized, and 
quantified using a plate reader.  
 
 
 
 
Secondary 
antibody 
 
Primary 
antibody 
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The NGF ELISA is designed to sensitively and specifically detect NGF in an antibody 
sandwich format. The kit manufacturers state that this test demonstrates a less than 3% cross-
reactivity with other neurotrophic factors at 10ng/ml and offers a sensitivity of detecting a 
minimum of 7.8pg/ml of NGF. This is a three-day ELISA with two overnight incubations 
using a flat-bottom 96-well plate. The anti-NGF pAb, captures the soluble NGF. The 
captured NGF is bound by a second specific monoclonal antibody (mAb). After washing this 
specifically bound mAb is detected using a species specific antibody conjugated to 
horseradish peroxidise (HRP) as a tertiary reactant. The unbound conjugate is removed by 
washing, and following incubation with a chromogenic substrate, a colour change is observed 
and measured. The amount of NGF in the solution is proportional to the intensity of the 
colour generated in the oxidation reaction. The absorbance of the light intensity is recorded at 
450nm on a plate reader. The ELISA protocol is described below, as per the instructions for 
product use provided by Promega. The quantities of solutions described are those required for 
a full 96-well plate. The procedure is described below. 
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The Procedure 
Day ONE 
Step one: The wells are coated with the primary anti-NGF polyclonal antibody (pAb) and left 
to incubate overnight at 4°C. This involves creating a solution of 10mls of carbonate coating 
and 10l of anti-NGF pAb. 100l of this solution is added to each well (see figure below). 
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Day TWO 
Step two: Wash once 
 The contents of the well need to be emptied and washed. This is achieved by turning the 
plate upside down, to discard the contents and the slap it down on to paper towels. Each well 
is then washed once, by applying 200µl of TBST wash buffer and then slapped out again 
numerous times on to paper towels. 
Step three: Block nonspecific antibody binding 
To prevent non-specific bind of NGF to the parts of the well which are not coated with pAb, 
200l of block and sample buffer 1X are added to each well. The plate is then incubated at 
room temperature for one hour. At the end of this hour, the plate contents should be emptied 
into a waste tray, and then slapped onto paper towels.  
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Step four: Wash once 
The plate should then be washed once with TBST wash buffer (200l/well) and slapped out 
onto paper towels. 
Step five: Create the standard curve and load samples into plate 
During the one hour incubation in step three, the standard curve needs to be prepared, and the 
aliquots of urine samples should be removed from the freezer and allowed to thaw.  
Standard curve: The standard curve is a quantitative research tool. This is a method of 
plotting assay data, using a known set of concentrations of a protein, against the assay 
measure, in this case NGF and absorbance. Once these are plotted in a graph, the relationship 
between the two can be identified, and an equation for this derived. After this, absorbances 
from the patient samples can be used to calculate the level of NGF in the urine sample. 
Nine eppendorfs should be lined in a rack. The standard curve created from the NGF standard 
provided with this kit, will generate a linear standard curve from 3.9-250pg/ml. Only values 
within this linear range can be used to determine the NGF concentration of the test samples. 
The NGF standard provided is at 1g/ml. The standard is accurately diluted to a 
concentration of 1:4,000 in block and sample (B&S) 1X buffer. This dilution represents 
250pg/ml of NGF standard.  
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For example:  
1:50 dilution is created first 5l of NGF standard is added to 245l of B&S 1X 
Then a 1:80 dilution is created 10l of (1:50) is added to 790l of B&S 1X.  
This results in a 1:4,000 dilution which represents 
250pg/ml. 
                           
The first eppendorf contains the 1:50 dilution and the second the 1:4,000 which represents 
250pg/ml. At this stage 250l of B&S 1X should be pipetted into all of the other eppendorfs. 
Once the 1:4,000 dilution is created, then a serial doubling dilution is performed down the 
eppendorfs in the rack, creating the following concentrations 250pg/ml, 125pg/ml, 62.5pg/ml, 
31.3pg/ml, 15.6pg/ml, 15.6pg/ml, 7.8pg/ml, 3.9pg/ml, & 0pg/ml. Figure eight illustrates how 
these 1:2 dilutions are performed to produce the standard column. 
The standard curve is run in duplicate, in case of contamination out of or into one of the wells 
within the standard column. The average value will then be taken from the two results. The 
two standard columns can be arranged together or at either end of the plate. Figure nine is an 
example of a plate format with two standard columns. The curve can then be transferred from 
the eppendorfs into the wells. Each well should contain 100l.  
Once the standard curve has been created, the participant urine samples should have thawed 
and can now be arranged. These will be added in duplicate and the average result taken. 
Participant samples will also be added as a neat concentration and a 1:2 dilution. In case the 
signal strength of the neat sample is too high for the assay, above the range of measureable 
NGF of 250pg/ml, then the 1:2 dilution may then be within this range. The NGF value can be 
extrapolated from the standard curve acquired and multiplied by two for the true NGF 
concentration. 
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Figure eleven: An example of a plate format with two standard columns. 
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Throughout the ELISA, care needs to be taken not to handle or touch the bottom of the plate, 
as any finger prints or dirt that may be imprinted on the under surface can reduce the 
absorbance value for those wells when being read in the plate reader. 
Once the standard columns and samples are all added to the wells, 100l in each well, then 
this is left to incubate for 6 hours with the plate is left shaking on a plate shaker. 
Step six: Wash five times  
Stop the 6 hour incubation, and wash the plate 5 times using TBST wash buffer, as performed 
previously.  
Step seven: Overnight incubation with secondary antibody (monoclonal anti-NGF mAb) 
The secondary antibody is prepared, with 2.5l of anti-NGF mAb and 10mls of B&S 1X. 
100l of this mixture is then pipette into each well. The plate is then stored at 4°C without 
shaking, to allow effective incubation. 
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Step eight: Wash five times 
The plate is washed five times as previously described. 
Step nine: Incubation with tertiary antibody 
The tertiary antibody is prepared. This is 100 l of anti-Rat IgG-HRP conjugate mixed with 
9.9ml of B&S 1X. 100l total of this mixture is added to each well. The plate is then 
incubated for 2.5 hours at room temperature on a plate shaker. 
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Step ten: Wash plate five times 
Step eleven: Colour development with TMB one solution  
100l of TMB one solution is then added to each well. The plate is then incubated with 
shaking for 10 minutes. An intense blue light is produced with this reaction. After ten 
minutes 100l of 1N hydrochloric acid (HCl) is added to the wells to stop the reaction. The 
blue colour becomes yellow upon acidification. The absorbance is then read at 450nm on a 
plate reader, within 30 minutes of stopping the reaction.                                 
                                         
A picture of the plate and wells can be seen in photo one below. The blue colours of the 
peroxidase reaction turn yellow once this is stopped with HCl. The intensity of the yellow 
colour is proportional to the concentration of NGF within each well. This is analysed by the 
plate reader at 450nm. 
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Photograph One. The loaded plate with ELISA.  (Photo taken by author JS from the 
neurometabolic unit laboratory at Queen Square). 
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METHOD DEVELOPMENT 
The method development was full of challenges and several steps had to be taken to optimise 
this. During the course of this study, it took many attempts, by changing one parameter at a 
time to perfect the ELISA. Some examples of the challenges faced are shown below from 
individual plates.  
 
Plate One 
The results for the first plate: 
Table thirteen below. Plate plan for plate one. Only four columns of this plate were used. 
Table thirteen 1 2 3 4 
A 250 P1 1:1 (neat) P3 1:1 (neat) 250 
B 125 P1 1:1 (neat) P3 1:1 (neat) 125 
C 62.5 P1 1:2 P3 1:2 62.5 
D 31.3 P1 1:2 P3 1:2 31.3 
E 15.6 P2 1:1 (neat) P4 1:1 (neat) 15.6 
F 7.8 P2 1:1 (neat) P4 1:1 (neat) 7.8 
G 3.9 P2 1:2 P4 1:2 3.9 
H 0 P2 1:2 P4 1:2 0 
 
The placing of the standard columns: Each standard is loaded twice, and the average 
absorbance reading will be taken, in case of any well to well contamination. The wells loaded 
with the standard curves have been placed on either end of the plate. This can be seen from 
the absorbances acquired in table three below. The plate is loaded manually, well by well, 
from the left side to the right.  
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Four participant samples, number P1 to P4, have been loaded in the middle two columns. 
Participant samples were loaded as neat and as a one in two dilution. The absorbances for this 
plate are tabulated below in table fourteen: 
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Table fourteen: The absorbances from the plate reader for plate one. 
ABSORBANCES 1 2 3 4 
A 0.919 0.075 0.094 0.917 
B 0.592 0.076 0.094 0.57 
C 0.363 0.077 0.121 0.358 
D 0.235 0.071 0.099 0.228 
E 0.159 0.084 0.073 0.155 
F 0.117 0.084 0.077 0.119 
G 0.18 0.079 0.075 0.096 
H 0.083 0.08 0.075 0.075 
 
Inference from plate: Insufficient participant sample signal 
From this table it can be seen that the average absorbance values for 0pg/ml in wells H1 and 
H4 is 0.079. This absorbance represents the average background absorbance value in the 
blank wells, and needs to be subtracted from the rest of the values in the remaining wells to 
provide the true absorbance being produced from the enzyme-substrate reaction.  
The absorbances from the standard columns have replicated the doubling dilutions of the 
NGF standard appropriately. This can be verified as the values from well B1 and B4 and 
approximately half of A1 and A4 respectively, and the values from C1 and C4 are 
approximately half of B1 and B4, and this pattern is observed down to G1 and G4. However 
there is an anomaly for the disproportionally high absorbance of 0.18 in well G1, which was 
loaded with 3.9pg/ml of NGF, when compared to the duplicate in G4 which is 0.096. This 
could represent contamination from another well during one of the numerous washing steps 
of the assay.  
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From table fourteen, it can be seen that the absorbance readings for the participant sample 
one to four are small and not significantly different from that observed from the 0pg/ml 
loaded wells from the standard column.  
The absorbance values of the standard column can be plotted against the concentrations of 
standard NGF loaded into each well, to produce a line which represents a linear relationship. 
This can be seen in figure twelve below.   
 
 
 
 
Figure twelve: The linear relationship between the standard dilutions of NGF concentrations 
and absorbances are demonstrated. The equation for the relationship is provided, and this can 
be used to detect NGF concentrations from the absorbances acquired from the patient 
samples. The R-squared value of 0.987 reflects a truly linear relationship between the NGF 
concentration and the absorbance. This value for r-squared represents a strong correlation 
between NGF concentration and absorbance. 
Troubleshooting: 
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The absorbances from the sample wells are very low, and not significantly different from the 
wells containing 0pg/ml. This particular plate therefore detected 0pg/ml in each sample P1 to 
P4. A low sample absorbance could be due to: 
• Instability of NGF (it has been previously reported that NGF is unstable, and levels 
deteriorate rapidly, and the time from sample collection to storage at -70°C to be 
minimised) 
• A collection error (whereby the method of collection is leading to the loss of NGF 
protein) 
• The urine samples being too dilute, which may need concentrating to increase the 
NGF signal 
• There is no measurable NGF in any of the samples 
It was concluded that the plate had not been successful, as there was insufficient signal 
strength from the absorbances of the wells with patient samples. To tackle this, based upon 
these possibilities, the protocol was modified to try and maximise the signal strength from 
these wells. 
To correct this numerous steps were taken, changing one variable at a time. Each step taken 
and the rationale for its change is summarised below. After each single modification, a new 
ELISA plate was processed to assess the impact of that change. For the purposes of brevity, 
not all of the individual plate plans and absorbances are shown, but just some to illustrate 
how the challenges were overcome. 
 
Modification step one: Place urine samples on ice immediately after collection 
Previous reported protocols on the collection of urine for NGF measurement suggest, placing 
urine samples on ice immediately [96]. Studies examining other urinary proteins have 
 
demonstrated that these proteins are often unstable when not in their native environments, 
and short term storage at room temperature can lead to degradation [177]. Up to this stage 
collected urine samples were collected and transferred to the lab, and within 60 minutes were 
then centrifuged at 4°C, before storage at -70°C. This measure should minimise the risk of 
NGF protein deteriorating, during this time.  
Therefore the sample collection protocol was changed and samples placed on ice immediately 
after collection and then immediately transferred to the laboratory to reduce any time delay to 
freezer storage.  
 
Plate Two 
The results from plate two were very similar to plate one. The absorbances of the standard 
columns were reproducible, with accurate doubling dilutions. However there was still 
negligible signal from the sample wells. 
 
Modification step two: Using an internal quality control  
 
It is well known that urine contains proteases and proteinases, which could theoretically 
break down any measurable NGF [178]. Therefore any NGF protein within the urine samples 
could be degraded and broken down by other urinary constituents, and hence by the time of 
analysis there is no measurable quantity remaining. To ensure that NGF is stable with the 
natural matrix of the urine samples provided, urine samples were spiked with a known 
quantity of standard NGF.  
Table fifteen below shows the plan of plate three with a standard column of spiked control 
urine from an asymptomatic, healthy volunteer. These control samples were freshly collected 
and once provided, were spiked with standard NGF and immediately loaded into the wells. 
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Patient samples (P1 and 3) were also loaded into wells in a neat or a 1:2 dilution. Control 
urine was spiked (SC) with doubling dilutions of a known concentration of standard NGF and 
loaded as a standard column in wells 2E to 2H and 3E to 3H.  
 
 
 
Again only four columns in total were loaded in this plate seen in table fifteen. 
Table fifteen 1 2 3 4 
A 250 P1 1:1 (neat) P3 1:1 (neat) 250 
B 125 P1 1:1 (neat) P3 1:1 (neat) 125 
C 62.5 P1 1:2 P3 1:2 62.5 
D 31.3 P1 1:2 P3 1:2 31.3 
E 15.6 SC 250 SC 15.6 15.6 
F 7.8 SC 125 SC 7.8 7.8 
G 3.9 SC 62.5 SC 3.9 3.9 
H 0 SC 31.3 SC 0 0 
 
Table fifteen shows the plan of plate three 
SC: Control urine spiked with a known standard quantity of NGF 
 
 
 
 
 
 
 
The absorbances of the ELISA for plate three are illustrated below in table sixteen 
below: 
ABSORBANCES 1 2 3 4 
A 
0.578 0.068 0.072 0.498 
B 
0.404 0.068 0.067 0.31 
C 
0.255 0.064 0.067 0.198 
D 
0.167 0.062 0.066 0.133 
E 
0.115 0.527 0.081 0.098 
F 
0.09 0.342 0.079 0.078 
G 
0.078 0.2 0.066 0.074 
H 
0.063 0.106 0.064 0.067 
 
Inference from plate: Reproducible standard curve for spiked control urine (wells E2-H2, E3-
H3). Spiked NGF is therefore stable within the urine matrix. There remains to be negligible 
signal in participant samples. 
The standard columns on either end of the plate are reproducible and the doubling dilutions 
are clear and appropriate from the absorbances. The absorbances from the spiked control 
urine, also corresponds well to the absorbances from the standard curve. The absorbances 
demonstrate the effective doubling dilutions that have been performed in the SC urine. There 
was still no signal acquired from the patient samples. 
However it was noted that the signal strength from the absorbances acquired for the standard 
columns (A1 to G1 and A4 to G4) were becoming reduced, compared to plate one. The wells 
loaded with 250pg/ml of NGF standard in plate one demonstrated absorbances of above 0.9, 
whereas the absorbances for plate three are just above 0.5. The plot of the dilutions of NGF 
concentrations versus the absorbances also provides a linear relationship that was previously 
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demonstrated, although the intensity of the absorbances is lower. This is demonstrated in 
figure thirteen below. 
 
 
 
 
 
 
Figure thirteen: The linear relationship between the standard NGF concentrations and 
absorbances are demonstrated. The equation for the linear relationship is also 
described, with a strong correlation as demonstrated by the R-squared value. 
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Troubleshooting: 
There was a lack of significant signal from the patient samples. The difference in signal 
strength of the standards from the previous plates, was thought to be from premature expiry 
of the standard. Instructions from Promega (see Appendices), suppliers of the standard, which 
is frozen on delivery at -20°C, is to store the standard NGF, after first use, once opened and 
thawed at 4°C, which should be stable for three months. At this stage the standard used had 
been stored at 4°C for three weeks, which is within this recommended time frame. However 
since the standard columns were reproducible and produced a similar linear relationship when 
plotted, this stock of standard was still used to develop the assay.  
 
Modification step three: Change the collecting tubes from polystyrene to polypropylene. 
The different types of sample collecting tubes available can have an effect on an ELISA. It 
has been demonstrated to have an effect on the concentration of particular proteins. An 
experiment examining concentrations of protein biomarkers for neurodegenerative diseases, 
in cerebrospinal fluid (CSF) showed that there is significantly less detectable protein when 
polystyrene collection tubes are used [179]. Samples collected with polypropylene collection 
tubes, on the other hand had significantly higher levels of these proteins or biomarkers [179]. 
This is suspected to be due to adherence of these molecules to the polystyrene surface [179]. 
It has also been reported that many proteins can adhere to a solid polystyrene surface, and 
affect the outcome of immunoassays [180]. 
Previously, all patient samples had been collected in a 25ml polystyrene collection tube. The 
protocol was then changed to using polypropylene tubes for collecting patient urine samples, 
which caused a slight delay as it took some time to recruit a sufficient number of new 
samples. Once enough samples were collected using polypropylene tubes, another ELISA 
was performed. Participant samples 1 to 6 (P1 to 6) were loaded into the wells.  
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Internal quality control (IQC): numerous aliquots of control urine had previously been spiked 
with 125pg/ml of NGF, and were stored at -70°C. The NGF concentration within this IQC 
would represent the total of 125pg/ml and the background NGF level in the control sample. 
This was loaded into the wells in G2, G3 respectively. The use of an internal quality control 
is a well recognised way to monitor the performance of an ELISA [176]. This is part of good 
laboratory practice, along with regular charting of all data, and monitoring the assays 
between different plates to identify any trends such as poorly performing kits or differences 
between operators [176]. As the specified range of sensitivity for the assay, advised by the 
suppliers is from 3.9 to 250pg/ml of NGF, a concentration of 125pg/ml was used to spike the 
IQC as this is comfortably within this range for sample detection.  
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Photograph two: Left a polystyrene tube, which is more clear in appearance. Right, a 
polypropylene tube which appears more cloudy. Photos taken from 
www.djblabcare.co.uk 
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Table seventeen: The plate plan for plate four. 
Table six 1 2 3 4 
A 250 P1 1:1 P1 1:2 250 
B 125 P2 1:1 P2 1:2 125 
C 62.5 P3 1:1 P3 1:2 62.5 
D 31.3 P4 1:1 P4 1:2 31.3 
E 15.6 P5 1:1 P5 1:2 15.6 
F 7.8 P6 1:1 P6 1:2 7.8 
G 3.9 IQC  IQC  3.9 
H 0 0 0 0 
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Table eighteen: The absorbances of plate four. 
ABSORBANCES 1 2 3 4 
A 
0.445 0.291 0.09 0.435 
B 
0.241 0.121 0.063 0.243 
C 
0.157 0.074 0.07 0.153 
D 
0.118 0.148 0.059 0.107 
E 
0.088 0.125 0.063 0.088 
F 
0.078 1.171 0.282 0.079 
G 
0.074 0.692 0.68 0.074 
H 
0.057 0.058 0.058 0.081 
 
Inference from plate: The ELISA has worked, as there is now a stronger signal detected from 
the patient samples. The importance of the types of tubes used to collect urine samples for 
measuring uNGF was therefore identified. 
However, as with the previous plate, the signal strength from the standard curve is evidently 
decreasing further, and the signal from the IQC at 125 pg/ml from the standard stock remains 
high. This can be seen by comparing the absorbance from wells G2, G3 to B1 and B4. 
However by this stage the NGF standard had been stored at 4°C, for two months, since it was 
thawed, as advised by the supplier, whilst the IQC has been stored at -70°C. By using the 
IQC, it was identified that the NGF standard stock, once out of -70°C deteriorates rapidly. It 
can be seen that the signal acquired by IQC, corresponds well with the absorbances of 
125pg/ml acquired from the first plate, when the fresh standard stock was first thawed, and 
can be compared from table three. The stock has evidently denatured during this time, and 
this was fedback to the supplier, who had suggested its stability for 3 months at 4°C.  
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Using the polypropylene tubes to collect and centrifuge the urine, appears to have provided 
an absorbance in the wells containing patient samples. From the graph of the standard curve, 
the concentration of NGF in the patient samples can be deduced. However as the absorbances 
from the standard column are deteriorating over time, this would progressively lead to falsely 
high sample absorbances and therefore values as a result.  
 
Standard denaturisation would affect all absorbances, and can impact on the accuracy of the 
assay. As it can be seen in figure five below that it does not denature in a linear fashion. This 
graph demonstrates the deterioration of the absorbances from the stock at 125pg/ml, 
250pg/ml, stored at 4°C and the slower deterioration of the IQC, aliquots of which was stored 
in the freezer at -70°C. This stock of NGF standard was first used in the plate on the 14th 
February and by the 14th March, absorbances from the same standard concentrations are 
considerably less.  
 
As a result all of the study patient samples were analysed using standards from a fresh kit 
straight away once opened to limit the effect of freeze-thaw signal protein degradation and 
signal deterioration.  
 
 
 
 
 
 
 
 
Figure fourteen above: This graph shows the deterioration of the absorbances from the 
125pg/ml, 250pg/ml and IQC dilution of NGF standard over a two month period. Series 
1: 125pg/ml. Series 2: 250pg/ml. Series 3: IQC (spiked urine from healthy control number 4 
with 125pg/ml). 
 
 
 
 
 
 
 
 
 
 
As another quality control measure, to ensure that the low absorbances from the standards 
were not due to operator error from lack of experience, a scientist more familiar with 
performing ELISA’s also performed an independent plate for comparison. The results of two 
plates with identical plate plans, but with two different operators have been compared in 
figure fifteen below.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure fifteen: Bar chart showing the comparable ELISA results from two different 
operators. 
 
 
This bar chart demonstrates the effect of using double operators to perform the ELISA. It is 
observes that the absorbances and NGF/Cr ratios acquired for 12 participant samples, from 
two operators on two separate plates are comparable. As these values are obtained from the 
standard curves loaded in each plate, this also demonstrates that the low absorbances from the 
NGF stock are not due to an error with technique, but more likely due to an expiry of the 
stock. 
 
 
 
 
 
 
RESULTS 
A total of 97 subjects were recruited into the study. Urine samples were collected from sixty 
seven patients with MS and OAB (mean age 45.5, SD: 8.6), 10 patients with MS and no OAB 
(mean age 43.3, SD 8.0) and twenty healthy controls (mean age 44, SD 9.9). There was no 
significant difference in the mean age between the control group and MS patients (p=0.62). 
Six out of the sixty-seven (9.0%) patients with MS and OAB were on antimuscarinic therapy. 
Results are presented in table nineteen.    
 
 Healthy 
Controls 
(n=20) 
MS no 
OAB 
(n=10) 
MS with 
OAB  
(n=67) 
Overall  
(n=97) 
P-value  
Mean Age 
yrs (SD) 
based on 
ANOVA as 
the data is 
normally 
distributed 
43.9 (9.9) 43.3 (8.0) 45.5 (8.6) 44.9 (8.7) 0.62 
Gender 
Number 
Female:Male 
Percentage 
Female:Male 
Based on chi-
12:8 
60%:40% 
7:3 
70%:30% 
46:21 
69%:31% 
65:32 
67%:33% 
0.75 
 
squared test 
Median OAB 
subscore 
(IQR) 
0 (0) 0 (0) 7 (5, 10.5) 5 (0, 8)  
Median 
EDSS score 
(IQR) from 
Mann-
Whitney U 
test between 
the two MS 
groups 
n/a 2 (1.5, 
2.5) 
3 (2.5, 3.5) 3 (2, 3.5) 0.02 
Median 
uNGF/Creat 
(IQR) based 
on Kruskall 
Wallis test 
4.8  
(1.0, 9.5) 
5.3  
(2.3, 14.7) 
10.8  
(3.0, 27.0) 
8.4  
(2.4, 21.0) 
0.04 
Median 
uBDNF/Creat 
(IQR) based 
9.0  
(6.1, 38.5) 
27.9  
(4.2, 53.1) 
53.3  
(13.6, 127.5) 
38.4 
(10.2, 
101.6) 
0.002 
 
on Kruskall 
Wallis test 
   
Table nineteen: Characteristics of the three groups. 
EDSS: Expanded disability status scale 
uNGF/Creat: urinary NGF to creatinine ratio 
uBDNF/Creat: urinary BDNF to creatinine ratio 
IQR: interquartile range 
SD: Standard deviation 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Subjects age followed a normal distribution between the three groups and was assessed using 
ANOVA. There are differences between groups in NGF levels with the highest levels seen in 
MS-OAB patients (median 10.8 (IQR: 3.0, 27.0)) and the lowest levels seen in controls 
(median 4.8 (IQR: 1.0, 9.5)), Kruskal Wallis p-value=0.04. Similarly larger differences are 
observed between groups in BDNF with the highest levels seen in MS-OAB patients (median 
53.3 (IQR: 13.6, 127.5)) and the lowest levels seen in controls (median 9.0 (IQR: 6.1, 38.5)), 
Kruskal Wallis p-value=0.002. 
When the urinary NGF/Cr was compared against the OAB symptom score of the USP 
questionnaire for the patients with MS and OAB, there was a slight correlation between 
symptom severity and urinary NGF/Cr levels with Pearsons correlation coefficient (r= 
0.0558, p=0.65), as can be seen in figure sixteen below.  
 
 
 
 
 
 
 
Figure sixteen: Correlation between y-axis: urinary NGF/Cr levels (pg/µmol) and x-axis: 
OAB score for the patients with MS reporting OAB symptoms (n=67).  R value=0.06. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Unadjusted analysis 
Variable Estimate  
(95% CI) 
P-value 
Group: 
Control 
MS No-OAB 
MS-OAB 
 
Ref 
0.73 (-0.47, 1.93) 
1.07 (0.28, 1.86) 
0.03 
OAB score  
(per unit increase) 
0.08 (0.01, 0.15) 0.03 
Age  
(per year older) 
-0.01 (-0.04, 0.03) 0.75 
On Antimuscarinics 
(Yes versus No) 
-0.56 (-0.78, 1.91) 0.41 
 
Table twenty: Unadjusted linear regression analysis to explore factors related to the log 
NGF/Cr levels. 
 
The log of the NGF/Cr values were calculated to follow a normal distribution. Table twenty 
suggests that no factor is independently related to NGF/Cr levels. In unadjusted analysis there 
is a 0.73 (95% CI: -0.47, 1.93) higher log NGF/Cr level among those with MS and no OAB 
and a 1.07 (95% CI: 0.28, 1.86) higher log NGF/Cr level among those with MS-OAB 
compared to controls, global p-value 0.03. There is no significant difference in NGF/Cr level 
between the MS and no OAB and the control group. MS-OAB patients have a significantly 
higher NGF/Cr level compared to controls. Confidence intervals overlap between the MS no 
OAB and the MS-OAB, and hence they are unlikely to be significantly different, however the 
sample size is insufficiently powered to do pairwise comparisons. 
There is also a 0.08 (95% CI: 0.01, 0.15) higher log NGF/Cr level for each unit increase in 
OAB score. Neither age or antimuscarinic usage is significantly related to the log NGF levels. 
 
 
 
 
There was a fair correlation between Urinary BDNF/Cr and OAB symptom score for the 
patients with MS and OAB, with Pearsons correlation coefficient (r=0.26, p=0.03) as seen in 
figure seventeen below.   
 
 
Figure seventeen: The plot of urinary BDNF/Cr levels (pg/µmol) (y-axis) versus OAB score 
(x-axis) for the patients with MS and OAB symptoms (n=67). R value=0.26. 
 
 
 
 
 
 
 
 
Table twenty-one: Unadjusted linear regression analysis to explore factors related to the log 
BDNF/Cr levels 
 Unadjusted analysis 
Variable Estimate  
(95% CI) 
P-value 
Group: 
Control 
MS No-OAB 
MS-OAB 
 
Ref 
0.23 (-0.79, 1.24) 
1.19 (0.52, 1.85) 
0.0009 
OAB score  
(per unit increase) 
0.11 (0.05, 0.17) <0.0001 
Age  
(per year older) 
0.02 (-0.01, 0.06) 0.10 
On AMS  
(Yes versus No) 
-0.15 (-1.33, 1.02) 0.80 
 
The BDNF/Cr values were skewed, therefore a log transformation of the BDNF/Cr values 
were calculated to follow a normal distribution prior to the analysis. The above table suggests 
that no factor is independently related to BDNF/Cr levels. In unadjusted analysis there is a 
0.23 (95% CI: -0.79, 1.24) higher log BDNF/Cr level among those with MS and no OAB and 
a 1.19 (95% CI: 0.52, 1.85) higher log BDNF/Cr level among those with MS-OAB compared 
to controls, global p-value 0.0009. There is no significant difference in BDNF/Cr level 
between the MS and no OAB and the control group. MS-OAB patients have a significantly 
higher BDNF/Cr level compared to controls. Confidence intervals overlap between the MS 
no OAB and the MS-OAB, and hence they are unlikely to be significantly different, however 
again the sample size is insufficiently powered to do pairwise comparisons. 
There is also a 0.11 (95% CI: 0.05, 0.17) higher log NGF/Cr level for each unit increase in 
OAB score.  
 
 
 
 
 
Receiver operator curves for urinary NGF/Creat and OAB symptoms  
 
 
Figure eighteen: Receiver operator curves for urinary NGF/Creat and OAB score for the MS 
patients with and without OAB symptoms (n=77).  
OAB score has been dichotomized into >0 versus 0 and then seen whether NGF/Cr levels can 
predict having an OAB score >0. Using the Youden Index, the cutpoint in NGF/Cr levels is 
18.97. This gives a 37% sensitivity and a 93% specificity for predicting that the patient will 
have an OAB score of > 0 (using the USP OAB subscore). The AUC at this point is 0.65. 
 
 
 
 
 
 
 
Receiver Operator curves for urinary BDNF/Creat and OAB symptoms  
 
Figure nineteen: Receiver Operator Curves (ROC) for urinary BDNF/Creat and OAB score 
for the MS patients with and without OAB symptoms (n=77).  
Using the Youden Index, the cutpoint in BDNF/Cr levels is 17.37. This gives a 70% 
sensitivity and a 67% specificity for predicting that the patient will have an OAB score of > 0 
(using the USP OAB subscore). The AUC at this point is 0.68. 
 
 
 
 
 
 
 
 
Figure twenty: The correlation between EDSS and OAB score in MS patients both with and 
without OAB symptoms. 
 
 
X-axis: EDSS score and Y-axis: OAB subscore. This shows a positive relationship with 
R2=0.28.  
The correlation between EDSS and uNGF/Cr and uBDNF/Cr levels demonstrate a coefficient 
of R2=0.06 and R2=0.006 respectively.  
 
 
 
 
 
 
 
 
 
 
 
DISCUSSION 
 
This study is the first to analyse the levels of urinary neurotrophins NGF and BDNF in MS 
patients with mild to moderate OAB symptoms and without OAB symptoms compared to 
healthy controls. The results obtained confirm that urinary neurotrophin levels are 
significantly raised in patients with MS compared to healthy controls. This was more marked 
for patients with MS and OAB than for those with no OAB symptoms. Since the group with 
no OAB symptoms was small in number, no comment can be made with statistical 
significance, however there is a trend for the levels to be higher than healthy controls. 
However, interestingly there was only a slight correlation between symptom severity of the 
USP OAB symptom subscore and urinary neurotrophin levels, though it was slightly better 
for BDNF (r=0.26) than for NGF (r=0.06).  This relationship is not as strong as that shown in 
a group of patients with idiopathic OAB where a correlation coefficient of 0.65 and 0.51 was 
observed respectively [144].  
The correlation with the MS patients and OAB symptoms in this study also compares poorly 
to the relationship demonstrated in a group of twenty-six women with painful bladder 
syndrome with an R2=0.73 and R2=0.61 for urinary BDNF and NGF respectively [124].  
The ROC curves achieved for uBDNF/Cr and uNGF/Cr in this cohort showed an AUC of 
0.72 and 0.65 respectively. Compared to a similar study with ninety women diagnosed with 
idiopathic OAB, the accuracy was stronger for idiopathic patients with an AUC of 0.95 and 
0.78 respectively [144]. Similarly another study in patients with idiopathic OAB showed 
stronger receiver operator characteristics of 0.78 and 0.68 have been shown for BDNF/Cr and 
NGF/Cr respectively [120].   
 
 
Using the Youden Index, the optimized cut-off point in NGF/Cr levels is 18.97. This gives a 
37% sensitivity and a 93% specificity for predicting that the patient will have an OAB score 
of > 0 (using the USP OAB subscore). Whilst using the Youden Index, the optimized cut-off 
point in BDNF/Cr levels is 17.37. This gives a 70% sensitivity and a 67% specificity for 
predicting that the patient will have an OAB score of > 0 (using the USP OAB subscore). 
Both of these values compare poorly to that demonstated in a group of women with 
idiopathic OAB where the optimized cut off points for NGF/Cr was 0.14 for a 54% 
sensitivity and 96% specificity for predicting OAB, and a BDNF/Cr value of 4.6 for a 89% 
sensitivity and 100% specificity [144]. This again suggests that baseline urinary neurotrophin 
levels in this patient cohort with MS are higher than that expected for an age matched 
population with idiopathic OAB. The cut-off points are important to determine to provide an 
idea of the normal range of values to expect from a healthy control population before 
defining where the abnormal range would begin. 
 
This suggests that the ability of urinary neurotrophins to act as a biomarker for severity of 
OAB symptoms in patients with MS, using the urinary symptom profile, is less reliable. This 
is further supported by the observed levels from the group of MS patients with no OAB 
symptoms. The mean urinary NGF/Cr and BDNF/Cr levels were higher in this group 
compare to the healthy controls, which suggests that this group may have a higher baseline 
level. Due to the small number of patients within this group, statistically significant 
comparisons cannot be made. This seems to suggest that urinary neurotrophins are derived 
from sources other than the lower urinary tract.  
 
There was a positive correlation between EDSS and OAB subscore which demonstrates that 
patients with more severe disability from the MS are more likely to have a greater OAB 
 
symptom score. The correlation between EDSS and uNGF/Cr and uBDNF/Cr levels 
demonstrate a coefficient of R2=0.06 and R2=0.006 respectively, which suggests there is no 
strong correlation between EDSS and urinary neurotrophin level.  
 
Possible reasons for higher baseline levels of circulating neurotrophins in MS 
Enhanced expression of NGF and its receptors in MS lesions and cerebrospinal fluid have 
been previously described [181, 182].  It is thought that NGF plays an important role in 
myelin repair, through promoting axonal regeneration, survival and protection, and 
differentiation of oligodendrocytes [183]. It also facilitates migration and proliferation of 
oligodendrocyte precursors to sites of myelin damage, and directly regulates key structural 
proteins that comprise myelin, and induce the production of BDNF, which is also integral for 
myelination. It has been suggested that NGF could even be a promising therapeutic candidate 
in white matter disorders such as MS [183].  
It has been suggested that initially there is a relative neurotrophin deficiency in the damaged 
CNS tissue in MS, and that there may be a resultant increase in the expression of peripheral 
blood mononuclear cells (PBMCs), which also express neurotrophins [184]. It is thought that 
these PBMCs can provide some additional neurotrophin support for the CNS tissue, and 
failure to produce this may eventually lead to the atrophy that is seen and is the main 
determinant of the end-point disability for patients with MS. The expression of neurotrophins 
in circulating PBMCs is depicted in figure twenty one below. Whether this immunological 
mechanism can contribute to the raised serum and urinary neurotrophin levels is unknown. 
 
 
 
 
 
 
 
 
 
Figure twenty-one: Interactions between neurotrophins and the immune cells [184].  
NGF: nerve growth factor, BDNF: brain-derived neurotrophic factor, NT-3: neurotrophin 3, 
NT-4/5: neurotrophin 4/5, trk: tropomyosin related kinase receptor, M: macrophage, T: T 
lymphocyte, B: B lymphocyte. Dotted lines indicate secretion. Straight lines indicate affinity 
towards receptors. 
 
 
 
 
 
 
 
 
 
 
 
BDNF has been shown in animal models of MS, to mediate axon protection [185]. Mice 
deficient for BDNF in immune cells displayed an attenuated immune response in an 
experimental model of autoimmune encephalomyelitis. Once lentiviral BDNF overexpressing 
T-cells were injected, this lead to direct axonal protection and a less severe course of 
encephalomyelitis.  
Therefore the possible source for the urinary levels, may be at the site of CNS inflammation, 
where there may be an upregulation of these neurotrophic factors to promote neuronal repair, 
resulting in a raised systemic level of circulating neurotrophins as a byproduct [183]. 
Therefore these patients may have higher urinary neurotrophin levels as a baseline, regardless 
of LUT symptoms, compared to healthy controls. As a result, urinary neurotrophin levels 
may be skewed and therefore less reliable as a sole biomarker for OAB and DO, but 
potentially more so as a generic marker of inflammation.  
 
There may likely be a difference in the pathophysiology of the OAB between idiopathic and 
MS patients. The expression of neurotrophins in the lower urinary tract is complex and not 
fully understood. Several other factors are thought to be involved with the regulation of NGF 
expression including TNF-, interleukin-1, transforming growth factor- (TGF-), platelet-
derived growth factor (PDGF), steroid hormones, -adrenergic agonists, direct camp 
activators, and stretch [94]. The expression of these numerous growth promoting substances 
may differ in patients with MS, due to complex inflammatory processes that are ongoing, and 
therefore less of a strong correlation than with idiopathic OAB is seen. Other biological 
molecules that may have a role in the pathogenesis of OAB include prostaglandins [136], 
cytokines and CRP although, and the activity of these in the urinary tract in MS is also 
unknown. This could also possibly explain the poor correlation between uNGF/Cr and 
uBDNF/Cr levels and OAB symptoms in this group.   
 
Neurotrophins and other conditions – lack of specificity for the OAB? 
As mentioned in chapter two, the specificity of urinary neurotrophins for diagnosing OAB 
alone is also in question. A rise in urinary levels of NGF are not limited to OAB, but has also 
been shown to be elevated in other urological conditions such as interstitial cystitis, urinary 
tract stones, urothelial cancer, bladder outflow obstruction, prostate cancer with perineural 
invasion, asthma, Alzheimers disease, allergies, keratoconjunctivitis, and most recently in 
patients post renal transplantation where it has been proposed to have a role in chronic 
allograft nephropathy [117, 125, 134, 186, 187]. Raised serum NGF levels have been noted in 
several inflammatory and auto-immune diseases such as systemic lupus erythematosus 
(SLE), and juvenile arthritis [188] although whether this represents a causal or counter-
regulatory mechanism is unknown.   
NGF is also thought to have a neuroendocrine role, involved with homeostasis and coping 
with emotion and psychological stressors. Raised serum levels have been observed for 
example in soldiers experiencing their first parachute jump, thought to be triggered by the 
stress and the highly arousing experience [189]. Whether these factors can influence resultant 
levels in the urine is unknown. High serum levels have been significantly correlated with 
raised urinary levels in patients with idiopathic OAB, and these levels remained raised in 
patients who were refractory to antimuscarinic therapy suggesting a chronic inflammatory 
process in these patients [122]. In the same way it is possible that the raised baseline serum 
levels of NGF in patients with MS, as previously described can be related to raised baseline 
urinary levels [172].   
 
These generic characteristics of NGF, which appears to have a ubiquitous presence and role, 
may explain the lack of specificity of uNGF as a marker for the OAB alone. Raised levels 
could therefore represent other urological or neurological pathologies that may be ongoing.  
 
Urinary BDNF/Cr, however has demonstrated a stronger correlation with OAB symptoms 
than uNGF/Cr which is in agreement with other studies assessing idiopathic OAB and 
bladder pain syndrome [124]. The reason for this is unclear, and has not previously been 
examined in MS. However evidence is emerging suggesting that BDNF is a more sensitive 
marker of idiopathic OAB than NGF, although the latter has been more extensively 
investigated. Urinary BDNF levels have been shown to be raised in patients with OAB 
compared to healthy controls, and that this responds to behavioural changes such as bladder 
training, limiting fluid intake, avoiding caffeinated, acidic or carbonated drinks [120]. It does 
appear therefore that between these two neurotrophins investigated, BDNF shows more 
promise as a urinary biomarker.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Study challenges and limitations  
There were numerous challenges to the ELISA technique employed as discussed in the 
method development section. The main ones included the fast deterioration of the reference 
standard NGF and BDNF protein provided by the kit manufacturers. To get around this the 
kit had to be used promptly once opened and first thawed from -70°C. The other issue that 
took numerous attempts before discovery, was the actual device used to collect the urine, as 
described in modification step three. The urinary NGF was evidently sensitive to the use of 
polystyrene collection tubes, where much of the protein was sequestered to the tube itself and 
causing apparent loss of signal and false negatives errors from the urine samples being 
analysed. This was immediately evident once polypropylene tubes were used and sample 
protein was not being lost. Once these hurdles were identified, the ELISA was more 
straightforward, although the considerations that face its integration into a clinical service 
remain its cost, it collection requires rapid placement of the sample onto ice and its 
immediate transfer to the laboratory for centrifugation at 4°C, the technique itself involves a 
lengthy and labour intensive, with numerous manual steps, that require two overnight 
incubations, therefore requiring three days to obtain a result. This is far from being a urine 
dipstick like analysis such as when assessing for -HCG content, with an immediate result, 
which would be the gold standard. 
Practical issues that also need to be considered concern patient selection to avoid false 
positives and negatives. There are many circumstances where false positives can be forseen 
such as patients with urinary tract infections, performing self-catheterisation, both of which 
are common circumstances for patients with MS. False negatives can be encountered from 
patients taking antimuscarinic medications and antibiotics again both of which are frequent 
occurrences [190]. 
 
 
One of the limitations of this study is the lack of urodynamic data to further define the patient 
groups. It is unknown whether those patients in this cohort with MS and no OAB had poor 
detrusor contractility, or whether DO was present alongside poor bladder sensation. This may 
therefore also influence the levels of urinary neurotrophins in some way. However the OAB 
itself is a symptom complex and not a urodynamic diagnosis, and the objectives of this study 
were to assess and compare neurotrophin levels in patients with and without the symptoms of 
OAB rather than with or without DO. 
 
It proved difficult to recruit patients with MS and no OAB symptoms, with only ten of the 
patients in this group. This could reflect that the MS patients attending hospital outpatients, 
have a higher disease severity and therefore may have more urinary symptoms. Those 
patients with the more mild MS, who are community dwelling may be a more appropriate 
population of patients to source for this particular group.  
 
As serum neurotrophin levels were not assayed, no comment can be made on whether urinary 
levels correlate with raised serum neurotrophin level in patients with MS, however this 
requires further study. It has been shown in other inflammatory conditions that the levels of 
circulating serum NGF is raised in certain systemic inflammatory conditions that may or may 
not involve or originate from the lower urinary tract [121, 122, 150, 151]. Patients with 
higher circulating serum neurotrophin levels may have higher urinary levels as a result, and 
therefore measurement of urinary levels alone cannot distinguish whether these proteins 
originate from a dysfunctional lower urinary tract, or from inflammatory CNS pathology.  
 
 
 
 
Future study 
These are relatively new markers in the field of functional urology, however it seems that for 
MS the reliability and validity is yet to be proven, and not superior to current methods of 
assessing bladder function. To complete a more comprehensive study of urinary biomarkers 
for the OAB, it would be valuable to conduct a multicentre study involving a larger 
population group, especially with more patients with MS and no OAB symptoms, to assess 
what is the normal baseline value for patients with MS. Within the same study there could be 
an arm consisting of patients with idiopathic OAB. To answer whether circulating levels are 
higher in patients with this condition and whether this causes a resultant increase in urinary 
levels, both urine and serum samples should be collected. Alongside measuring NGF and 
BDNF levels, the quantities of other suggested potential biomarkers such as ATP, 
neurotrophin 3, and 4/5 (NT3 and NT4/5), and prostaglandins can be collected to assess the 
characteristics of the group as a whole to have a greater chance of identifying the most 
accurate biomarker [191, 192]. It may be that the ideal biomarker will be an array of 
molecules, that when assessed in combination, can more accurately represent the pathological 
state of the bladder.  
 
 
 
 
 
 
 
 
 
 
CONCLUSION 
Translational clinical-science research has clearly shown that neurotrophins play a role in the 
plasticity of afferent nerves and spinal micturition pathways controlling bladder function. 
They seem to have a normal physiological role in the development of normal and strong 
desires to void, and an even more dominant role in the development of lower urinary tract 
dysfunction that accompanies numerous conditions such as inflammatory bladder states, 
bladder outflow obstruction and idiopathic and neurogenic OAB both in the animal and 
human models. Whether these molecules can be used as a biomarker for OAB still needs to 
be investigated more thoroughly in these conditions. However in patients with multiple 
sclerosis, it appears there is more to the pathophysiology of OAB than neurotrophins alone, 
and there must be other growth factors that also need to be considered before an ideal 
biomarker is found. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER FOUR 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter Synopsis 
Chapter four brings the first three chapters together. Chapter one introduced PTNS, an 
upcoming treatment for the OAB. The limitations of PTNS were also discussed such as the 
need for recurrent outpatient visits and the option of a transcutaneous device that would be 
highly desirable. Patients could self-treat at home, avoid numerous hospital visits, avoid the 
few adverse effects that come with PTNS and needle insertion, whilst having a portable 
treatment without the need for being connected to an external power source. Cost analyses 
studies will need to be performed, however on an initial glance, a transcutaneous treatment 
option would also be more cost-effective. 
This chapter reports a prospective randomised study, evaluating the efficacy of a novel 
transcutaneous device, called the GekoTM used to provide tibial nerve stimulation for 
treatment of the OAB over 12 weeks. Patients with idiopathic and neuropathic OAB were 
recruited. 
Chapter three also examined the accuracy of urinary neurotrophins in evaluating patients with 
MS and OAB syndrome, and discussed the need for an objective assessment tool. The 
suggested reasons for a biomarker as mentioned in chapter two included: 
• to objectively monitor and quantify responses to treatment (to help define a treatment 
responder),  
• to research and evaluate the mechanism of action of various treatments (especially 
new treatments such as PTNS) 
• to identify any placebo effect with new treatments and 
• to predict response to treatment 
Chapter four examine these requirements further, by measuring urinary neurotrophin levels to 
help evaluate this new treatment.  
 
 
Single centre randomised pilot study of two regimens (30mins daily or 30mins weekly 
for 12 weeks) of Transcutaneous Tibial Nerve Stimulation for the treatment of patients 
with Overactive Bladder (OAB) Syndrome 
 
Abstract 
 
Hypothesis / aims of study  
The aim of this study was to evaluate the clinical efficacy of a novel transcutaneous device 
for the treatment of patients with either multiple sclerosis or idiopathic OAB. A 
transcutaneous device, effective at treating OAB, with minimal side effects and simple  
enough for patients to self treat at home, would be very a convenient addition to the 
armentary of therapy available. The geko™ is a discrete, self-contained and portable, CE 
marked device that sticks to the skin.   
  
Study design, materials and methods  
A randomized, single centre, phase II pilot study, which enrolled 48 patients (24 with MS and 
24 with idiopathic OAB), suffering from OAB. Patients were randomized into either daily or 
weekly treatment arms. Both arms involved 30 minutes of stimulation for 12-weeks. Patients 
complete a Global Response Assessment Score (GRA) at 12-weeks, and those that reported 
moderate or significant improvement in symptoms with this were defined as a responder. 
Objective outcome measures were used to evaluate symptoms at baseline, week 4, 8, and 12. 
This included the ICIQ-OAB, ICIQLUTS-QoL, bladder diary scores and urinary 
neurotrophin levels NGF and BDNF were also measured at baseline, week 4 and 12. Ethics 
committee approval was obtained prior for the study.  
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Results  
Forty eight patients were recruited into the study, with thirty four patients completing the 
study (19 with MS and 15 idiopathic OAB). Significant improvements in the ICIQ-OAB by 
mean (SD) -9.9 (11.5) (p=0.001) and ICIQ-LUTSqol by -34.0 (60.1) (p=0.001) scores for 
both patient groups by week 12. Weekly treatment seemed equivalent to daily, and there were 
no significant adverse effects. Likert scales showed that patients rated the treatment as easy to 
use, comfortable, and were very satisfied wth this as a treatment modality.   
 
Neurotrophins:  
Idiopathic OAB and uNGF/Cr:  
In patients who responded to therapy, mean NGF/Creat levels were 11.3 (2.7-18.9) and 13.6 
(1.8-22.4) pg/mg at baseline and week 12 respectively (p=0.99). Non-responders had mean 
levels of 96.6 (40.6-97.8) to 48.4 (4.5-133.6) pg/mg at baseline and week 12 respectively 
(p=0.23). The NGF/Creat levels at baseline for the non-responders were significantly higher 
than the responders (p=0.05). This could suggest potential for uNGF as a predictor of 
treatment response. 
Idiopathic OAB and uBDNF/Cr:  
There was a trend for baseline BDNF/Cr levels to be higher in the non-responders than 
responders. In patients who responded to therapy, mean BDNF/Creat levels significantly 
reduced from 66.6 to 19.1pg/mg (p=0.03) by week 12. Non-responders had a change of mean 
levels from 117.7 (6.7-337.8) to 76.8 (0-182.5) pg/mg at week 12 (p=0.89). BDNF appeared 
more sensitive to response to treatment in those that have a successful response to treatment. 
MS and OAB urinary neurotrophins:  
There were no significant changes in the urinary NGF/Creat or BDNF/Creat scores from 
baseline to week 12 for the patients with MS and OAB, in either the responders or non-
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responders.  
Interpretation of results  
Significant improvements were seen in subjective and objective symptom and QOL 
assessment parameters for patients using this novel form of tibial nerve stimulation. Adverse 
effects were minimal. Weekly treatments were equivalent to daily. Response from the MS 
patients was comparable to the idiopathic patients. Patients reported the treatment as easy to 
use, comfortable, very satisfactory. Urinary neurotrophin assessment in the idiopathic OAB 
group shows that perhaps higher levels of NGF/Creat at baseline may be a predictor of poor 
response, whilst urinary BDNF/Creat levels could be investigated further to monitor response 
to treatment as they significantly reduce in the patients who respond to therapy. Urinary 
Neurotrophin levels did not change significantly in the patients with MS during treatment.   
  
Conclusion 
This randomised pilot study shows that transcutaneous tibial nerve stimulation, using the 
geko™ device, appears to be an effective, safe and convenient method of management for 
patients with severe OAB symptoms. Additional work is required for a multicentre study to 
demonstrate the long-term efficacy of this treatment.  
 
 
 
 
 
 
 
INTRODUCTION 
 
The success of posterior tibial nerve stimulation (PTNS) in the management of the overactive 
bladder (OAB) against placebo has opened a novel modality of peripheral nerve stimulation 
for managing the overactive bladder [40]. Clinical efficacy has been demonstrated through 
clinical studies and its use is supported by NICE guidance in the United Kingdom.   
However it is yet to be considered as a perfect solution for patients. Its non-inferiority 
compared to current treatments such as onabotulinumtoxinA and SNM is yet to be proven. 
There are non-serious adverse events to consider. These have been reported in up to 8.5% of 
patients and include pain, bruising, tingling or bleeding at the insertion site [193]. Patients 
have also reported leg cramps, and pain and numbness in the sole of the foot. Other rare side 
effects which have been reported include swelling, worsening of incontinence and vaso-vagal 
response to needle placement. The practicality of offering PTNS within the framework of an 
NHS clinical service needs to be considered. With current treatment regimes, patients must 
attend an outpatients department on a weekly basis for a total of 12 weeks.  This may be a 
limitation for those travelling considerable distances, or may be too much of a time 
commitment for patients with busy schedules. This would take longer for patients with 
neurological disorders who may have problems with mobility.  In the STEP study, out of 
those patients attending follow up sessions, two out of the fifty patients (4%) withdrew due to 
practical difficulties in attending regular follow-up visits [71]. A further 4% of the patients 
withdrew as they moved further away from the hospital. The requirement of regular 
attendances may negatively impact compliance and adherence to this treatment regime.  
In addition the resources required for providing medical and nursing staff to deliver the 
treatment must also be considered when preparing a cost-effectiveness model.  
 
 
Transcutaneous nerve stimulation 
The option of transcutaneous tibial nerve stimulation (TTNS) is therefore an attractive option 
[194]. Transcutaneous electrical nerve stimulation (TENS) has been used as a medical 
remedy for musculoskeletal complaints such as pain management and spastic paraparesis. 
TENS is thought to be able to modify central CNS signaling, for example when applied to the 
palm for median nerve stimulation, it was observed that this suppressed some cortical 
amplification. Likewise when applied to somatovisceral complaints, it was observed that 
gastric electrical activity can also be modified by TENS. This has been studied by measuring 
gastric myoelectric activity and electrogastrography, and it has been shown that TENS can 
activate centrally mediated somato-visceral reflexes and be therefore used to treat gastric 
dysrhythmia [195]. 
 
Transcutaneous tibial nerve stimulation studies 
A handful of TTNS studies have been conducted previously to explore the effects for the 
OAB, the early results of which show some promise with efficacy. However further study is 
clearly required to investigate this treatment further. 
Amarenco et al in 2003, carried out a study using TENS for a heterogeneous group of 
patients with demonstrated DO [51]. A total of 44 patients were included with a background 
of neurogenic and idiopathic origin. The acute urodynamic affects of TTNS were assessed. 
Patients had a baseline cystometric study, which was recorded. A self-adhesive, disposable, 
stimulation patch was then placed over the posterior tibial nerve behind the medial malleolus 
with two contact electrodes (positive and negative), and stimulation was applied at a 
frequency of 10Hz with a pulse width of 200 milliseconds in a continuous mode, and toe 
flexion was confirmed. Second cystometry was performed during stimulation. It was 
observed that during stimulation there was an increase in the mean volume at first involuntary 
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detrusor contraction from 162.9mls to 232.1, and and the mean cystometric capacity from 
221 mls to 277.4mls which was statistically significant.  
Another small study assessed the affects of TTNS on a group of six female patients with 
OAB secondary to Parkinson’s disease or Multiple System Atrophy [196]. This was 
performed daily for 20minutes for six weeks and patients were assessed at the end with the 
patient global impression of improvement scale and urodynamics. Five out of six patients 
considered this to be an effective treatment, and were still using the treatment six months 
after the end of the study. There was no significant improvement in urodynamic or symptom 
scores, however. 
Schreiner et al in 2010 performed a placebo controlled, randomized trial of 12-weeks of 
TTNS in addition to standard therapy versus standard therapy alone, to treat urgency 
incontinence in a group of fifty-one older women (>60years of age). Standard therapy 
consisted of 12-weeks of bladder training and pelvic floor muscle exercises. Sixty eight 
percent of patients in the TTNS group reported cure or improvement versus 35% in the 
control group, with supported evidence from bladder diary parameters and quality of life 
questionnaires [197]. 
De Seze et al, performed a multi-centric study of 70 patients with MS and symptoms of OAB 
across five neurorehabilitation departments [75]. The mean duration of MS was 13.4 years 
and LUTS 8.2 years. Patients were excluded if they had an Expanded Disability Status Scale 
of >7, indicating that patients were able to walk at least 20m with or without assistance, were 
relapse free for the last three months and not wheelchair bound. All patients were refractory 
to antimuscarinic therapy either due to lack of efficacy or intolerable side effects. Clinical 
efficacy was assessed with questionnaire tools at baseline, 30 and 90 days following initiation 
of treatment, and cystometry was performed before and at the end of the 90-day study. The 
transcutaneous patches of a TENS machine were applied through two adhesive electrodes, 
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above and behind the medial malleolus. These were attached to an external stimulator 
through wires. Stimulations were delivered as 200sec pulses with a pulse rate of 10Hz and a 
value of 19-30 mA. The intensity was aimed at a threshold above perception of stimulation 
but below that of pain being caused. Patients were taught the technique of self directed 
stimulation and performed this for 20 minutes daily. This study demonstrated significant 
efficacy and safety of this device. By day 30, significant improvements in urgency were seen 
in 51.3%, and frequency in 66.7% of patients with a reduction of 2.7 voiding episodes per 
day. Continence was improved in 62% of patients with a reduction of 2.7 leakage episodes 
per week. Psychological burden due to LUTS was also noted to decrease through quality of 
life assessment scores.  
It was concluded that TTNS is safe, effective, with no local or systemic adverse effects noted 
from this cohort. There was no development of voiding dysfunction after this treatment, 
which is relevant in patients with MS where CISC may be difficult due to problems with co-
ordination. Other advantages of this treatment option were related to feasibility as this device 
could easily be used at the home setting either by the patient or a carer. This provides a useful 
management option for patients with MS, where options can be limited. The effects of more 
intermediate to chronic term stimulation need to be evaluated. 
 
The limitation of a TENS machine, where the patient is attached to an external power source, 
is the inherent restriction to activity and limited portability of such devices.  The availability 
of a patch electrode would address these limitations, and provide a patient-delivered option. 
The aim of this study was to evaluate the safety and efficacy of TTNS using a novel portable 
device, which acts as a single stick-on patch electrode. 
 
An introduction to - The geko™ device 
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Sky Medical Technologies Ltd (also trading as Firstkind Ltd) have developed a novel method 
and produced a CE marked medical device [geko™] for transcutaneous nerve stimulation. 
The geko™ is a discrete, self-contained and portable, CE marked device that sticks to the 
skin via an adhesive conductive hydrogel and weighing just 16g can be worn at home without 
impeding most normal activities (see www.gekodevices.com).  
The geko™ device is an internally powered, that uses a new technology called OnPulse™ a 
neuromuscular stimulation technology enclosed in a disposable device, that is applied 
externally to the leg. It was developed by Firstkind Ltd as a portable, disposable, 
neuromuscular stimulation device of the popliteal fossa for the improvement of blood flow in 
the lower limb [198]. The device has received the CE Marking for increasing blood 
circulation and for the prevention of venous thrombosis (MDD Annex II certificate CE 
558928 issued by BSI (Notified Body number 0086, expires 25 Oct 2015). 
In its original application for prevention of deep vein thrombosis, geko™ triggers small 
electrical impulses that gently activate the common peroneal nerve within the popliteal fossa, 
behind the knee, in turn activating the venous muscle pumps of the calf and foot. Substantive 
increases in lower limb blood flow have been demonstrated to improve venous return and 
thereby reduce stasis with no reported morbidity [198]. NICE is currently developing 
guidance on this technology for this indication [199].  
 
The device fits behind the medial malleolus of the ankle (positioned as figure 1) where it can 
readily stimulate the posterior tibial nerve. Upon activation, by pressing the on-off switch of 
the device, the abductor hallucis muscle in the foot contracts. Positioning the adhesive geko 
device for use in this way is straightforward and the application surface is flat making good 
contact via the conductive hydrogel. Paraesthesias are essentially confined to the foot.  These 
sensations are not expected at the point of contact as the current density is spread across a 
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wide area. Devices should be set to the highest comfortable setting using one of the seven 
settings available which alter the pulse width whilst maintaining a constant current. 
The device has default stimulation parameters at 27mA constant current, at a frequency of 
1Hz. The pulse width (sec) will vary between 70 and 560s depending on the maximum 
tolerable sensory and best motor responses (movement of toes) as determined by the patient 
using one of the seven settings in the device selected using the single push button switch. 
Apart from antimuscarinic therapy patients could continue all other medications ad libitum 
during the trial, although these will be recorded.  
With the device attached, the patient was able to continue with normal daily activities with no 
restriction to ambulation (although vigorous activity e.g. running and gym visits are not 
encouraged, driving is prohibited whilst wearing the device, swimming or bathing are not 
possible as the hydrogel adhesive is water soluble). It is fully insulated by the protective 
moulding and there is no risk of electric shock. (Refer to Appendices for Instructions for use 
of the device). The device has been assessed to current medical-electrical equipment safety 
standards. 
 
 
The portable disposable device design is well suited for this application as: 
 
• It is non-invasive. Adoption could offer a significant reduction in the number of 
surgical procedures undertaken per annum with associated reduction in risk. 
 
• It will reduce the cost of treatment of mild to moderate OAB. The cost of a 12 week 
course of the geko™ device is estimated to be £300, as compared to £1,800 or 
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£16,000 for PTNS outpatient treatment or Sacral Nerve Stimulation, respectively, 
according to NHS tariffs. 
 
• It does not require specialist skills or knowledge to apply. The device can be applied 
by the patient at home with minimal initial instruction. Many patients decline PTNS 
because of the associated time and travel inconvenience. 
 
• The patient is fully mobile during therapy, and the device is invisible beneath clothing 
in contrast to the TENS approach which requires physical connection to a stimulator 
unit.  
 
A study evaluating the Geko device would assess changes in OAB symptoms over the period 
of time of the intervention. However considering the subjective nature of OAB symptoms, 
evaluating a biomarker of OAB might provide more robust evidence of benefit.  The urinary 
levels of two neurotrophic factors involved in the pathogenesis of OAB [135], known as 
nerve growth factor (NGF) and brain derived neurotrophic factor (BDNF),  have been 
identified in the urine and are being explored currently as biomarkers for the overactive 
bladder (as discussed in chapters two and three).  Studies have shown a reduction in the 
urinary levels of the neurotrophic factors after successful BTX-A, antimuscarinic therapy, 
SNM and acupunture therapy for OAB, and therefore can be used to assess response to 
therapy [118, 119] [112, 128].  Therefore, the measurement of urinary neurotrophins was also 
performed before, during and after treatment to provide an objective biological marker for 
treatment response. 
 
 
 
Study Aims and objectives 
The aim of our study was to Investigate the clinical efficacy and safety of transcutaneous 
tibial nerve stimulation using the geko™ on OAB symptoms in patients with MS and 
Idiopathic OAB. To determine both a subjective outcome using patient reported outcomes 
and an objective outcome by evaluating urinary neurotrophins for response to treatment. 
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A picture of this device can be seen in figure 1 below. 
Figure 1: Proposed Ankle application of the geko™ device 
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MATERIALS AND METHODS 
This study was performed with the approval of the London Surrey Borders Health Research 
Authority National Health Service Research Ethics Committee (REC) approval, with REC 
reference number 12/LO/1613 and was sponsored by the Research and Development 
department of University College London. These documents can be seen in the Appendices. 
All subjects gave written informed consent prior to enrollment into the study. The study was 
supported by external funding from FirstKind Ltd.   
 
Study design 
In this randomised open label investigator-led clinical study, forty-eight (48) patients with 
OAB symptoms attending the Department of Uro-Neurology, at the National Hospital for 
Neurology and Neurosurgery, Queen Square, for treatment were recruited. Patients enrolled 
were male and females, aged 18 years with symptoms of OAB (urgency, urinary frequency, 
and/or urge incontinence) for 3months. Patients had either eight or more micturitions, and 
one urgency episode (with or without incontinence) per 24hours based on the three-day 
bladder diary and the ICIQ-OAB symptom questionnaire. Prior to starting the study, subjects 
had a 2-week run-in washout period, where prior OAB medications (including antimuscarinic 
or B3-agonist mirabegron) were stopped. The intention to treat included twenty-four (24) 
patients with multiple sclerosis and twenty-four (24) patients with idiopathic OAB. 
 
It is accepted that ideally this study would have a validated sham arm. However, an 
appropriate validated sham was not available at the time of study design. Therefore an 
internal control was incorporated into the study design, where patients were randomised to 
receive different doses of neurostimulation ie a ‘large and small dose’ by introducing weekly 
and daily arms. This has the advantage of giving basic information on dosing and 
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acceptability. Also in the literature, various studies have used a range of PTNS regimes from 
daily, twice weekly, three times and four times per week and weekly [40, 43, 44, 46, 52, 75]. 
Whilst the most widely recognised regime remains weekly, a daily arm was chosen to see if 
this would offer superior efficacy due to the higher dose of therapy. The previous study 
evaluating TPTNS in patients with MS, by de Seze et al in 2011, also used a daily stimulation 
regime [75]. 
 
The patients were provided with a full explanation of the nature, purpose and requirements of 
the study including Patient Information Leaflet (PIL) and signed an Informed Consent Forms 
(ICF). They were invited to participate in a screening assessment, which included collection 
of information about past medical history, drug history and a physical examination. Voiding 
diaries and questionnaires were used to determine severity of symptoms prior to treatment. 
No study related procedure was undertaken prior to the signing of the ICF. 
Patients were randomised into two potential treatment arms of:  
1. 30 minutes of TPTNS once a day 
2. 30 minutes of TPTNS once a week 
 
Randomisation was undertaken using a web-based programme ‘Sealed Envelope’ 
https://www.sealedenvelope.com/freerandomiser/v1/lists that generated the randomisation list 
for both patients with MS and idiopathic patients. Thus giving:  
• 12 patients with MS randomised to 30mins/day 
• 12 patients with MS randomised to 30mins/week 
• 12 patients with idiopathic OAB randomised to 30mins/day 
• 12 patients with idiopathic OAB randomised to 30mins/week 
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Assessments (See Appendices) 
All of the documents mentioned as part of the patient’s assessment can be found in the 
Appendices. 
Assessments were made at inclusion, then at week 4, week 8 and week 12 following the start 
of treatment. ICIQ-OAB and ICIQ-LUTSqol questionnaires and 3-day bladder diaries were 
completed for each of these visits to assess the severity of symptoms and the social and 
psychological burden. These questionnaire tools have been thoroughly validated and have 
received a grade A rating from the fourth ICI [14]. ICIQ-OAB is divided into parts A and B. 
A assesses symptom severity and B questions the patient about the degree of bother for this 
symptom, giving a score of up to 16 for A, 40 for B, and 56 in total. The ICIQ-LUTSqol, also 
divided into part A and B, examines the impact of urinary symptoms on the restriction of 
activities of daily living and various psycho-social aspects of the patients life (A), and how 
much each restriction bothers the patient. 
Patients were required to attend outpatient visits at 0, 4, and 12 weeks during the treatment 
period, and were telephoned on a weekly basis by a member of the research team to enquire 
about device use and any adverse events. At the end of the study patients also completed a 
Global Response Assessment (GRA), which assesses whether patients perceive their 
symptoms to have improved, deteriorated or remained unchanged after 12 weeks of therapy, 
on a visual analogue scale as well as indicating the degree of this change. Responders were 
defined as those whose bladder symptoms are moderately or markedly improved on a 7-level 
GRA, as used in the SUmiT study [40]. Patients also completed a Patient Satisfaction 
Questionnaire that assesses their treatment tolerability and satisfaction.  
 
The electrical stimulus setting was dependent upon each patient and their stimulus response, 
regardless of which arm of the study the patient was in. Once the device was applied, patients 
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had to demonstrate a sensory-motor response in their toes. The device setting was adjusted 
chosen according to this response. At the initial education session regarding the device, the 
patient was shown the device, and demonstrated how it works. The device was then be 
applied by the research team member, and set to an appropriate stimulation to achieve the 
required motor and sensory response in the toes [59]. The device was applied unilaterally, 
and the patient was taught the technique of application to self-apply at home.  
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Inclusion and Exclusion Criteria 
Inclusion criteria 
In order to be eligible to enter the study, patients must have met the following criteria: 
 
1. Age 18 – 70 years 
2. Self-reported overactive bladder symptoms for >3 months 
3. Average urinary frequency of 8 voids per day 
4. Self-reported failed conservative management  
5. Discontinued all anti-muscarinics for at least 2 weeks 
6. In patients with Multiple Sclerosis: The Kurtzke Expanded Disability Status Scale 
(EDSS) score 6.5 and below and free of relapses in the previous 3 months 
7. Intact cutaneous sensations to nociception in the lower limb, as determined by the 
investigator  
8. Able to understand the Patient Information Sheet and capable and willing to give 
informed consent and follow the protocol requirements (including attending all 
follow-up visits) 
9. Willing to delay treatment with botulinum toxin for 12 weeks 
10. On effective contraception if sexually active – oral contraceptive pill (> 3 months 
use), condoms, intrauterine contraceptive device, depot injection 
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Exclusion criteria 
Patients would be excluded from the study if they met any of the following exclusion criteria: 
 
1. Pregnant or planning to become pregnant during study duration 
2. Use of botulinum toxin for the bladder or pelvic floor within the past one year 
3. Pacemakers or implantable defibrillators 
4. Bladder scans consistently showing an elevated post void residual > 100 mL 
5. Current urinary tract infection 
6. Current vaginal infection 
7. Use of any other neuro-modulation device such as Interstim® 
8. Current use of TENS in pelvic region, back or legs 
9. Recent PTNS treatment 
10. Use of investigational drug/device therapy within past 4 weeks that may interfere with 
this study 
11. Participation in any clinical investigation involving or impacting gynaecologic, 
urinary or renal functions within past 4 weeks 
12. Clinical symptoms of peripheral arterial disease, significant varicose veins or lower 
limb ulceration 
13. Recent surgery (such as abdominal, gynaecological, hip or knee replacement). 
14. Recent trauma to lower limbs. 
15. Chronic Obesity (BMI Index >34) 
16. Any medication judged to be significant by the Principal Investigator 
17. Any significant illness during the four (4) weeks preceding the screening period of the 
study 
18. Recent diagnosis of Deep Vein Thrombosis 
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19. If a patient was deemed to clinically have a benign enlarged prostate by clinical 
examination, an elevated residual volume, and evidence of an obstructed flow on 
uroflowmetry 
 
Urine sample collection and ELISA 
Urine samples were collected for measurement of urinary NGF and BDNF (uNGF) and 
(uBDNF) in patients with MS and idiopathic OAB. Samples were collected at baseline, and at 
week 4 visits and at week 12 (end of therapy). Urine samples were collected at full bladder 
sensation, immediately placed on ice, transferred to the laboratory, and centrifuged 
(3000rpm; 10 min at 4°C). The supernatant was collected in 1ml eppendorf tubes and stored 
at -70°C. NGF and BDNF concentrations were measured using ELISA (Emax Immunoassay 
System, Promega, Madison, WI, USA), with a minimum sensitivity of 3.9pg/ml and 7.8 
pg/ml, respectively, following the manufacturers instructions. 
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Outcomes 
Primary endpoint: 
To assess the patient response to 12 weeks of treatment with geko™ to manage OAB 
symptoms using the Global Response Assessment Score (GRA). (This score can be found in 
the Appendix section) 
 
Secondary endpoints: 
• To determine the efficacy of a 12 week course of tibial nerve stimulation by the 
geko™ device using two treatment frequency paradigms, as measured by the ICIQ-
OAB, ICIQ-QoL and bladder diary. 
• To assess the patient’s satisfaction of the treatment using the Likert scale.  
• To estimate dose response using two treatment duration paradigms by comparison of 
daily versus weekly efficacy. 
• To evaluate the urinary NGF and BDNF levels in patients before, during and after 12 
weeks of transcutaneous tibial nerve stimulation. 
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RESULTS 
Population 
Sixty-two patients were screened in total, to identify 48 eligible patients to begin the study. 
Forty-eight patients were recruited into the study, with nine males and thirty-nine females 
with a mean age of 46 years. Fourteen patients withdrew from the study after starting, leaving 
34 patients (5 men and 25 women) completing 12 weeks of treatment. Of this group, 19 and 
15 patients had MS and Idiopathic OAB respectively. The groups of those having daily 
versus weekly treatments is illustrated in the table twenty-two below. 
 
 Daily Weekly Total 
Multiple Sclerosis 9 10 19 
Idiopathic OAB 10 5 15 
Total  19 15 34 
 
Table twenty-two: The distribution of diagnoses in the two treatment arms 
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The summary flow chart of patients enrolling into the study is shown below in figure 
twenty-two: 
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Failed screening 
The reasons why 14 patients failed screening are listed in the table twenty-three below. 
Reason for failed screening Number 
No sensory-motor response in feet once 
device applied 
12 
Raised post-void residual volume 2 
Total 14 
 
It is evident that the device was unable to elicit a sensory-motor response in the feet of 12 
patients. For sufficient stimulation of the PTNS, as reported in the SuMIT study, there should 
be sensory and or motor responses in the feet of the subject. Evidence of effective stimulation 
should cause toe flexion of the great toe and/or of digits two to five. Patients should also 
notice some sensory paraesthesia in the sole of the foot. It has been shown in a previous study 
that patients with unsufficient sensory motor response in the feet do not respond to PTNS 
[59], and therefore these 12 patients were not included in the study. However before 
exclusion, the device position was altered and adjusted to try to evoke a response, considering 
the possibility of intersubject variability in local anatomy. More than one device was tried in 
case there was a manufacturing fault with that particular device. If this failed, an attempt was 
also made using the contralateral leg to establish a response. Notably these patients had intact 
sensation in their lower limbs on neurological examination to both touch and pin prick over 
the L5 and S1 dermatomes. Six out of these twelve patients had a degree of ankle oedema, 
which may have limited the efficiency of the stimulation. 
 All patients went on to have a trial sensory-motor stimulation using the percutaneous 
technique with a fine needle, and eleven out of these twelve patients were able to feel some 
sensory-motor response with this. 
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Study withdrawals 
The reasons for withdrawal from the study are presented in table three below. To note 
thirteen patients withdrew from the study, and one was lost to follow up. Two out of the 
thirteen patients who withdrew from the study were due to lack of efficacy, and three due to 
discomfort from the device stimulations. In the table these are classified as device related and 
non-device related withdrawals of which the former comprises 8/14 of the cases. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Device related Unrelated to device 
Reason Number of patients Reason Number of patients 
Skin reaction to 
device (redness) 
1 Family 
bereavement 
1 
Discomfort from 
device stimulations 
4 Lost to follow-up  1 
Withdrew from 
study as ineffective 
2 Became ill with 
MS prior to starting 
device 
2 
Daily stimulation 
was too intense for 
patient 
1 MS related leg 
weakness 
1 
  Could not come off 
antimuscarinic 
medication 
1 
Total 8 Total 6 
 
 
Table twenty-four: The device related and non-device related reasons for patient 
withdrawal from the study. 
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Adverse events 
Adverse events from the study were 7 in total, which again can be divided into device related 
and unrelated adverse events. Five out of seven were device related whilst 2/7 were unrelated 
to the device. These are tabulated in table four below. Four of the device related adverse 
events were due to discomfort from the device stimulations, and one due to skin redness after 
a reaction to the adhesive on the device. The two non-device related adverse events include 
one UTI in a patient who performed clean intermittent self-catheterisation, and the other 
bilateral leg weakness in a patient who had a history of episodic leg weakness due to her MS. 
There were no systemic side effects and no patient reported voiding dysfunction or urinary 
retention.  
 
 
 
 
 
 
 
 
Table twenty-five: Describes the adverse events – classified into either related or 
unrelated to the device. 
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The spread of EDSS scores for the patients with MS ranged from one to six, and there was no 
clear correlation between EDSS score and the response to treatment. The graph below shows 
that for the mean change from baseline to the end of study for ICIQ-OAB scores, 
improvements were seen in both patients with low or high EDSS. There were also 2 patients 
whose questionnaire score had worsened by 12 weeks. Improvements in symptoms after 
twelve weeks of treatment, were not affected by the severity of disability imposed by MS. 
 
 
 
Figure twenty-three: A graph to show the change in ICIQ-OAB score among the MS 
patients with differing EDSS scores. X-axis EDSS score, Y-axis change in ICIQ-OAB 
score (the baseline score subtracted from the end of study score). A negative value 
denotes an improvement in symptoms, whilst a positive value suggests a worsening of 
score in the questionnaire. 
 
 
 
 
 
Primary endpoint:  
Eighteen out of thirty four 18/34 (53%) patients self scored their response after 12 weeks of 
treatment as moderate or significant improvement on the GRA scale, and were termed as 
responders. The remaining sixteen out of thirty-four (47%) patients who were non-responders 
scored themselves as having no or only mild improvement on the GRA. No patients scored 
themselves to have worsened on the GRA visual analogue scale.  
 
Secondary endpoints: 
The baseline scores for responders and non-responders for the ICIQ-OAB and ICIQ-
LUTSqol are not significantly different, implying that non-responders did not start the study 
with significantly worse symptoms. The symptom and QOL scores over time can be seen in 
figure four and five below: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure twenty-four: Mean ICIQ-OAB total scores in responders versus non-responders  
 
 
Visit 1, 2, 3, 4 relate to week 0, 4, 8 and 12 
Figure twenty-five: Mean ICIQ-LUTSqol total scores in responders versus non-
responders  
 
 
 
Visit 1, 2, 3, 4 relate to week 0, 4, 8 and 12 
 
 
The demographics of the responders and non-responders are displayed in the table 
twenty-six below: 
Responders Non-Responders  
Mean age (yrs) 42 Mean age (yrs) 48.3 
Mean EDSS (MS 
patients) 
4 Mean EDSS (MS 
patients) 
3.7 
Group Weekly Daily  Group Weekly Daily  
MS 7 6 13 
(72%) 
MS 3 4 7 (44%) 
IDO 2 3 5 (28%) IDO 3 6 9 (56%) 
 9 9   6 10  
 
 
There was no significant difference in age or EDSS of either group of responders or non-
responders. Interestingly the majority, 13 (72%), of the responders had MS. There was a 
comparable number of responders and non-responders in the daily and weekly arms.  
 
 
 
 
 
 
 
 
 
The table twenty-seven below shows the baseline characteristics which are comparable 
between the two groups. 
Table twenty-seven: Study characteristics at baseline according to diagnosis 
 Those who completed 12 
weeks follow up N=34 
Range 
 
Characteristic: 
Idiopathic 
N=15 
MS 
N=19 
 
Sex (M/F)    
Daily treatment; N (%) 10 (66.7%) 10 (53.6%)  
Wet; N (%) 13 (86.7%) 17 (89.5%)  
Age; mean (SD) 41.9 (18.2) 48.3 (9.2)  
    
Perceived day frequency 
ICIQ-OAB; median (IQR) 
2 (2, 2) 2 (1, 2.5) 0: 1 to 6 times 
1: 7 to 8 times 
2: 9 to 10 times 
3: 11 to 12 times 
4: 13 or more times 
Perceived nocturia ICIQ-
OAB; median (IQR) 
3 (2, 3) 2 (1.5, 3) 0: none 
1: one 
2: two 
3: three 
4: four or more 
Perceived urgency ICIQ-
OAB; median (IQR) 
3 (2, 3) 2 (2, 3) 0: never 
1: occasionally 
2: sometimes 
 
3: most of the time 
4: all of the time 
Perceived leakage ICIQ-OAB; 
median (IQR) 
2 (2, 3) 2 (2, 3) 0: never 
1: occasionally 
2: sometimes 
3: most of the time 
4: all of the time 
    
ICIQ OAB total; median 
(IQR) 
41 (35, 46) 38 (28, 44) 0-56 
ICIQ-LUTSqoL total; median 
(IQR) 
145 (135, 
235) 
155 (118, 
204) 
0-276 
    
Mean voided volume; median 
(IQR) 
202 (151, 
238) 
150 (112, 
184) 
 
    
24 hour freq (BD); median 
(IQR) 
10.7 (8, 11) 12 (9, 14)  
Mean bladder urge (BD); 
median (IQR) 
2.5 (2.3, 
3.3) 
2.9 (2.2, 3.1)  
Mean leakages (BD); median 
(IQR) 
2.7 (1, 4) 1.7 (1, 4)  
Leakage severity (BD); 
median (IQR) 
1.2 (1, 2) 1 (1, 1.3) 1: mild 
2: moderate 
3: severe 
 
IQR: Interquartile range 
BD: Bladder diary 
From the bladder diary, patients with MS did have significantly smaller mean and maximum 
voided volumes compared to the patients with idiopathic OAB, at the end of study, from the 
three-day bladder diary (169 and 271 mls versus 312 and 466 mls respectively). This suggests 
that the patients with MS may have had smaller functional bladder capacities to the patients 
with idiopathic OAB. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table twenty-eight: Mean (SD) absolute changes in the ICIQ questionnaire and bladder 
diary outcomes from baseline to week 12 according to diagnosis 
 
Characteristic: 
Idiopathic 
N=15 
MS 
N=19 
Overall 
N=34 
    
Perceived day frequency change; 
mean (SD) 
-0.62 (0.77) -0.50 (0.89) -0.55 (0.83) 
Perceived nocturia change; mean (SD) -0.69 (1.11) -0.56 (0.73) -0.62 (0.90) 
Perceived urgency change; mean (SD) -0.54 (0.88) -0.88 (0.72) -0.72 (0.80) 
Perceived leakage change; mean (SD) -0.69 (0.95) -0.88 (0.89) -0.79 (0.90) 
    
ICIQ OAB total change; mean (SD) -9.2 (10.4) -10.6 (12.7) -9.9 (11.5) 
ICIQ QoL total change; mean (SD) -20.3 (65.5) -44.9 (55.4) -34.0 (60.1) 
    
Mean voided volume change; mean 
(SD) 
43.4 (94.1) -3.4 (55.7) 16.3 (75.7) 
    
24 hour freq change (BD); mean (SD) -1.03 (3.55) -1.56 (2.76) -1.32 (3.06) 
Mean bladder urge change (BD); 
mean (SD) 
-0.70 (0.93) -0.56 (0.79) -0.62 (0.83) 
Mean leakages change (BD); mean 
(SD) 
-0.70 (1.53) -0.97 (1.48) -0.85 (1.47) 
Leakage severity change (BD); mean 
(SD) 
-0.46 (0.59) 0.05 (0.67) -0.23 (0.64) 
 
 
BD: Bladder diary 
(SD): standard deviation 
The above table shows the absolute changes in the individual parameters, from end of study 
to baseline. For the ICIQ-OAB, ICIQ-LUTqol, and BD parameters, a negative value, 
suggests fewer symptoms and an improved outcome. For mean voided volume, only 
improvement was seen in the idiopathic OAB group, with no improvement observed for the 
patients with MS. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
All of the below tables (twenty-nine to thirty-nine) have been produced using mixed 
effects models to take into account the multiple observations on each patient. These 
tables show the effect of time, diagnosis or treatment frequency on each of the outcome 
parameters. 
Table twenty-nine: Change in perceived day frequency according to baseline 
characteristics 
 Unadjusted analysis Adjusted analysis 
 
Characteristic: 
Regression 
coefficient (95% 
CI) 
P-value Regression 
coefficient (95% 
CI) 
P-value 
Time; per each extra 
week of therapy 
-0.04 (-0.06, -0.02) 0.001 -0.04 (-0.06, -0.02) 0.001 
Diagnosis; MS vs IDO  -0.03 (-0.67, 0.61) 0.93 -0.02 (-0.68, 0.63) 0.95 
Treatment; weekly vs 
daily  
-0.04 (-0.66, 0.57) 0.88 -0.04 (-0.68, 0.60) 0.90 
 
 
Table thirty: Change in perceived nocturia according to baseline characteristics 
 Unadjusted analysis Adjusted analysis 
 
Characteristic: 
Regression 
coefficient (95% 
CI) 
P-value Regression 
coefficient (95% 
CI) 
P-value 
Time; per each extra 
week of therapy 
-0.05 (-0.08, -0.02) <0.0001 -0.05 (-0.08, -0.02) <0.0001 
Diagnosis; MS vs IDO  -0.26 (-0.84, 0.32) 0.38 -0.29 (-0.88, 0.30) 0.34 
Treatment; weekly vs 
daily  
0.10 (-0.47, 0.68) 0.72 0.21 (-0.38, 0.79) 0.49 
 
 
Table thirty-one: Change in perceived urgency according to baseline characteristics 
 Unadjusted analysis Adjusted analysis 
 
Characteristic: 
Regression 
coefficient (95% 
CI) 
P-value Regression 
coefficient (95% 
CI) 
P-value 
Time; per each extra 
week of therapy 
-0.07 (-0.09, -0.04) <0.0001 -0.07 (-0.09, -0.04) <0.0001 
Diagnosis; MS vs IDO  -0.32 (-0.75, 0.10) 0.14 -0.29 (-0.71, 0.13) 0.18 
Treatment; weekly vs 
daily  
-0.34 (-0.77, 0.09) 0.12 -0.27 (-0.69, 0.16) 0.22 
 
 
 
 
 
 
 
 
Table thirty-two: Change in perceived urge leakage according to baseline 
characteristics 
 Unadjusted analysis Adjusted analysis 
 
Characteristic: 
Regression 
coefficient (95% 
CI) 
P-value Regression 
coefficient (95% 
CI) 
P-value 
Time; per each extra 
week of therapy 
-0.06 (-0.09, -0.03) <0.0001 -0.06 (-0.09, -0.03) <0.0001 
Diagnosis; MS vs IDO  -0.27 (-0.84, 0.30) 0.36 -0.23 (-0.79, 0.32) 0.41 
Treatment; weekly vs 
daily  
-0.32 (-0.86, 0.21) 0.24 -0.27 (-0.80, 0.26) 0.32 
 
 
 
Table thirty-three: Change in ICIQ OAB total according to baseline characteristics 
 Unadjusted analysis Adjusted analysis 
 
Characteristic: 
Regression 
coefficient (95% 
CI) 
P-value Regression 
coefficient (95% 
CI) 
P-value 
Time; per each extra 
week of therapy 
-0.82 (-1.13, -0.51) <0.0001 -0.82 (-1.13, -0.51) <0.0001 
Diagnosis; MS vs IDO  -4.63 (-9.76, 0.51) 0.08 -4.65 (-9.84, 0.54) 0.08 
Treatment; weekly vs 
daily  
-2.98 (-8.19, 2.23) 0.26 -2.14 (-7.47, 3.19) 0.43 
 
 
Table thirty-four: Change in ICIQ QoL total according to baseline characteristics 
 Unadjusted analysis Adjusted analysis 
 
Characteristic: 
Regression 
coefficient (95% 
CI) 
P-value Regression 
coefficient (95% 
CI) 
P-value 
Time; per each extra 
week of therapy 
-3.22 (-5.04, -1.41) 0.001 -3.17 (-5.00, -1.35) <0.0001 
Diagnosis; MS vs IDO  -16.1 (-48.7, 16.5) 0.33 -15.3 (-47.1, 16.5) 0.35 
Treatment; weekly vs 
daily  
-27.3 (-57.9, 3.3) 0.08 -25.2 (-57.9, 7.5) 0.13 
 
 
 
Table thirty-five: Change in mean voided volume according to baseline characteristics 
 Unadjusted analysis Adjusted analysis 
 
Characteristic: 
Regression 
coefficient (95% 
CI) 
P-value Regression 
coefficient (95% 
CI) 
P-value 
Time; per each extra 
week of therapy 
0.83 (-1.58, 3.23) 0.50 0.86 (-1.52, 3.23) 0.48 
Diagnosis; MS vs IDO  -64.3 (-108.1, -20.6) 0.004 -65.0 (-109.2, -20.7) 0.004 
Treatment; weekly vs 
daily  
-17.2 (-63.3, 28.9) 0.47 -4.1 (-48.0, 39.8) 0.86 
 
 
Table thirty-six: Change in 24 hour bladder frequency according to baseline 
characteristics 
 Unadjusted analysis Adjusted analysis 
 
Characteristic: 
Regression 
coefficient (95% 
CI) 
P-value Regression 
coefficient (95% 
CI) 
P-value 
Time; per each extra 
week of therapy 
0.09 (-0.33, -0.51) 0.68 0.07 (-0.33, -0.46) 0.74 
Diagnosis; MS vs IDO  -2.34 (-9.20, 4.51) 0.50 -2.89 (-10.53, 4.75) 0.46 
Treatment; weekly vs 
daily  
3.32 (-2.82, 9.46) 0.29 3.77 (-3.28, 10.82) 0.30 
 
 
Table thirty-seven: Change in mean urge according to baseline characteristics 
 Unadjusted analysis Adjusted analysis 
 
Characteristic: 
Regression 
coefficient (95% 
CI) 
P-value Regression 
coefficient (95% 
CI) 
P-value 
Time; per each extra 
week of therapy 
-0.05 (-0.07, -0.02) <0.0001 -0.05 (-0.07, -0.02) <0.0001 
Diagnosis; MS vs IDO  0.17 (-0.27, 0.61) 0.45 0.17 (-0.27, 0.62) 0.45 
Treatment; weekly vs 
daily  
-0.00 (-0.42, 0.41) 0.99 -0.00 (-0.42, 0.42) 0.99 
 
 
Table thirty-eight: Change in mean leakages according to baseline characteristics 
 Unadjusted analysis Adjusted analysis 
 
Characteristic: 
Regression 
coefficient (95% 
CI) 
P-value Regression 
coefficient (95% 
CI) 
P-value 
Time; per each extra 
week of therapy 
-0.06 (-0.12, -0.01) 0.03 -0.06 (-0.12, -0.01) 0.03 
Diagnosis; MS vs IDO  -0.01 (-1.57, 1.55) 0.99 -0.00 (-1.55, 1.54) 0.99 
Treatment; weekly vs 
daily  
-0.03 (-1.60, 1.55) 0.97 -0.04 (-1.59, 1.51) 0.96 
 
 
Table thirty-nine: Change in leakage severity according to baseline characteristics 
 Unadjusted analysis Adjusted analysis 
 
Characteristic: 
Regression 
coefficient (95% 
CI) 
P-value Regression 
coefficient (95% 
CI) 
P-value 
Time; per each extra 
week of therapy 
-0.01 (-0.03, 0.01) 0.26 -0.01 (-0.03, 0.01) 0.36 
Diagnosis; MS vs IDO  -0.00 (-0.26, 0.25) 0.98 0.05 (-0.23, 0.33) 0.72 
Treatment; weekly vs 
daily  
-0.17 (-0.41, 0.07) 0.16 -0.20 (-0.46, 0.07) 0.15 
 
 
 
 
Clinical efficacy 
It can seen that for all individual ICIQ-OAB, ICIQ-LUTSqol patient self reported parameters, 
there are significant improvements in symptoms of urinary frequency, nocturia, urgency and 
urge leakage and these are improvements are sustained for every week that the patient 
receives therapy. The clinical benefits appear to be cumulative for up to end of therapy at 12 
weeks. These improvements are also related to the impact symptoms are having on patient 
QOL, suggesting reduced psychosocial burden which appears to improve significantly with 
each week of therapy. 
 
 MS versus Idiopathic 
As can be seen in the tables above, for all ICIQ-OAB, ICIQ-LUTSqol and BD parameters, 
there is no significant difference between the performance of either group of patients in 
response to therapy. The TPTNS seems to have equal efficacy for idiopathic OAB and MS. 
 
Weekly versus daily treatment 
Likewise there are no significant differences in the efficacy using these parameters for 
patients in the weekly or daily arm. This suggests non-inferiority of weekly treatments 
compared to daily stimulations. This has important implications for clinical application, as 
can be seen from table three, one patient withdrew from treatment due to the onerous 
intensity of daily stimulation. Therefore weekly treatments would be more suitable for patient 
satisfaction, compliance and cost-effectiveness. 
 
 
 
 
 
Using a multilevel regression model for all patients whether MS and Idiopathic OAB, and 
including those from both daily and weekly arms, all patients had significant improvements 
in ICIQ-LUTSqol at the week 4, 8 and 12 visits by 25.9, 28.2 and 40.8 points respectively 
compared to baseline. Likewise there were significant improvements for the ICIQ-OAB score 
at the week 4, 8, and 12 visits by -6.5, -7.4 and -10.2 points respectively. It can be seen that 
the most significant improvement for both questionnaires is by week 12. This suggests that 
treatment beyond 8 weeks, as carried out by some previous studies, and up to 12 weeks is 
justified, as the benefit from the stimulation is most evident at the end of study. This is 
illustrated in table fourty and fourty-one. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table fourty and fourty-one: the absolute change in ICIQ-LUTSqol and ICIQ-OAB 
score over the visits. 
 Change in ICIQ-
LUTSqol total 
score from baseline 
Std Error P value 95% Confidence interval 
Week 4 -25.9 8.1 0.001 -41.7 -10.1 
Week 8 -28.2 8.7 0.001 -45.2 -11.2 
Week 12 -40.8 8.5 <0.0001 -57.4 -24.3 
 
 Change in ICIQ-
OAB total score 
from baseline 
Std Error P value 95% Confidence interval 
Week 4 -6.5 1.6 <0.0001 -9.8 -3.2 
Week 8 -7.4 1.9 <0.0001 -11.0 -3.8 
Week 12 -10.2 1.7 <0.0001 -13.5 -6.9 
 
 
 
  
 
 
 
 
 
 
 
Patient satisfaction 
Results of the 7-point Likert scale evaluating patient satisfaction suggests patients were 
satisfied with the ease of operating the device, comfort and mobility.  
 
 
Figure twenty-six: Patient satisfaction survey. Y-axis 1-The device instructions are easy 
to understand; 2- The device is easy to attach and remove; 3- The device is easy to 
operate; 4. The device is comfortable to use; 5. I have full mobility when I am wearing 
the device; 6. The device improved my symptoms; 7. Overall I am satisfied with the 
device; 8. I would recommend the device to a friend for this use.  X-axis seven point 
Likert scale (Strongly disagree- 1; Strongly agree- 7).   
 
 
 
 
 
 
 
 
Urinary Neurotrophin Analysis 
 
Nerve Growth Factor 
In patients with MS who responded to therapy, mean NGF/creat levels changed from 30.1 at 
baseline to 32.4 at week 12. For the non-responders, mean levels were 33.8 at baseline to 
30.5 at week 12.   
 
Figure twenty-seven: The change in NGF/Cr levels over the course of treatment in 
patients with MS 
X-axis: Visit 1, 2 and 3 relate to visits at baseline, week 4 and 12 
Y axis: urinary NGF/Creat level pg/millimol/L 
 
 
 
 
 
 
 
In patients with Idiopathic OAB who responded to therapy, mean NGF/Creat levels were 
11.3 (2.7-18.9) and 13.6 (1.8-22.4) pg/mg at baseline and week 12 respectively (p=0.99). 
Non-responders had a change of mean levels from 96.6 (40.6-97.8) to 48.4 (4.5-133.6) pg/mg 
at baseline and week 12 respectively (p=0.23). The NGF/Creat levels at baseline were 
significantly different between the responders and non-responders (p=0.05).  
 
Figure twenty-eight: The change in NGF/Cr levels over the course of treatment in 
patients with idiopathic OAB 
X-axis: Visit 1, 2 and 3 relate to visits at baseline, week 4 and 12 
Y axis: urinary NGF/Creat level pg/millimol/L 
 
 
 
 
 
 
 
 
 
Brain derived neurotrophic factor 
In patients with MS who responded to therapy, mean BDNF/Cr levels changed from 67.2 at 
baseline to 46.8 at week 12 (p=0.49). For the non-responders, mean levels were 77.0 at 
baseline to 28.2 at week 12 (p=0.33).   
 
 
Figure twenty-nine: The change in BDNF/Cr levels over the course of treatment in 
patients with MS 
X-axis: Visit 1, 2 and 3 relate to visits at baseline, week 4 and 12 
Y axis: urinary BDNF/Cr level pg/millimol/L 
 
 
 
 
 
 
 
In patients with Idiopathic OAB who responded to therapy, mean BDNF/Cr levels changed 
from 66.6 to 19.1pg/mg (p=0.03). Non-responders had mean levels of 117.7 (6.7-337.8) to 
76.8 (0-182.5) pg/mg at week 12 (p=0.89).   
 
 
Figure thirty: The change in BDNF/Cr levels over the course of treatment in patients 
with idiopathic OAB 
X-axis: Visit 1, 2 and 3 relate to baseline, week 4 and 12 
Y axis: urinary BDNF/Cr level pg/millimol/L 
 
 
 
 
 
 
 
 
 
 
DISCUSSION 
This is the first study to assess the clinical efficacy of the gekoTM device as a mode of 
Transcutaneous Tibial Nerve Stimulation (TTNS) to manage OAB in idiopathic or patients 
with MS. Fifty three percent of patients completing 12 weeks of treatment had a positive 
response by reporting a moderate to significant improvement on the GRA scale. This is 
comparable to the improvement seen in the SUmiT study where 54.5% of the patients in the 
treatment arm reported moderate or marked improvements in bladder symptoms [40]. Patient 
using this form of TPTNS demonstrated that this treatment significantly improved their 
symptoms and its associated psychosocial burden. 
Significant improvements were observed in this responder group with reductions in the 
symptoms of OAB and disturbance to QOL. A 40% reduction in perceived urgency, and 
42%, 44% and 34% reduction in urge leakages, nocturia and daytime frequency respectively 
from the ICIQ-OAB questionnaire. These reductions in OAB symptom score were matched 
by 43% improvements in the bothersome QOL score. These benefits appear to be evident 
after the first week of therapy and are sustained and cumulative over the twelve-week 
treatment period. 
 
The device also was demonstrated to be safe with minimal adverse effects, where only four 
out of thirty five patients experienced some discomfort with the device stimulations. The 
prevalence of OAB increases significantly with age [200] and there is a need for treatment 
alternatives that do not have any adverse effects for this group of patients who may already 
rely on numerous medications. With the efficacy of TPTNS, if proven with larger placebo 
controlled phase III studies, with its minimal adverse effect profile could be considered as a 
first line treatment in such populations. 
 
 
No significant differences were seen in the performance of TPNS for OAB symptoms 
between patients with MS or idiopathic OAB. There was a trend for MS patients to perform 
better since 72% of the responders were MS patients. This efficacy of TTNS in patients with 
MS supports the findings from the study by de Seze et al, and the handful of small PTNS 
studies demonstrating success of symptom control in this neurogenic population of patients 
[51, 55-60, 75]. These findings also match the findings observed from the responses to PTNS 
described in chapter one. 
 
The study design included weekly and daily arms to investigate whether one was superior to 
the other. The SUmiT study design treated patients on a weekly basis, whilst de Seze et al 
who studied another method of transcutaneous delivery used a daily treatment regime both 
over a three-month period [40, 75]. In this study patients receiving daily stimulations were 
equivalent and did no better than those on the weekly regime, and thus demonstrates non-
inferiority of either treatment frequency. This may have significant cost implications as the 
cost of twelve devices over three months would be considerably less than that for 84 devices 
which would be required for daily use. This would also be favourable for patient compliance 
as weekly use would be much less intrusive to their daily routine, than a daily use of thirty 
minutes. As a result patient compliance to treatment may be more successful. It can be seen 
that one patient withdrew from the study due to the burden of daily stimulations. Also for 
patients who find the stimulations uncomfortable, which lead to three patients to withdraw, 
weekly use would be more bearable. 
 
Urinary Neurotrophins 
Interestingly no significant changes in neurotrophin levels were seen in the responders and 
non-responders with MS throughout the treatment programme. There appeared to be some 
 
trend for neurotrophin level increase after four weeks of stimulation, especially with the non-
responders to therapy, and the significance of this is unclear. This could possibly reflect some 
remodeling of the nerve activity at the level of the urothelium or the local neural circuitry. 
However as can be seen from our experience in chapter three, the reliability of urinary 
neurotrophins as a marker for OAB in patients with MS is unclear.  
 
Whereas for the idiopathic OAB patients, baseline NGF levels were significantly higher in 
the non-responding patients compared to the responders. It is interesting to observe that all 
idiopathic patients who had comparable OAB symptom severity prior to starting therapy, yet 
there remains a large difference in the uNGF levels at baseline. This may reflect the severity 
of the underlying disease processes that are producing the symptoms. This may suggest that a 
very high baseline NGF/Cr score may be a poor predictor for response to treatment. No 
significant change in the NGF/Cr levels were seen however in the responders to therapy. The 
reason for this is unclear and this could be due to the small sample of patients, which could 
only identify trends and is not powered to offer accurate biomarker analyses. The other 
explanation for the lack of response seen in uNGF/Cr reason could suggest some evidence of 
placebo effect in this cohort, however this is confounded by the improvement in BDNF/Cr 
levels. Placebo effect is present to some degree in most clinical trials, however without a 
sham arm the actual extent of this is unknown. 
 
With regards to BDNF/Cr levels in the idiopathic patients, the baseline levels were different 
with the non-responders having higher levels, similar to the NGF/Cr levels, however this was 
not to significance. However the BDNF/Cr levels significantly reduced by the end of study 
compared to baseline, in the clinical responders, suggesting that the BDNF levels may be of 
some use to monitor response to treatment. There was no reduction seen in the non-
 
responders to therapy. Further study of these biomarkers is required in larger numbers to 
uncover the role of urinary neurotrophins as a biomarker for assessing response to treatment. 
The evidence for its use for idiopathic OAB is growing, however this is largely lacking for 
the MS patients. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Study limitations 
Only 34 out of an intended 48 patients completed this study, significantly reducing the 
sample size by almost 30%. The reasons for withdrawal were documented and eight of the 
fourteen patients were device related. Two of these were due to lack of efficacy and five due 
to adverse effects. However this study was not powered to draw significant statistical 
conclusions, but to be considered as a phase II pilot study to test the principle of this device 
as a potential treatment option, and to document its safety. A larger volume of patients will be 
recruited for any phase III study, which will be appropriately powered to adjust for the 
patients who withdraw. 
 
Study outcomes were reliant on patient reporting and therefore not wholly objective. This is 
always a consideration for OAB trials as this is essentially a condition that is patient self-
reported symptom complex. On the whole therefore the ICS recommends the use of validated 
tools that can assess symptoms and the impact on QOL [67]. Some studies evaluating PTNS 
have included urodynamic parameters to correlate with questionnaire scores. The three-day 
bladder diary is more objective than the symptom questionnaires, however this is also reliant 
on patients accurately measuring urine outputs and fluid intake over three 24hour periods, 
which some patients admittedly found difficult to do. 
Urodynamic assessment of patients at baseline and end of therapy was not performed in this 
phase II study. Therefore no comment can be made on the detrusor pressures during filling, 
and the compliance and bladder capacity and its response to TTNS. Whether a new treatment 
modality can reduce detrusor pressures is important and this requires evaluation in a future 
study, as severe neurogenic DO may risk upper urinary tract function, and these candidates 
may therefore not be suitable for this therapy. However in an attempt to provide some 
objective evaluation of treatment response, urinary neurotrophins were analysed.  
 
There was no placebo arm in this study and hence the extent of the placebo response is 
unknown. This form of peripheral nerve stimulation urgently requires large volume trials 
comparing the treatment to placebo. It has been noted during OAB drug trials that the placebo 
effect can effect up to 64% of patients for urinary incontinence symptoms and the actual 
placebo effect for this device needs to be appropriately evaluated [27]. This is particularly 
relevant as it has been demonstrated in a study that the effect of a sham device has a greater 
placebo effect than that of an inert pill. This study involved the use of an acupuncture needle 
for arm pain versus a placebo pill, over an eight-week period [201]. However the observed 
reduction in urinary BDNF/Cr levels in response to treatment in the responders, and the lack 
of any level reduction in the non-responders, would support that any placebo effect would be 
minimised. 
 
Since the study duration was limited to 12 weeks, the continuation of efficacy past this period 
is unknown. Therefore the long-term reliability of this as a treatment needs further 
investigation with an extended study period to identify the optimal treatment period, and 
whether treatment efficacy is sustained with top up therapy as described in the STEP study 
with PTNS [71, 202].  
 
Patient’s who respond to antimuscarinic therapy for OAB may indicate that they have mild to 
moderate OAB. It is likely that the severe OAB patients would not respond to antimuscarinic 
therapy for sufficient symptomatic control, and would therefore require treatment with 
intravesical BTX-A or SNM. The patient cohort recruited for this study were either 
antimuscarinic naïve, responsive and those who had failed therapy. Since this is a 
heterogenous group of patients, although with comparable baseline symptom scores, some 
patients would have more significant disease that is resistant to therapy. If patients were all 
 
responders to antimuscarinic therapy, then the overall performance and response to TTNS 
may be better than demonstrated in this study. To control the effect of antimuscarinic therapy, 
patients were asked to stop AM treatment with a two week washout period, so the risk of 
patients who may have been having a combination of AM and TTNS is avoided and the 
outcomes are not skewed as a result.  
There was also heterogeneity in the group of patients with MS who had a range of EDSS 
scores. It has been demonstrated that the likelihood of a urodynamic abnormality in MS was 
higher in patients who had an EDSS score of more than 6.5, and hence more severe bladder 
dysfunction, and more resistant to treatment [163]. Therefore to limit the impact this may 
have on the range of baseline symptom severity, recruitment was restricted to patients with 
EDSS scores of less than 6.5 and free of relapses for the previous 3 months. 
 
Twelve patients out of the sixty-two screened patients (19%) were unable to feel any sensory 
motor response once the patch was applied, and were defined as screen failures. All of these 
patients had intact sensory nerve examination of their lower limbs, both to touch and to 
pinprick. Fifty percent of this group had evidence of ankle oedema, which may have impeded 
signal transduction from the device. Eleven of these patients then went on to have a positive 
peripheral nerve evaluation with the PTNS needle system (UrgentPC), where a sensory motor 
response was successfully demonstrated. This would indicate that the needle is more effective 
at locating and delivering the stimulation to the posterior tibial nerve. This could possibly be 
due to the preferable anatomical proximity the needle has to access the deeper nerve, 
compared to a skin patch which is more superficial.  
The nature of the stimulus may also be important to the clinical outcome. PTNS uses a 
current level of 0.5 to 9mA at 20Hz with a fixed pulse width of 200microseconds, and the 
current amplitude is adjusted to a setting that is found to be tolerable for the patient, which is 
 
usually 1.5 times that sufficient to evoke fanning or planting flexion of toes. In comparison, 
the gekoTM device delivers single pulse of 27mA, with an adjustable width, at a frequency of 
1Hz. The pulse width is adjustable to one of seven settings between 70 and 560s. The level 
of electrical stimulation with the gekoTM is adjusted by changing the pulse width. The effect 
of the different modes of stimulation delivery is unknown. The optimal power and frequency 
of delivery of electrical stimulation that would be closest to the biology of a true action 
potential and provide the most significant clinical impact is also unknown. This is an area for 
further research investigation.  
To address the issue with numerous patients unable to demonstrate a sensory motor response 
to the device, a newer modified device, called gekoT-2, has been developed with more 
effective stimulation delivery, and requires some clinical evaluation and validation. The lack 
of sensory motor response in 19% of patients screened immediately excludes patients from 
treatment, and the transcutaneous delivery of stimulation needs to optimized to minimize this 
patient loss.  
  
Tolerance and Withdrawal 
There were a few patients reporting local side effects to therapy with four out of 34 patients 
(12%) having discomfort with the device. One patient complained of skin redness as a 
hypersensitivity reaction to the adhesive of the device, which became apparent after only a 
few minutes of wearing the device. No patient reported any symptoms or signs of urinary 
retention, and the one patient who was self-catheterising did not recover voiding function at 
the end of study. 
Patients found using the device to be easy to understand and operate, as well as relatively 
comfortable whilst allowing mobility during stimulation. This would be of significant benefit 
to patients to be able to continue their treatment at home, with minimal interruption to their 
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daily activities. Some patients reported that they were able to wear the device whilst at work 
or having dinner at a restaurant. In contrast, patients undergoing PTNS would need to attend 
an outpatient clinic weekly for their treatment. This may have implications for adherence and 
compliance to treatment. Some patients from this cohort of patients reported that they were 
able to wear the device whilst sitting at a desk at work or whilst sitting, dining at a restaurant. 
Satisfaction levels of the treatment and device itself were on the whole high and most would 
recommend this form of treatment to a friend.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Future directions 
This study demonstrates that a 12-week course of transcutaneous stimulation of the posterior 
tibial nerve using the gekoTM device is safe and effective for the management of overactive 
bladder symptoms. However a larger, multicentric study is required to confirm the results of 
this pilot study, with a sham arm, to specifically assess the optimal frequency of device use. 
This study should include randomized arms into placebo, TTNS, PTNS and antimuscarinic 
therapy.  
If TTNS shows non-inferiority to these other modalities, with a minimal adverse effect 
profile and high patient satisfaction scores, this could represent an ideal first line treatment.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The potential benefits over these other treatments are summarized in table fourty-two 
below: 
 
 TPTNS PTNS Antimuscarinic 
therapy 
Adverse effect Similar minimal 
adverse effect 
profile to PTNS. 
Avoid the use of a 
needle puncture by 
using an adhesive 
pad. 
Discomfort and 
bruising at needle 
point insertion. 
 
Significant drop out 
rate due to 
intolerability. A recent 
systematic review 
reports that ongoing 
adherence and 
persistence of therapy 
is as low as 12% at 12 
months after starting 
therapy, due to poor 
tolerability and lack of 
efficacy [203]. 
Signifincant adverse 
effect profile 
including dry eyes, 
mouth, constipation, 
cognitive decline, and 
contra-indicated with 
closed angle 
glaucoma. 
 
Cost 
effectiveness 
To be evaluated by 
further study. 
Weekly therapy 
equivalence to 
daily therapy will 
have significant 
cost benefits. 
To be evaluated 
compared to the 
other modalities. 
To be evaluated 
compared to the other 
modalities. 
Convenience of 
treatment 
Superior to PTNS 
as patients can 
avoid weekly 
outpatient visits, 
and self-apply 
treatment in the 
community, with 
minimal restriction 
to mobility. 
Patients need to 
attend weekly to 
the outpatients 
department and are 
immobile for thirty 
minutes during the 
stimulation 
delivery. 
May be less 
convenient especially 
for patients already 
taking numerous 
medications due to 
drug interactions.  
    
 
 
 
 
 
 
 
 
 
CONCLUSION 
Neuromodulation techniques have been evolving over the last two decades and the less 
invasive options will be welcome to patients, and change the approach to the OAB. The 
gekoTM device can be safely used for stimulating the posterior tibial nerve at the ankle. A 12 
week course of transcutaneous stimulation of the posterior tibial nerve using the gekoTM 
device is effective in reducing the severity of OAB symptoms, and improving lower urinary 
tract related QOL, as assessed by standardized questionnaires of lower urinary tract functions 
and bladder diaries.  Patients with both neurogenic OAB, due to MS, and idiopathic OAB 
show clinical improvement. Patients undergoing weekly stimulation showed an equivalent 
response compared to daily stimulation. Patients report a high level of satisfaction and 
tolerability, and would recommend the treatment to a friend.  There were no significant safety 
concerns.  There was a cohort of individuals, however, who were unable to feel the 
stimulation and were defined as screen failures. High baseline levels of urinary NGF/Cr may 
predict poor response to treatment in patients with idiopathic OAB. BDNF/Cr levels reduced 
with response to treatment in the clinical responders, but not with the non-responders to 
therapy. Further phase III, placebo controlled study is required to evaluate whether this 
device has a place in the management of the OAB.  
 
 
 
 
 
 
 
 
 
REFERENCES 
 
[1] Yoshimura N, Kaiho Y, Miyazato M, et al. Therapeutic receptor targets for lower 
urinary tract dysfunction. Naunyn Schmiedebergs Arch Pharmacol. 2008 Jun: 377:437-48 
[2] Apostolidis A, Dasgupta P, Fowler CJ. Proposed mechanism for the efficacy of 
injected botulinum toxin in the treatment of human detrusor overactivity. Eur Urol. 2006 Apr: 
49:644-50 
[3] Fowler CJ, Griffiths D, de Groat WC. The neural control of micturition. Nat Rev 
Neurosci. 2008 Jun: 9:453-66 
[4] Kuo HC, Liu HT, Chancellor MB. Can urinary nerve growth factor be a biomarker for 
overactive bladder? Rev Urol. 2010 Spring: 12:e69-77 
[5] Abrams P. Describing bladder storage function: overactive bladder syndrome and 
detrusor overactivity. Urology. 2003 Nov: 62:28-37; discussion 40-2 
[6] Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology of lower 
urinary tract function: report from the Standardisation Sub-committee of the International 
Continence Society. Neurourol Urodyn. 2002: 21:167-78 
[7] Coyne KS, Sexton CC, Irwin DE, Kopp ZS, Kelleher CJ, Milsom I. The impact of 
overactive bladder, incontinence and other lower urinary tract symptoms on quality of life, 
work productivity, sexuality and emotional well-being in men and women: results from the 
EPIC study. BJU Int. 2008 Jun: 101:1388-95 
[8] Milsom I, Abrams P, Cardozo L, Roberts RG, Thuroff J, Wein AJ. How widespread 
are the symptoms of an overactive bladder and how are they managed? A population-based 
prevalence study. BJU international. 2001 Jun: 87:760-6 
[9] Coyne KS, Wein A, Nicholson S, Kvasz M, Chen CI, Milsom I. Economic burden of 
urgency urinary incontinence in the United States: a systematic review. J Manag Care Pharm. 
2014 Feb: 20:130-40 
[10] Marinkovic SP, Rovner ES, Moldwin RM, Stanton SL, Gillen LM, Marinkovic CM. 
The management of overactive bladder syndrome. BMJ. 2012: 344:e2365 
[11] Onukwugha E, Zuckerman IH, McNally D, Coyne KS, Vats V, Mullins CD. The total 
economic burden of overactive bladder in the United States: a disease-specific approach. Am 
J Manag Care. 2009 Mar: 15:S90-7 
[12] Stewart WF, Van Rooyen JB, Cundiff GW, et al. Prevalence and burden of overactive 
bladder in the United States. World J Urol. 2003 May: 20:327-36 
[13] Irwin DE, Kopp ZS, Agatep B, Milsom I, Abrams P. Worldwide prevalence estimates 
of lower urinary tract symptoms, overactive bladder, urinary incontinence and bladder outlet 
obstruction. BJU Int. 2011 Oct: 108:1132-8 
[14] Abrams P, Andersson KE, Birder L, et al. Fourth International Consultation on 
Incontinence Recommendations of the International Scientific Committee: Evaluation and 
treatment of urinary incontinence, pelvic organ prolapse, and fecal incontinence. Neurourol 
Urodyn. 2010: 29:213-40 
[15] Basra RK, Wagg A, Chapple C, et al. A review of adherence to drug therapy in 
patients with overactive bladder. BJU Int. 2008 Sep: 102:774-9 
[16] Kelleher CJ, Cardozo LD, Khullar V, Salvatore S. A medium-term analysis of the 
subjective efficacy of treatment for women with detrusor instability and low bladder 
compliance. Br J Obstet Gynaecol. 1997 Sep: 104:988-93 
[17] Brazzelli M, Murray A, Fraser C. Efficacy and safety of sacral nerve stimulation for 
urinary urge incontinence: a systematic review. J Urol. 2006 Mar: 175:835-41 
 
[18] Cruz F, Herschorn S, Aliotta P, et al. Efficacy and safety of onabotulinumtoxinA in 
patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, 
double-blind, placebo-controlled trial. Eur Urol. 2011 Oct: 60:742-50 
[19] Ginsberg D, Gousse A, Keppenne V, et al. Phase 3 efficacy and tolerability study of 
onabotulinumtoxinA for urinary incontinence from neurogenic detrusor overactivity. J Urol. 
2012 Jun: 187:2131-9 
[20] Famm K, Litt B, Tracey KJ, Boyden ES, Slaoui M. Drug discovery: a jump-start for 
electroceuticals. Nature. 2013 Apr 11: 496:159-61 
[21] Woock JP, Yoo PB, Grill WM. Activation and inhibition of the micturition reflex by 
penile afferents in the cat. Am J Physiol Regul Integr Comp Physiol. 2008 Jun: 294:R1880-9 
[22] Farag FF, Martens FM, Rijkhoff NJ, Heesakkers JP. Dorsal genital nerve stimulation 
in patients with detrusor overactivity: a systematic review. Curr Urol Rep. 2012 Oct: 13:385-
8 
[23] Purinton PT, Fletcher TF, Bradley WE. Innervation of pelvic viscera in the rat. 
Evoked potentials in nerves to bladder and penis (clitoris). Invest Urol. 1976 Jul: 14:28-32 
[24] Dalmose AL, Rijkhoff NJ, Kirkeby HJ, Nohr M, Sinkjaer T, Djurhuus JC. 
Conditional stimulation of the dorsal penile/clitoral nerve may increase cystometric capacity 
in patients with spinal cord injury. Neurourol Urodyn. 2003: 22:130-7 
[25] Ohlsson BL, Fall M, Frankenberg-Sommar S. Effects of external and direct pudendal 
nerve maximal electrical stimulation in the treatment of the uninhibited overactive bladder. 
Br J Urol. 1989 Oct: 64:374-80 
[26] Peters KM, Killinger KA, Boguslawski BM, Boura JA. Chronic pudendal 
neuromodulation: expanding available treatment options for refractory urologic symptoms. 
Neurourol Urodyn. 2010 Sep: 29:1267-71 
[27] van Leeuwen JH, Castro R, Busse M, Bemelmans BL. The placebo effect in the 
pharmacologic treatment of patients with lower urinary tract symptoms. Eur Urol. 2006 Sep: 
50:440-52; discussion 53 
[28] Sajadi KP, Goldman HB. Percutaneous tibial nerve stimulation and overactive 
bladder. Curr Urol Rep. 2010 Sep: 11:293-5 
[29] Martinson M, MacDiarmid S, Black E. Cost of neuromodulation therapies for 
overactive bladder: percutaneous tibial nerve stimulation versus sacral nerve stimulation. J 
Urol. 2013 Jan: 189:210-6 
[30] Groen J, Blok BF, Bosch JL. Sacral neuromodulation as treatment for refractory 
idiopathic urge urinary incontinence: 5-year results of a longitudinal study in 60 women. J 
Urol. 2011 Sep: 186:954-9 
[31] M.G. Lucas DB, J.L.H.R. Bosch, , F. Burkhard FC, A.K. Nambiar, C.G. Nilsson, , 
D.J.M.K. de Ridder AT, R.S. Pickard European Urology Guidelines on Urinary Incontinence 
2014 
[32] Kacker R, Lay A, Das A. Electrical and mechanical office-based neuromodulation. 
Urol Clin North Am. 2013 Nov: 40:581-9 
[33] Fandel TT, E. Neuromodulation in Voiding Dysfunction: A historical overview of 
neurostimulation and its application. In Daneshgari F ed, Urologic Clinics of North 
America.Chapt 1, 2005:1-9 
[34] Chang CJ, Huang ST, Hsu K, Lin A, Stoller ML, Lue TF. Electroacupuncture 
decreases c-fos expression in the spinal cord induced by noxious stimulation of the rat 
bladder. J Urol. 1998 Dec: 160:2274-9 
[35] Danisman A, Kutlu O, Akkaya E, Karpuzoglu G, Erdogru T. Tibial nerve stimulation 
diminishes mast cell infiltration in the bladder wall induced by interstitial cystitis urine. 
Scand J Urol Nephrol. 2007: 41:98-102 
 
[36] Tai C, Chen M, Shen B, Wang J, Roppolo JR, de Groat WC. Irritation induced 
bladder overactivity is suppressed by tibial nerve stimulation in cats. J Urol. 2011 Jul: 
186:326-30 
[37] McPherson A. The effects of somatic stimuli on the bladder in the cat. J Physiol. 1966 
Jul: 185:185-96 
[38] McGuire EJ, Zhang SC, Horwinski ER, Lytton B. Treatment of motor and sensory 
detrusor instability by electrical stimulation. J Urol. 1983 Jan: 129:78-9 
[39] Stoller MLC, S., Millard, R.J. et al. The efficacy of acupuncture in reversing the 
unstable bladder in pig-tailed monkeys., Vol. 137, 1987:104A 
[40] Peters KM, Carrico DJ, Perez-Marrero RA, et al. Randomized trial of percutaneous 
tibial nerve stimulation versus Sham efficacy in the treatment of overactive bladder 
syndrome: results from the SUmiT trial. J Urol. 2010 Apr: 183:1438-43 
[41] Moossdorff-Steinhauser HF, Berghmans B. Effects of percutaneous tibial nerve 
stimulation on adult patients with overactive bladder syndrome: a systematic review. 
Neurourol Urodyn. 2013 Mar: 32:206-14 
[42] Peters KM, Macdiarmid SA, Wooldridge LS, et al. Randomized trial of percutaneous 
tibial nerve stimulation versus extended-release tolterodine: results from the overactive 
bladder innovative therapy trial. J Urol. 2009 Sep: 182:1055-61 
[43] Vecchioli-Scaldazza C, Morosetti C, Berouz A, Giannubilo W, Ferrara V. Solifenacin 
Succinate versus Percutaneous Tibial Nerve Stimulation in Women with Overactive Bladder 
Syndrome: Results of a Randomized Controlled Crossover Study. Gynecol Obstet Invest. 
2013: 75:230-4 
[44] Finazzi-Agro E, Petta F, Sciobica F, Pasqualetti P, Musco S, Bove P. Percutaneous 
tibial nerve stimulation effects on detrusor overactivity incontinence are not due to a placebo 
effect: a randomized, double-blind, placebo controlled trial. J Urol. 2010 Nov: 184:2001-6 
[45] Karademir K, Baykal K, Sen B, Senkul T, Iseri C, Erden D. A peripheric 
neuromodulation technique for curing detrusor overactivity: Stoller afferent neurostimulation. 
Scand J Urol Nephrol. 2005: 39:230-3 
[46] Klingler HC, Pycha A, Schmidbauer J, Marberger M. Use of peripheral 
neuromodulation of the S3 region for treatment of detrusor overactivity: a urodynamic-based 
study. Urology. 2000 Nov 1: 56:766-71 
[47] Vandoninck V, van Balken MR, Finazzi Agro E, et al. Percutaneous tibial nerve 
stimulation in the treatment of overactive bladder: urodynamic data. Neurourol Urodyn. 
2003: 22:227-32 
[48] Vandoninck V, Van Balken MR, Finazzi Agro E, et al. Posterior tibial nerve 
stimulation in the treatment of urge incontinence. Neurourol Urodyn. 2003: 22:17-23 
[49] van Balken MR, Vandoninck V, Gisolf KW, et al. Posterior tibial nerve stimulation as 
neuromodulative treatment of lower urinary tract dysfunction. J Urol. 2001 Sep: 166:914-8 
[50] Govier FE, Litwiller S, Nitti V, Kreder KJ, Jr., Rosenblatt P. Percutaneous afferent 
neuromodulation for the refractory overactive bladder: results of a multicenter study. J Urol. 
2001 Apr: 165:1193-8 
[51] Amarenco G, Ismael SS, Even-Schneider A, et al. Urodynamic effect of acute 
transcutaneous posterior tibial nerve stimulation in overactive bladder. J Urol. 2003 Jun: 
169:2210-5 
[52] van der Pal F, van Balken MR, Heesakkers JP, Debruyne FM, Bemelmans BL. 
Percutaneous tibial nerve stimulation in the treatment of refractory overactive bladder 
syndrome: is maintenance treatment necessary? BJU Int. 2006 Mar: 97:547-50 
[53] van Balken MR, Vergunst H, Bemelmans BL. Prognostic factors for successful 
percutaneous tibial nerve stimulation. Eur Urol. 2006 Feb: 49:360-5 
 
[54] Nuhoglu B, Fidan V, Ayyildiz A, Ersoy E, Germiyanoglu C. Stoller afferent nerve 
stimulation in woman with therapy resistant over active bladder; a 1-year follow up. Int 
Urogynecol J Pelvic Floor Dysfunct. 2006 May: 17:204-7 
[55] Kabay S, Kabay SC, Yucel M, et al. The clinical and urodynamic results of a 3-month 
percutaneous posterior tibial nerve stimulation treatment in patients with multiple sclerosis-
related neurogenic bladder dysfunction. Neurourol Urodyn. 2009: 28:964-8 
[56] Gobbi C, Digesu GA, Khullar V, El Neil S, Caccia G, Zecca C. Percutaneous 
posterior tibial nerve stimulation as an effective treatment of refractory lower urinary tract 
symptoms in patients with multiple sclerosis: preliminary data from a multicentre, 
prospective, open label trial. Mult Scler. 2011 Dec: 17:1514-9 
[57] Kabay SC, Yucel M, Kabay S. Acute effect of posterior tibial nerve stimulation on 
neurogenic detrusor overactivity in patients with multiple sclerosis: urodynamic study. 
Urology. 2008 Apr: 71:641-5 
[58] Fjorback MV, van Rey FS, van der Pal F, Rijkhoff NJ, Petersen T, Heesakkers JP. 
Acute urodynamic effects of posterior tibial nerve stimulation on neurogenic detrusor 
overactivity in patients with MS. Eur Urol. 2007 Feb: 51:464-70; discussion 71-2 
[59] Zecca C, Digesu GA, Robshaw P, et al. Motor and sensory responses after 
percutaneous tibial nerve stimulation in multiple sclerosis patients with lower urinary tract 
symptoms treated in daily practice. Eur J Neurol. 2014 Mar: 21:506-11 
[60] Zecca C, Digesu GA, Robshaw P, Singh A, Elneil S, Gobbi C. Maintenance 
percutaneous posterior nerve stimulation for refractory lower urinary tract symptoms in 
patients with multiple sclerosis: an open label, multicenter, prospective study. J Urol. 2014 
Mar: 191:697-702 
[61] Kabay SC, Kabay S, Yucel M, Ozden H. Acute urodynamic effects of percutaneous 
posterior tibial nerve stimulation on neurogenic detrusor overactivity in patients with 
Parkinson's disease. Neurourol Urodyn. 2009: 28:62-7 
[62] Fingerman JS, Finkelstein LH. The overactive bladder in multiple sclerosis. J Am 
Osteopath Assoc. 2000 Mar: 100:S9-12 
[63] Fowler CJ, Panicker JN, Drake M, et al. A UK consensus on the management of the 
bladder in multiple sclerosis. J Neurol Neurosurg Psychiatry. 2009 May: 80:470-7 
[64] Kessler TM, La Framboise D, Trelle S, et al. Sacral neuromodulation for neurogenic 
lower urinary tract dysfunction: systematic review and meta-analysis. Eur Urol. 2010 Dec: 
58:865-74 
[65] J. Donovan RB, M. Gotoh, S. Jackson, M. Naughton, S.Radley, L Valiquette, J.E. 
Bastista, K.Avery. Symptom and Quality of Life Assessment. In Paul Abrams LC, Saad 
Khoury, Alan Wein ed, Incontinence.Chapt 10, 2005:519-84 
[66] Abrams P, Avery K, Gardener N, Donovan J. The International Consultation on 
Incontinence Modular Questionnaire: www.iciq.net. J Urol. 2006 Mar: 175:1063-6; 
discussion 6 
[67] Brubaker L, Chapple C, Coyne KS, Kopp Z. Patient-reported outcomes in overactive 
bladder: importance for determining clinical effectiveness of treatment. Urology. 2006 Aug: 
68:3-8 
[68] MacDiarmid SA, Peters KM, Shobeiri SA, et al. Long-term durability of percutaneous 
tibial nerve stimulation for the treatment of overactive bladder. J Urol. 2010 Jan: 183:234-40 
[69] Patti F. Optimizing the benefit of multiple sclerosis therapy: the importance of 
treatment adherence. Patient Prefer Adherence. 2010: 4:1-9 
[70] Quinn P, Goka J, Richardson H. Assessment of an electronic daily diary in patients 
with overactive bladder. BJU Int. 2003 May: 91:647-52 
 
[71] Peters KM, Carrico DJ, Wooldridge LS, Miller CJ, MacDiarmid SA. Percutaneous 
tibial nerve stimulation for the long-term treatment of overactive bladder: 3-year results of 
the STEP study. J Urol. 2013 Jun: 189:2194-201 
[72] Goldman HB, Wyndaele JJ, Kaplan SA, Wang JT, Ntanios F. Defining response and 
non-response to treatment in patients with overactive bladder: a systematic review. Curr Med 
Res Opin. 2014 Mar: 30:509-26 
[73] Gaziev G, Topazio L, Iacovelli V, et al. Percutaneous Tibial Nerve Stimulation 
(PTNS) efficacy in the treatment of lower urinary tract dysfunctions: a systematic review. 
BMC Urol. 2013: 13:61 
[74] Wagg A, Compion G, Fahey A, Siddiqui E. Persistence with prescribed 
antimuscarinic therapy for overactive bladder: a UK experience. BJU Int. 2012 Dec: 
110:1767-74 
[75] de Seze M, Raibaut P, Gallien P, et al. Transcutaneous posterior tibial nerve 
stimulation for treatment of the overactive bladder syndrome in multiple sclerosis: results of a 
multicenter prospective study. Neurourology and urodynamics. 2011 Mar: 30:306-11 
[76] Turner Warwick R. Clinical Urdoynamics. Urol Clin North Am. 1979: 6:8-9 
[77] Blaivas JG. The bladder is an unreliable witness. Neurourol Urodyn. 1996: 15:443-5 
[78] Chapple CR. Is a Voiding Diary Really Necessary in 2014? Eur Urol. 2014 May 15:  
[79] Marschall-Kehrel D, Roberts RG, Brubaker L. Patient-reported outcomes in 
overactive bladder: the influence of perception of condition and expectation for treatment 
benefit. Urology. 2006 Aug: 68:29-37 
[80] Brubaker LC, C. Introduction to Patient-Reported Outcomes in Overactive Bladder 
Urology. 2006: 68:1-2 
[81] Coyne K, Kelleher C. Patient reported outcomes: the ICIQ and the state of the art. 
Neurourol Urodyn. 2010 Apr: 29:645-51 
[82] Coyne KS, Tubaro A, Brubaker L, Bavendam T. Development and validation of 
patient-reported outcomes measures for overactive bladder: a review of concepts. Urology. 
2006 Aug: 68:9-16 
[83] Avery K, Donovan J, Peters TJ, Shaw C, Gotoh M, Abrams P. ICIQ: a brief and 
robust measure for evaluating the symptoms and impact of urinary incontinence. Neurourol 
Urodyn. 2004: 23:322-30 
[84] Cotterill N, Goldman H, Kelleher C, Kopp Z, Tubaro A, Brubaker L. What are the 
best outcome measures when assessing treatments for LUTD?--achieving the most out of 
outcome evaluation: ICI-RS 2011. Neurourol Urodyn. 2012 Mar: 31:400-3 
[85] Flood AB, Lorence DP, Ding J, McPherson K, Black NA. The role of expectations in 
patients' reports of post-operative outcomes and improvement following therapy. Med Care. 
1993 Nov: 31:1043-56 
[86] Bright E, Cotterill N, Drake M, Abrams P. Developing and Validating the 
International Consultation on Incontinence Questionnaire Bladder Diary. Eur Urol. 2014 Mar 
11:  
[87] Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology in lower 
urinary tract function: report from the standardisation sub-committee of the International 
Continence Society. Urology. 2003 Jan: 61:37-49 
[88] Bates CP, Corney CE. Synchronous cine-pressure-flow cystography: a method of 
routine urodynamic investigation. Br J Radiol. 1971 Jan: 44:44-50 
[89] Mosso AP, P. . Sur les fonctions de la vessie. Archives Italiennes de Biologie. 1882: 
1:97-128 
[90] Hosker GR, P. Gajewski, J. Sand, P. Szabo, L. Capewell, A. Dynamic Testing. In 
Abrams PC, L. Khoury, S. Wein, A. ed, Incontinence, 4th Edition edn, 2009:417-42 
 
[91] Wyndaele JJ. Normality in urodynamics studied in healthy adults. J Urol. 1999 Mar: 
161:899-902 
[92] J. Christian Winters RRD, Howard B. Goldman, C.D. Anthony , Herndon KCK, 
Stephen R. Kraus, Gary E. Lemack, Victor W. Nitti, , Eric S. Rovner AJW. Adult 
Urodynamics AUA/SUFU guideline. American Urological Association Education and 
Research, 2012:1-30 
[93] Levi-Montalcini R, Calissano P. The nerve-growth factor. Sci Am. 1979 Jun: 240:68-
77 
[94] Ochodnicky P, Cruz CD, Yoshimura N, Michel MC. Nerve growth factor in bladder 
dysfunction: Contributing factor, biomarker, and therapeutic target. Neurourol Urodyn. 2011 
Apr 21:  
[95] Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology of lower 
urinary tract function: report from the Standardisation Sub-committee of the International 
Continence Society. Am J Obstet Gynecol. 2002 Jul: 187:116-26 
[96] Liu HT, Chancellor MB, Kuo HC. Urinary nerve growth factor levels are elevated in 
patients with detrusor overactivity and decreased in responders to detrusor botulinum toxin-A 
injection. Eur Urol. 2009 Oct: 56:700-6 
[97] Michel MC, Chapple CR. Basic mechanisms of urgency: roles and benefits of 
pharmacotherapy. World J Urol. 2009 Dec: 27:705-9 
[98] Kuo HC, Liu HT, Chancellor MB. Can urinary nerve growth factor be a biomarker for 
overactive bladder? Rev Urol.  Spring: 12:e69-77 
[99] Liu HT, Chen CY, Kuo HC. Urinary nerve growth factor levels in overactive bladder 
syndrome and lower urinary tract disorders. J Formos Med Assoc. 2010 Dec: 109:862-78 
[100] Birder LA, Wolf-Johnston AS, Chib MK, Buffington CA, Roppolo JR, Hanna-
Mitchell AT. Beyond neurons: Involvement of urothelial and glial cells in bladder function. 
Neurourol Urodyn. 2010: 29:88-96 
[101] Vizzard MA. Changes in urinary bladder neurotrophic factor mRNA and NGF protein 
following urinary bladder dysfunction. Exp Neurol. 2000 Jan: 161:273-84 
[102] Hu VY, Zvara P, Dattilio A, et al. Decrease in bladder overactivity with REN1820 in 
rats with cyclophosphamide induced cystitis. J Urol. 2005 Mar: 173:1016-21 
[103] Ho DR, Chen CS, Lin WY, Chang PJ, Huang YC. Effect of hyaluronic acid on urine 
nerve growth factor in cyclophosphamide-induced cystitis. Int J Urol. 2011 Jul: 18:525-31 
[104] Yoshimura N, Bennett NE, Hayashi Y, et al. Bladder overactivity and 
hyperexcitability of bladder afferent neurons after intrathecal delivery of nerve growth factor 
in rats. J Neurosci. 2006 Oct 18: 26:10847-55 
[105] Schnegelsberg B, Sun TT, Cain G, et al. Overexpression of NGF in mouse urothelium 
leads to neuronal hyperinnervation, pelvic sensitivity, and changes in urinary bladder 
function. Am J Physiol Regul Integr Comp Physiol. 2010 Mar: 298:R534-47 
[106] Lee SR, Hong CH, Choi YD, Kim JH. Increased urinary nerve growth factor as a 
predictor of persistent detrusor overactivity after bladder outlet obstruction relief in a rat 
model. J Urol. 2010 Jun: 183:2440-4 
[107] Zvara P, Kliment J, Jr., DeRoss AL, et al. Differential expression of bladder 
neurotrophic factor mRNA in male and female rats after bladder outflow obstruction. J Urol. 
2002 Dec: 168:2682-8 
[108] Ha US, Park EY, Kim JC. Effect of botulinum toxin on expression of nerve growth 
factor and transient receptor potential vanilloid 1 in urothelium and detrusor muscle of rats 
with bladder outlet obstruction-induced detrusor overactivity. Urology. 2011 Sep: 78:721 e1- 
e6 
 
[109] Seki S, Sasaki K, Fraser MO, et al. Immunoneutralization of nerve growth factor in 
lumbosacral spinal cord reduces bladder hyperreflexia in spinal cord injured rats. J Urol. 
2002 Nov: 168:2269-74 
[110] Seki S, Sasaki K, Igawa Y, et al. Suppression of detrusor-sphincter dyssynergia by 
immunoneutralization of nerve growth factor in lumbosacral spinal cord in spinal cord 
injured rats. J Urol. 2004 Jan: 171:478-82 
[111] Giannantoni A, Di Stasi SM, Nardicchi V, et al. Botulinum-A toxin injections into the 
detrusor muscle decrease nerve growth factor bladder tissue levels in patients with 
neurogenic detrusor overactivity. J Urol. 2006 Jun: 175:2341-4 
[112] Liu HT, Kuo HC. Intravesical botulinum toxin A injections plus hydrodistension can 
reduce nerve growth factor production and control bladder pain in interstitial cystitis. 
Urology. 2007 Sep: 70:463-8 
[113] Lowe EM, Anand P, Terenghi G, Williams-Chestnut RE, Sinicropi DV, Osborne JL. 
Increased nerve growth factor levels in the urinary bladder of women with idiopathic sensory 
urgency and interstitial cystitis. Br J Urol. 1997 Apr: 79:572-7 
[114] Henry JL. Substance P and inflammatory pain: potential of substance P antagonists as 
analgesics. Agents Actions Suppl. 1993: 41:75-87 
[115] Mayeux R. Biomarkers: potential uses and limitations. NeuroRx. 2004 Apr: 1:182-8 
[116] Chan R, Munoz A, Wenker EP, Stewart J, Boone T, Khavari R. The Association of 
Urinary Nerve Growth Factor Levels With Bladder Outlet Obstruction in Women. Female 
Pelvic Med Reconstr Surg. 2014 Sep 2:  
[117] Liss MA, Gordon A, Morales B, et al. Urinary nerve growth factor as an oncologic 
biomarker for prostate cancer aggressiveness. Urol Oncol. 2014 Jul: 32:714-9 
[118] Aydogmus Y, Sunay M, Arslan H, Aydin A, Adiloglu AK, Sahin H. Acupuncture 
versus Solifenacin for Treatment of Overactive Bladder and Its Correlation with Urine Nerve 
Growth Factor Levels: A Randomized, Placebo-Controlled Clinical Trial. Urol Int. 2014 Jul 
16:  
[119] Shalom DF, Pillalamarri N, Xue X, et al. Sacral nerve stimulation reduces elevated 
urinary nerve growth factor levels in women with symptomatic detrusor overactivity. Am J 
Obstet Gynecol. 2014 Jul 11:  
[120] Antunes-Lopes T, Pinto R, Barros SC, et al. Urinary neurotrophic factors in healthy 
individuals and patients with overactive bladder. J Urol. 2013 Jan: 189:359-65 
[121] Liu HT, Kuo HC. Increased urine and serum nerve growth factor levels in interstitial 
cystitis suggest chronic inflammation is involved in the pathogenesis of disease. PLoS One. 
2012: 7:e44687 
[122] Liu HT, Lin H, Kuo HC. Increased serum nerve growth factor levels in patients with 
overactive bladder syndrome refractory to antimuscarinic therapy. Neurourol Urodyn. 2011 
Aug 8:  
[123] Liu HT, Chen CY, Kuo HC. Urinary nerve growth factor in women with overactive 
bladder syndrome. BJU Int. 2011 Mar: 107:799-803 
[124] Pinto R, Lopes T, Frias B, et al. Trigonal injection of botulinum toxin A in patients 
with refractory bladder pain syndrome/interstitial cystitis. Eur Urol. 2010 Sep: 58:360-5 
[125] Liu HT, Tyagi P, Chancellor MB, Kuo HC. Urinary nerve growth factor level is 
increased in patients with interstitial cystitis/bladder pain syndrome and decreased in 
responders to treatment. BJU Int. 2009 Nov: 104:1476-81 
[126] Kuo HC, Liu HT, Chancellor MB. Urinary nerve growth factor is a better biomarker 
than detrusor wall thickness for the assessment of overactive bladder with incontinence. 
Neurourol Urodyn. 2010 Mar: 29:482-7 
 
[127] Liu HT, Tyagi P, Chancellor MB, Kuo HC. Urinary nerve growth factor but not 
prostaglandin E2 increases in patients with interstitial cystitis/bladder pain syndrome and 
detrusor overactivity. BJU Int. 2010 Dec: 106:1681-5 
[128] Liu HT, Chancellor MB, Kuo HC. Decrease of urinary nerve growth factor levels 
after antimuscarinic therapy in patients with overactive bladder. BJU Int. 2009 Jun: 
103:1668-72 
[129] Liu HT, Liu AB, Chancellor MB, Kuo HC. Urinary nerve growth factor level is 
correlated with the severity of neurological impairment in patients with cerebrovascular 
accident. BJU Int. 2009 Oct: 104:1158-62 
[130] Liu HT, Kuo HC. Urinary nerve growth factor levels are elevated in patients with 
overactive bladder and do not significantly increase with bladder distention. Neurourol 
Urodyn. 2009: 28:78-81 
[131] Liu HT, Chancellor MB, Kuo HC. Urinary nerve growth factor level could be a 
biomarker in the differential diagnosis of mixed urinary incontinence in women. BJU Int. 
2008 Nov: 102:1440-4 
[132] Yokoyama T, Kumon H, Nagai A. Correlation of urinary nerve growth factor level 
with pathogenesis of overactive bladder. Neurourol Urodyn. 2008: 27:417-20 
[133] Jacobs BL, Smaldone MC, Tyagi V, et al. Increased nerve growth factor in 
neurogenic overactive bladder and interstitial cystitis patients. Can J Urol. 2010 Feb: 
17:4989-94 
[134] Liu HT, Kuo HC. Urinary nerve growth factor levels are increased in patients with 
bladder outlet obstruction with overactive bladder symptoms and reduced after successful 
medical treatment. Urology. 2008 Jul: 72:104-8; discussion 8 
[135] Liu HT, Kuo HC. Urinary nerve growth factor level could be a potential biomarker 
for diagnosis of overactive bladder. J Urol. 2008 Jun: 179:2270-4 
[136] Kim JC, Park EY, Seo SI, Park YH, Hwang TK. Nerve growth factor and 
prostaglandins in the urine of female patients with overactive bladder. J Urol. 2006 May: 
175:1773-6; discussion 6 
[137] Kim JC, Park EY, Hong SH, Seo SI, Park YH, Hwang TK. Changes of urinary nerve 
growth factor and prostaglandins in male patients with overactive bladder symptom. Int J 
Urol. 2005 Oct: 12:875-80 
[138] Mukerji G, Yiangou Y, Grogono J, et al. Localization of M2 and M3 muscarinic 
receptors in human bladder disorders and their clinical correlations. J Urol. 2006 Jul: 
176:367-73 
[139] Clemow DB, Steers WD, Tuttle JB. Stretch-activated signaling of nerve growth factor 
secretion in bladder and vascular smooth muscle cells from hypertensive and hyperactive 
rats. J Cell Physiol. 2000 Jun: 183:289-300 
[140] Steers WD, Creedon DJ, Tuttle JB. Immunity to nerve growth factor prevents afferent 
plasticity following urinary bladder hypertrophy. J Urol. 1996 Jan: 155:379-85 
[141] Michael GJ, Averill S, Nitkunan A, et al. Nerve growth factor treatment increases 
brain-derived neurotrophic factor selectively in TrkA-expressing dorsal root ganglion cells 
and in their central terminations within the spinal cord. J Neurosci. 1997 Nov 1: 17:8476-90 
[142] Pinto R, Frias B, Allen S, et al. Sequestration of brain derived nerve factor by 
intravenous delivery of TrkB-Ig2 reduces bladder overactivity and noxious input in animals 
with chronic cystitis. Neuroscience. 2010 Mar 31: 166:907-16 
[143] Antunes--Lopes  T. PR,   Carvalho-Barros  S.,  Diniz  P.,  Martins-Silva  C.,  , Duarte- 
Cruz C,  Cruz F. Urinary levels of brain derived neurotrophic factor (BDNF) in women with 
overactive bladder (OAB) syndrome correlate with the severity of symptoms. European 
Urology Supplements. 2011: 10:277-8 
 
[144] Wang LW, Han XM, Chen CH, Ma Y, Hai B. Urinary brain-derived neurotrophic 
factor: a potential biomarker for objective diagnosis of overactive bladder. Int Urol Nephrol. 
2014 Feb: 46:341-7 
[145] Koven NS, Collins LR. Urinary brain-derived neurotrophic factor as a biomarker of 
executive functioning. Neuropsychobiology. 2014: 69:227-34 
[146] Collins LR, Koven NS. Urinary BDNF-to-creatinine ratio is associated with aerobic 
fitness. Neurosci Lett. 2014 Jan 24: 559:169-73 
[147] Antunes-Lopes T, Carvalho-Barros S, Cruz CD, Cruz F, Martins-Silva C. Biomarkers 
in overactive bladder: a new objective and noninvasive tool? Adv Urol. 2011: 2011:382431 
[148] Okragly AJ, Niles AL, Saban R, et al. Elevated tryptase, nerve growth factor, 
neurotrophin-3 and glial cell line-derived neurotrophic factor levels in the urine of interstitial 
cystitis and bladder cancer patients. J Urol. 1999 Feb: 161:438-41; discussion 41-2 
[149] Apostolidis A, Jacques TS, Freeman A, et al. Histological changes in the urothelium 
and suburothelium of human overactive bladder following intradetrusor injections of 
botulinum neurotoxin type A for the treatment of neurogenic or idiopathic detrusor 
overactivity. Eur Urol. 2008 Jun: 53:1245-53 
[150] Bonini S, Lambiase A, Angelucci F, Magrini L, Manni L, Aloe L. Circulating nerve 
growth factor levels are increased in humans with allergic diseases and asthma. Proc Natl 
Acad Sci U S A. 1996 Oct 1: 93:10955-60 
[151] Serrano-Sanchez T, Robinson-Agramonte MA, Lorigados-Pedre L, Diaz-Armesto I, 
Gonzalez-Fraguela ME, Dorta-Contreras AJ. [Endogenous nerve growth factor in patients 
with Alzheimer s disease]. Rev Neurol. 2001 May 1-15: 32:825-8 
[152] Bruns DE. The STARD initiative and the reporting of studies of diagnostic accuracy. 
Clin Chem. 2003 Jan: 49:19-20 
[153] Bossuyt PM, Reitsma JB, Bruns DE, et al. Towards complete and accurate reporting 
of studies of diagnostic accuracy: the STARD initiative. Standards for Reporting of 
Diagnostic Accuracy. Clin Chem. 2003 Jan: 49:1-6 
[154] Melcon MO, Correale J, Melcon CM. Is it time for a new global classification of 
multiple sclerosis? J Neurol Sci. 2014 Jun 29:  
[155] Orton SM, Herrera BM, Yee IM, et al. Sex ratio of multiple sclerosis in Canada: a 
longitudinal study. Lancet Neurol. 2006 Nov: 5:932-6 
[156] Confavreux C, Vukusic S, Moreau T, Adeleine P. Relapses and progression of 
disability in multiple sclerosis. N Engl J Med. 2000 Nov 16: 343:1430-8 
[157] Betts CD, D'Mellow MT, Fowler CJ. Urinary symptoms and the neurological features 
of bladder dysfunction in multiple sclerosis. J Neurol Neurosurg Psychiatry. 1993 Mar: 
56:245-50 
[158] Hemmett L, Holmes J, Barnes M, Russell N. What drives quality of life in multiple 
sclerosis? QJM. 2004 Oct: 97:671-6 
[159] Kalsi V, Gonzales G, Popat R, et al. Botulinum injections for the treatment of bladder 
symptoms of multiple sclerosis. Ann Neurol. 2007 Nov: 62:452-7 
[160] Buljevac D, Flach HZ, Hop WC, et al. Prospective study on the relationship between 
infections and multiple sclerosis exacerbations. Brain. 2002 May: 125:952-60 
[161] Stohrer M, Blok B, Castro-Diaz D, et al. EAU guidelines on neurogenic lower urinary 
tract dysfunction. Eur Urol. 2009 Jul: 56:81-8 
[162] Hashim H, Abrams P. How should patients with an overactive bladder manipulate 
their fluid intake? BJU Int. 2008 Jul: 102:62-6 
[163] Wiedemann A, Kaeder M, Greulich W, et al. Which clinical risk factors determine a 
pathological urodynamic evaluation in patients with multiple sclerosis? an analysis of 100 
prospective cases. World J Urol. 2013 Feb: 31:229-33 
 
[164] Litwiller SE, Frohman EM, Zimmern PE. Multiple sclerosis and the urologist. J Urol. 
1999 Mar: 161:743-57 
[165] de Seze M, Ruffion A, Denys P, Joseph PA, Perrouin-Verbe B. The neurogenic 
bladder in multiple sclerosis: review of the literature and proposal of management guidelines. 
Mult Scler. 2007 Aug: 13:915-28 
[166] Y. Homma, J. Batista, S. Bauer, et al. Urodynamics. In Abrams P CL, Koury S, Wein 
A. ed, Incontinence, Second edn.Chapt Seven, 2001 
[167] Fry CH, Sahai A, Vahabi B, Kanai AJ, Birder LA. What is the role for biomarkers for 
lower urinary tract disorders? ICI-RS 2013. Neurourol Urodyn. 2014 Jun: 33:602-5 
[168] Qu HC, Yan S, Zhang XL, Zhu XW, Liu YL, Wang P. Urinary nerve growth factor 
levels could be a biomarker for overactive bladder symptom: a meta-analysis. Genet Mol 
Res. 2014 Apr 14: 13 
[169] Comelli MC, Guidolin D, Seren MS, et al. Time course, localization and 
pharmacological modulation of immediate early inducible genes, brain-derived neurotrophic 
factor and trkB messenger RNAs in the rat brain following photochemical stroke. 
Neuroscience. 1993 Jul: 55:473-90 
[170] Obata K, Noguchi K. BDNF in sensory neurons and chronic pain. Neurosci Res. 2006 
May: 55:1-10 
[171] Frias B, Allen S, Dawbarn D, Charrua A, Cruz F, Cruz CD. Brain-derived 
neurotrophic factor, acting at the spinal cord level, participates in bladder hyperactivity and 
referred pain during chronic bladder inflammation. Neuroscience. 2013 Mar 27: 234:88-102 
[172] Gold SM, Schulz KH, Hartmann S, et al. Basal serum levels and reactivity of nerve 
growth factor and brain-derived neurotrophic factor to standardized acute exercise in multiple 
sclerosis and controls. J Neuroimmunol. 2003 May: 138:99-105 
[173] Haab F, Richard F, Amarenco G, et al. Comprehensive evaluation of bladder and 
urethral dysfunction symptoms: development and psychometric validation of the Urinary 
Symptom Profile (USP) questionnaire. Urology. 2008 Apr: 71:646-56 
[174] Jacobs BL, Smaldone MC, Tyagi V, et al. Increased nerve growth factor in 
neurogenic overactive bladder and interstitial cystitis patients. Can J Urol.  Feb: 17:4989-94 
[175] Lipman NS, Jackson LR, Trudel LJ, Weis-Garcia F. Monoclonal versus polyclonal 
antibodies: distinguishing characteristics, applications, and information resources. ILAR J. 
2005: 46:258-68 
[176] Crowther JR. The ELISA guidebook: Humana press, 2001 
[177] Mao J, Chen S, Na Z, Xhang Y, Huang Y, Li Y. Frozen storage of urine samples 
before ELISA measurement of retinol-binding protein. Clin Chem. 1996 Mar: 42:466-7 
[178] Kaufman J, Tyagi V, Anthony M, Chancellor MB, Tyagi P. State of the art in 
intravesical therapy for lower urinary tract symptoms. Rev Urol. 2010 Fall: 12:e181-9 
[179] Lewczuk P, Beck G, Esselmann H, et al. Effect of sample collection tubes on 
cerebrospinal fluid concentrations of tau proteins and amyloid beta peptides. Clin Chem. 
2006 Feb: 52:332-4 
[180] Nanda SK, Scholz WK. A distinctive surface for phospholipid assays. Clin Chem. 
2000 Sep: 46:1508-10 
[181] Valdo P, Stegagno C, Mazzucco S, et al. Enhanced expression of NGF receptors in 
multiple sclerosis lesions. J Neuropathol Exp Neurol. 2002 Jan: 61:91-8 
[182] Laudiero LB, Aloe L, Levi-Montalcini R, et al. Multiple sclerosis patients express 
increased levels of beta-nerve growth factor in cerebrospinal fluid. Neurosci Lett. 1992 Nov 
23: 147:9-12 
[183] Acosta CM, Cortes C, MacPhee H, Namaka MP. Exploring the role of nerve growth 
factor in multiple sclerosis: implications in myelin repair. CNS Neurol Disord Drug Targets. 
2013 Dec: 12:1242-56 
 
[184] Kalinowska-Lyszczarz A, Losy J. The role of neurotrophins in multiple sclerosis-
pathological and clinical implications. Int J Mol Sci. 2012: 13:13713-25 
[185] Linker RA, Lee DH, Demir S, et al. Functional role of brain-derived neurotrophic 
factor in neuroprotective autoimmunity: therapeutic implications in a model of multiple 
sclerosis. Brain. 2010 Aug: 133:2248-63 
[186] Bonini S, Lambiase A, Levi-Schaffer F, Aloe L. Nerve growth factor: an important 
molecule in allergic inflammation and tissue remodelling. Int Arch Allergy Immunol. 1999 
Feb-Apr: 118:159-62 
[187] Gigliotti P, Lofaro D, Leone F, et al. High nerve growth factor blood concentration in 
renal transplantation: a new prognostic marker? Transplant Proc. 2013 Sep: 45:2654-6 
[188] Hellweg R, von Richthofen S, Anders D, et al. The time course of nerve growth factor 
content in different neuropsychiatric diseases--a unifying hypothesis. J Neural Transm. 1998: 
105:871-903 
[189] Aloe L, Bracci-Laudiero L, Alleva E, Lambiase A, Micera A, Tirassa P. Emotional 
stress induced by parachute jumping enhances blood nerve growth factor levels and the 
distribution of nerve growth factor receptors in lymphocytes. Proc Natl Acad Sci U S A. 1994 
Oct 25: 91:10440-4 
[190] Vijaya G, Cartwright R, Derpapas A, Gallo P, Fernando R, Khullar V. Changes in 
nerve growth factor level and symptom severity following antibiotic treatment for refractory 
overactive bladder. Int Urogynecol J. 2013 Sep: 24:1523-8 
[191] Cruz CD. Neurotrophins in bladder function: what do we know and where do we go 
from here? Neurourol Urodyn. 2014 Jan: 33:39-45 
[192] Silva-Ramos M, Silva I, Oliveira O, et al. Urinary ATP may be a dynamic biomarker 
of detrusor overactivity in women with overactive bladder syndrome. PLoS One. 2013: 
8:e64696 
[193] Burton C, Sajja A, Latthe PM. Effectiveness of percutaneous posterior tibial nerve 
stimulation for overactive bladder: a systematic review and meta-analysis. Neurourol Urodyn. 
2012 Nov: 31:1206-16 
[194] Wein AJ. Re: the efficacy of posterior tibial nerve stimulation for the treatment of 
overactive bladder in women: a systematic review. J Urol. 2013 Jun: 189:2202-3 
[195] Furgala A, Thor PJ, Kolasinska-Kloch W, Krygowska-Wajs A, Kopp B, Laskiewicz 
J. The effect of transcutaneous nerve stimulation (TENS) on gastric electrical activity. J 
Physiol Pharmacol. 2001 Dec: 52:603-10 
[196] Ohannessian A, Kabore FA, Agostini A, et al. [Transcutaneous tibial nerve 
stimulation in the overactive bladder syndrome in patients with Parkinson's syndromes]. Prog 
Urol. 2013 Sep: 23:936-9 
[197] Schreiner L, dos Santos TG, Knorst MR, da Silva Filho IG. Randomized trial of 
transcutaneous tibial nerve stimulation to treat urge urinary incontinence in older women. Int 
Urogynecol J. 2010 Sep: 21:1065-70 
[198] Warwick DJ, Shaikh A, Gadola S, et al. Neuromuscular electrostimulation viathe 
common peroneal nerve promotes lower limb blood flow in a below-kneecast: A potential for 
thromboprophylaxis. Bone Joint Res. 2013: 2:179-85 
[199] Hope M. The geko device for reducing the risk of venous thromboembolism.  2014  
[cited; Available from: http://guidance.nice.org.uk/MT/196 
[200] Irwin DE, Milsom I, Hunskaar S, et al. Population-based survey of urinary 
incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: 
results of the EPIC study. Eur Urol. 2006 Dec: 50:1306-14; discussion 14-5 
[201] Kaptchuk TJ, Stason WB, Davis RB, et al. Sham device v inert pill: randomised 
controlled trial of two placebo treatments. BMJ. 2006 Feb 18: 332:391-7 
 
[202] Peters KM, Carrico DJ, MacDiarmid SA, et al. Sustained therapeutic effects of 
percutaneous tibial nerve stimulation: 24-month results of the STEP study. Neurourol 
Urodyn. 2013 Jan: 32:24-9 
[203] Veenboer PW, Bosch JL. Long-term adherence to antimuscarinic therapy in everyday 
practice: a systematic review. J Urol. 2014 Apr: 191:1003-8 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Thesis corrections 
 
Reference to Chapter 1: Tibial nerve stimulation for the management of the neurogenic 
and idiopathic overactive bladder: A safe and effective treatment  
 
1. Detail of the patient population needs to be expanded on – reflecting on the 
heterogeneity of their past treatments and how this may influence outcomes of the 
studies 
 
This prospective study evaluates an non-invasive treatment for overactive bladder (OAB). 
This treatment has been evaluated in patients with idiopathic OAB, but less so in patients 
with neurogenic OAB. Our patient cohort represents a heterogenous group of 74 patients. 
Twenty-five patients (33.8%) had idiopathic OAB, 19 (25.7%) had multiple sclerosis (MS), 
and 30 (40.5%) other neurological diagnoses at entry.  
The 30 patients with ‘other neurological diagnoses’ do encompass a wide range of diagnoses. 
This may indeed represent a variety of severity of bladder dysfunction, however urodynamic 
evaluation was not carried out in our study as it is not standard of practice to perform 
invasive pressure-flow studies prior to offering treatment with PTNS.  
The variety of clinical diagnoses may certainly affect response to treatments in an 
unpredictable way, with the patients with more severe disease having less of a response to 
treatment. 
However the common aspect that all of these patients share is that lack of response to first 
line measures of treatment of OAB which are antimuscarinic medication and hence all 
patients are referred to having ‘refractory OAB’. 
 
It was also confirmed that idiopathic and neurogenic groups had comparable symptom 
severity scores prior to starting treatment. 
 
2. The difference in OAB between neuropathic and idiopathic forms needs to be drawn 
out 
 
Authors agree that distinction between diagnosis of idiopathic and neurogenic is an important 
one to make as both groups may represent a different pathophysiology behind the condition. 
Whereas OAB symptoms following a suprapontine lesion, such as in conditions such as PD, 
is due to uninhibited detrusor contractions, that following spinal cord pathology is thought to 
be due to the emergence of previously dormant C-fibres resulting in spinal cord mediated 
micturition reflex detrusor contractions. The cause for DO in patients with idiopathic DO is 
uncertain, with potential myogenic or urothelial mechanisms hypothesized. Investigations are 
unable to identify the pathophysiology for DO, however this study seems to suggest that 
irrespective of the underlying cause for OAB, PTNS was effective in managing symptoms.   
 
3. a. Write up needs to emphasise the rigorous ensurance of data collection 
 
Quality assurance (QA):  
Data collection was performed by the research team. Qualitative outcomes were measure 
using patient reported outcomes (PROMS) with the ICIQ-OAB, ICIQ-LUTSqol and patient 
satisfaction survey.  
More quantitative assessment was performed patient completed 3-day bladder diaries. 
Patients were all given the same advice and instruction on how to complete these. 
 
The QA measures was achieved by using a standardised protocol in that all patients were 
completing the PROMS at baseline and at 12 weeks after end of treatment as shown in figure 
4 of pg 58 of the thesis. 
 
Quality control: All collected data was carefully collated and stored in patient case report 
files and then uploaded into a study database which was secured in a password protected trust 
computer. 
 
3b. Display outcomes in a flow chart. 
Pls find below 
 
 
 
 
 
3.c Discuss the long-term time course of response year by year for group treatment 
 
The time of writing the thesis and end of data collection was at 12 months follow up, and so 
we are unable to give long term year by year response data. 24 (45%) patients attended for 
top-up therapy in that first one year after end of treatment at 12 weeks. 
Long term data is important to establish longevity of treatment. We can refer the examiners to 
The STEP study which identified that at least 75% of the patients who had a positive 
response to the first 12-weeks of therapy, went on to have sustained symptom improvements 
for up to three years with an average top up treatment of one per month. However this data 
amongst neuropathic patients has not yet been established. 
 
Peters KM, Carrico DJ, Wooldridge LS, Miller CJ, MacDiarmid SA. Percutaneous  
tibial nerve stimulation for the long-term treatment of overactive bladder: 3-year results of 
the STEP study. J Urol. 2013 Jun: 189:2194-201  
 
 
3.d. Impact of the literature review – what would you do in relation to findings from the 
review. 
 
There is emerging evidence to show that PTNS can be a beneficial, non-invasive  treatment 
for patients suffering from OAB symptoms. Its benefits which outweigh some of the 
alternative treatments such as onabotulinumtoxinA injections are the safety of the treatment 
with no adverse effects such as urinary tract infections, urinary retention and the need to 
 
perform clean intermittent self-catheterisation. Therefore it may represent a more desirable 
treatment for patients with less associated risk. 
Also it is far less invasive that sacral neuromodulation and clam-ileocystoplasty. 
 
PTNS clearly needs further evaluation for its cost-effectiveness, longevity of effect and 
comparison data against the other treatment alternatives, which form fertile ground for future 
study, especially in the neuropathic population. 
Based on the literature review, I would recommend continue PTNS as a treatment alternative, 
to our patients who do not wish to consider the alternative more invasive treatment options, 
as also recommened by the National Institute of Clinical Excellence (NICE), PTNS 
commissioning guidance. 
 
4a. The statistical test used to test for normality need to be specified. 
 
QOL Data was tested for normality by assessing spread of scores and standardizing these 
with the mean and standard deviations and creating a histogram to confirm it follows a 
normal distribution. 
 
 
 
4b. Regression analysis – were other factors missing in neuro patients that need 
consideration?  
 
There are a number of other factors that could have been considered in the other neurological 
patients include urodynamic demonstration of detrusor overactivity or bladder outflow 
 
obstruction. Furthermore how their neurological condition affects other aspects of managing 
with incontinence such as mobility which if impaired may affect their bother/number of pads 
worn/ and overall QOL impact. However these factors were not accounted for in the data 
collection or included in the regression analysis and this limitation has now been included in 
the discussed . 
 
  
4d. How did dropouts bias the outcomes?   
 
10 patients (14%) dropped out from the study. Their baseline QOL data was incorporated into 
the analysis, however the 12-week data will be absent from these patients. All patients were 
comparable at baseline for symptom severity and an attempt was made to follow up those 
who dropped out, to understand the reasons for attrition and these are listed in the results 
section of chapter 4. Only a per protoocl analysis had been performed in this pilot study.   
This does limit the interpretation of the efficacy outcomes of the study, and has been included 
in the discussion.  
  
 
4e. How was missing data handled and how did it influence outcomes? 
There was no missing data for the patient reported ICIQ-QOL and ICIQ-OAB scores. 
However only 53 patients completed the patient satisfaction survey out of the 64 patients who 
completed the treatment. As a result we don’t have a comprehensive overview of the entire 
cohorts view regarding satisfaction and desire for top-up treatments, reducing the sample size 
for this observation. We can however draw conclusions from those number of patients who 
completed the satisfaction survey of which 66% reported a desire to return for top-up 
 
treatments which is a meaningful observation that is comparative of the result observed in the 
SumIT study. 
 
4f. Discuss the limitations of having no control group? 
 
The lack of a control group certainly opens questions of the influence of placebo effect on 
subjective outcomes. Indeed it is challenging to introduce a placebo arm in a study evaluating 
TTNS  and this is a recommendation for future studies that has been proposed in the thesis.  It 
is notable however that data from the SuMIT study has proven the efficacy of PTNS over a 
validated sham, on which the basis of PTNS is recommended in clinical guidelines such as 
NICE. 
 
 
4g. Discuss the mechanistic possibilities and potential sexual/gastrointestinal effects of 
therapy? 
 
For OAB symptoms, it is unclear how PTNS has its affect on resolution of symptoms. There 
is scientific evidence in animals that PTNS can reduce c-fos expression (a marker of neuronal 
metabolic activity) in the sacral spinal cord 1. Urodynamics studies as discussed in the 
literature review have demonstrated increased bladder capacity in both cats and humans.  
The three main pathways have been debated for mechanism of action [33]:  
1. Direct stimulation of the hypogastric nerve through activation of sympathetic fibres at low 
bladder filling volumes  
2. Direct stimulation of the nuclei of the pudendal nerve in the spinal cord at maximal bladder 
filling  
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3. Supraspinal inhibition of the detrusor  
 
Sexual function: 
There has been evidence reported in the literature to suggest that PTNS can have a positive 
impact in female sexual function from a prospective series of 41 patients, self reporting 
outcomes using the female sexual function index (FSFI) 2. 
 
 
Gastro-intestinal: 
There is also some evidence that PTNS can reduce the number of faecal episodes of faecal 
incontinence from 7 to 3 per week 3. And improvements appear to be mainly to bowel 
symptoms over global pelvic floor complaints 4. However there is paucity of long-term data 
beyond 12 months of follow-up. In the recent CONFIDeNT trial, a double blind randomized 
controlled trial of PTNS versus sham for faecal incontinence, involving 227 patients, showed 
no benefit of PTNS over sham 5. 
The effects of PTNS on patients with chronic constipation were also recently reported, in 
groups with both slow transit and rectal evacuation difficulty, however there was no benefit 
to patients who had 12-weekly sessions of treatment 6. 
 
4h. How to interpret the Fowler data re 100msec timelag for conduction? What would 
be the influence of a full bladder during treatment in terms of afferent stimulation?  
 
The results of the study by Fowler et al.  carried out a few years demonstrating  prolonged 
latency following sacral root stimulation suggest that the anal contractions  are an afferent 
mediated response.  Studies evaluating the putative mechanism of action of tibial nerve 
 
stimulation are few however afferent stimulation is likely to result in modulation of reflexes 
at the level of the spinal cord and cortex 7. 
 
5.a Study 2 
How about looking at markers of immune activation – a neuro-immune effect of 
treatment? 
 
This has been done to some extent. Multiple inflammatory mediators have been examined in 
various animal models. Such as a upregulation of Prostaglandin receptors (PGE2) in the 
urothelium of rats with cyclophosphamide induced OAB 8. The role of inflammation and 
OAB has also been suggested with the reduction of spinal cord and bladder TRPV1 
(Transient receptor potential vanilloid receptor 1) and CGRP (a marker of neuronal 
inflammation) after intrathecal administration of resiniferatoxin in spinal cord injured rats, 
ameliorating detrusor overactivity 9. Furthermore the histological evidence of chronic 
urothelial inflammation with evidence of mast cells and apoptosis in patients with OAB 
compared to controls has been reported 10. Indeed the inflammatory and neurotrophin 
pathways are felt to be linked in an unclear way. None of these inflammatory targets have yet 
been successfully targeted in any form of treatment, butfurtuer developments are to be 
awaited.  
 
 
5.b.  
Discuss the effect of antimuscarinic drugs on measured levels. 
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There is evidence, from scientific/histological studies that antimuscarinic use does reduce the 
level of neurotrophin in urine 11. As a result this effects must be considered when measuring 
levels in patients who may have been taking these, as is discussed in the thesis. 
 
5c. Consider OAB vs interstitial Cystitis (IC) data 
 
There certainly does appear to be overlap in the clinic spectrum of IC and OAB. IC 
traditionally is a chronic condition that can be debilitating and histologically also described 
the diffuse infiltration of mast cells and lymphocytes. It has been questioned whether patients 
with OAB actually have early IC. It has been shown in scientific study that NGF levels from 
bladder biopsy tissue is actually equivalent between IC and OAB patients, although 
significantly raised compared to controls 12.    
 
5d. Discuss the time course of nerve growth factor response to treatment 
 
The concept of urinary NGF levels over time is interesting as there are many factors that need 
to be considered. It seems that the levels vary slightly on a day to day basis and is dynamic 
according to severity of urothelial inflammation/overactivity, symptom severity, and whether 
patient is taking any treatment. It has been shown that of patients with OAB taking treatment 
with tolterodine, with urinary NGF levels measured at baseline, 1, 2 and 3 months, it took 
three months for levels to significantly reduce, despite symptoms improving far earlier 11, 13. 
However after discontinuing medication for 1month, and urinary NGF levels are re-assayed it 
can seen that levels become significantly elevated as with return of symptoms. It has also 
been shown in a cohort of patients being treated with onabotulinumtoxinA, that levels 
significantly reduce with symptom amelioration, however on symptomatic return, 
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biologically detectable levels/indicator of disease also return to the baseline high levels 14. 
The response of uNGF therefore to treatment is a temporary one, which returns to baseline 
once therapy is either withdrawn or wears off. 
 
5e. Use a figure to display the degree of overlap between OAB and healthy controls 
 
This graph 1 below taken from a study by Yokoyama et al 2008, shows that there is a clear 
overlap in uNGF levels between healthy controls and pts with idiopathic OAB. 
Whereas graph 2, also from the same publication, demonstrates a more significant rise in 
levels in patients with neuropathic bladder due to spinal cord injury, when compared with 
healthy controls. 
The explanation for these differences may be due to the nature of the pathophysiology of the 
detrusor overctivity in patients with idiopathic OAB and neuropathic OAB. Those with the 
former may be explained with the myogenic theory where there are alterations in smooth 
muscle excitability, with potential genetic or hormonal components to the condition. Whereas 
the neurogenic cause, is felt to be due to enhanced urothelial c-fibre activity, triggered by a 
sodium ion channelopathy, increased electrical excitability and lower threshold, raised 
neurotrophin levels and the emergence of a c-fibre spinal reflex circuit 15.  
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DO: Detrusor overactivity 
 
 
 
 
 
 
 
CVD: cerebrovascular disease 
SCI: spinal cord injury 
 
5f. Discuss the philosophical role of a biomarker – is it better than symptoms to predict 
response? 
 
Biomarkers are a measurable characteristic that reflects a particular physiological state. 
Whilst with the case of uNGF and the OAB, certainly symptoms are the most reliable marker 
of disease activity and patient related Quality of Life impact. However the exploration of the 
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behaviour of potential biomarkers is essential to a) understand aetiology, b) monitor or 
predict response to potential treatments and c) to pave opportunity to develop new 
drug/therapy targets to slow or reverse the disease process.  
 
 
5g. How will biomarkers fluctuate with symptom variation – another question 
regarding utility  
 
In the studies reported uptodate, biomarker (uNGF) levels reflect symptom severity. Since 
NGF is thought to drive c-fibre growth in the urothelium, which is part of the 
pathophysiology of OAB symptoms, once symptoms are effectively treated with resultant 
reduced c-fibre growth, there is a reflection of reduced NGF activity and quantity detected in 
the urine. However how uNGF levels would vary day to day in patients with varying OAB 
symptoms, has not as yet been evaluated or described. It is also feasible that during symptom 
improvement due to lifestyle measures may cause less neurotrophin release from areas in the 
central nervous system, accompanied with the increased sensation of well-being and 
improved LUTS. 
 
5h. Discuss the effect of diurnal variation 
One study examined uNGF variation throughout the daytime, morning afternoon and 
evening, in healthy volunteers which identified stable values throughout the day and no 
circadian variation 16. 
 
6. Study 3 
a. We agree with this and has been noted 
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6b. ROC statistics need clarifying 
Using the Youden Index, the optimized cut-off point in NGF/Cr levels is 18.97. This gives a 
37% sensitivity and a 93% specificity for predicting that the individual will have OAB 
symptoms.  
 
The optimized cut-off point for BDNF/Cr levels is 17.37. This point gives a 70% sensitivity 
and a 67% specificity for predicting that the individual will have OAB symptoms.  
 
Both of these values compare poorly to that demonstated in a group of women with  
idiopathic OAB where the optimized cut off points for NGF/Cr was 0.14 for a 54%  
sensitivity and 96% specificity for predicting OAB, and a BDNF/Cr value of 4.6 for a 89% 
sensitivity and 100% specificity  
 
6c. Show table 19 as box and whisker plot  
 
Please see box plot performed 
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6d. Summarise lesson learnt from study succinctly 
 
Urinary NGF/creatinine and BDNF/creatinine levels were significantly raised in patients with 
MS and OAB as would be expected, when compared with healthy controls. Levels were also 
marginally raised in patients with MS and no OAB, when compared with controls. The raised 
levels therefore cannot be specific to OAB as having MS as a diagnosis also may lead to 
elevated detectable levels. 
There was no strong correlation with urinary neurotrophin level and symptom severity, with 
some patients complaining of mild symptoms having higher levels than those severely 
afflicted. This is contrary to the findings within an idiopathic population were higher levels 
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were found in those with worse symptom profiles 17. These molecules are clearly relevant in 
the pathophysiology of the OAB, however at this stage further study is required to understand 
their exact role and other molecules considered before an biomarker is found.  
 
6e. Consider the composite of NGF and EDSS as a possible measure 
 
There was indeed a more positive correlation in OAB score and EDSS than there was for 
uNGF. This mirrors a finding in another study which demonstrated higher levels of uNGF 
correlating with higher severity of neurological deficit after CVA 18. This was not evaluated 
in this study, however since there is a correlation with EDSS and biological neurotrophin 
activity in the urine, it may well have a role as a predictor of bladder involvement.  This 
warrants further study. 
 
6f. Could symptoms be better defined by urodynamic studies to stratify patients better. 
 
Urodynamics at present would represent a gold standard at providing an accurate evaluation 
of lower urinary tract symptoms. This allows a further differentiation between the OAB and 
detrusor overactivity. As we know from previous study that between 50-90% of patients with 
clinical OAB have urodynamic DO 19, depending on symtpoms severity. However this is an 
invasive test, with associated morbidity and therefore its use minimized. We did not use 
urodynamics in this study to stratify our patient population as it would not have changed our 
management. Furthermore in a previous study, the presence of DO did not strongly associate 
with higher uNGF levels compared to absence of DO, where it was the symptom of urgency 
that was more relevant affiliation with raised levels 20. 
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7. b. Is there enough data to support a non-controlled study? 
 
There is a paucity of evidence to support evidence for efficacy of transcutaneous tibial nerve 
stimulation. The main aim of this study was to acquire safety and acceptibity data as a phase 
two pilot, to base a larger, placebo controlled study on. 
 
c. Discuss the recent Knowles et al lancet paper and its implications in the findings of 
this chapter 
 
This recent high level muticentre placebo controlled study, examines PTNS for patients with 
faecal incontinence 21. This shows no significant difference between sham and treatment arms 
for symptom improvement. This demonstrates again the power of the placebo effect which is 
not measurable in our study, however our study was only powered as a pilot study to acquire 
initial safety data to base a larger study on. This highlights the importance of designing in a 
sham arm in any future efficacy study. 
 
d. Discuss the relationship between responders and those adherent to this therapy 
 
Examining the usage diaries, those in both the weekly and daily arms, the usage/adherence 
for those who completed the study was >90%. 34/48 patients completed the study, of which 
18 were responders. It is unlikely from this study there is evidence to suggest that those more 
adherent to therapy had higher response rates as our adherence rates were very high. 
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e. Where could the treatment fit in the pathway – before anticholinergics? Specify the 
studies that would be needed 
 
Certainly if this treatment option was proven to be efficacious ,the next phase would be to 
proves cost-effectiveness against other firstline treatment options. By its nature of having a 
minimal adverse effect profile and being non-invasive, would make it a highly desirable and 
acceptable treatment from a patient perspective as a first line option. Head to head or 
crossover studies between transcutaneous TNS and firstline medical therapy would need to be 
designed, with intermediate term follow-up to prove its place in the treatment ladder. 
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P.T.O 
 

 

 
 
 
 
Copy to: 
 
 
Ms Anjani Parmar 
UCL Joint Research Office 
1
st
 Floor, Maple House  Suite B 
149 Tottenham Court Road 
London  W1T 7DN 
 
 
 




 INFORMED CONSENT FORM 
 
Title of Study: Single centre randomised pilot study of two regimens (30mins daily or 
weekly for 12 weeks) of Transcutaneous Tibial Nerve Stimulation for the treatment of 
patients with Overactive Bladder (OAB) Syndrome 
 
Name of Chief Investigator (CI): Dr Jalesh Panicker  
 
Please initial box 
 
1.  I confirm that I have read and understand the information sheet dated 06 November 2012 
(version number 1.1) for the above study. I have had the opportunity to consider the 
information, ask questions and have had these answered satisfactorily. 
 
2. I confirm that I have had sufficient time to consider whether or not I want to be included in 
the study. 
 
3. I understand that my participation is voluntary and that I am free to withdraw at any time, 
without giving any reason, without my medical care or legal rights being affected. 
 
4. I understand that relevant sections of any of my medical notes and data collected during 
the study may be looked at by the sponsor (UCL) as well as responsible individuals from 
regulatory authorities from the NHS Trust for purposes of monitoring and auditing, where it is 
relevant to my taking part in this research. I give permission for these individuals to have 
access to my records. 
 
5. I Consent to the Research Team approaching me after the study if they wish to check on 
my wellbeing or in the future about this device if it has been of benefit.  
 
6. I agree for my GP to be informed about the study. 
 
7. I agree to take part in the above study 
 
 
Name of patient                           Date              Signature 
 
 
 
 
 
          Name of person taking consent          Date                Signature 
 
 
 
 
Comments or concerns during the study: If you have any comments or concerns you may 
discuss these with the investigator. If you wish to go further and complain about any aspect of 
the way you have been approached or treated while partaking in the study, you should write 
or get in touch with the Complaints Manager, UCL hospitals. 
 
When completed: 1 form for the patient: 1 to be kept as part of the study documentation for the trial 
master/investigator site file: 1 original to be kept with the hospital medical notes. 
REC Study 
Number: 
12/LO/1613 
Patient Information Sheet Version and Date:  
Version 1.1; 13 November 2012  
Patient Number:   
 
 
 
 
 
 
 
 

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Treatment Flow Chart – What will we assess at each visit 
 
 Screening 
Randomisation/ 
start of 
treatment W1-W3 W4 W5-7 W8 W9-W11 
W12/end 
of study 
 Visit 0 Visit 1 Telephone Visit 2 Telephone Telephone Telephone Visit 3 
Signed Consent Form        
Vital Signs, Height, Weight, BMI        
Pregnancy Test (if required)        
Bladder diary        
Questionnaires        
Usage diary        
Patient Satisfaction Questionnaire 
and GRA        
Protocol version 1.0 5th September 2012 

Dear Dr. 
I am writing to 
inform you that your patient has expressed an interest in taking part in a study 
entitled “Randomised pilot study of Transcutaneous Tibial Nerve Stimulation 
for patients with Overactive Bladder Syndrome”.  This will be a prospective 
study using a new device called geko™ for patients with overactive bladder 
syndrome.  It is a UK single centre study sponsored by UCL as part of the 
UCL/UCLH/Royal Free Joint Research Office.   
After consent, there will be a baseline assessment period (days -3 to 0 with bladder 
diary and questionnaires), 12 weeks treatment protocol and finally post treatment 
assessment (repeat 3 day bladder diary and questionnaires).  Your patient will apply 
the geko™ device daily for the 12 weeks period and the duration of application will 
depend on randomisation (30 mins daily or 30 minutes weekly).  They will be 
contacted on a weekly basis.   
Your patient will be allowed to continue taking medications which are considered 
necessary for their welfare.  They should not be started on any new treatment that 
can affect bladder functions.   
I am enclosing a copy of the patient information leaflet.  For the period of this study I 
will be grateful if you could inform me, should you see the patient at your surgery for 
any reason. This will enable me to record and report any adverse event, change in 
medical condition or medication and comply with International Good Clinical Practice 
Guidelines. 
If you have any concerns or comments regarding this participation please feel free to 
contact me or members of my department at the above number, or at 08451555000 
and dial one of the following extensions: 
Dr Jalesh Panicker  Consultant      ext 83148 
Dr. Jai Seth   Honorary Research Assistant ext 83139 
Mrs Juliana Ochulor  Clinical Nurse Specialist  ext 84713  
Mrs Collette Haslam  Clinical Nurse Specialist  ext 84713 
  Clinical Nurse Specialist 
 
Yours Sincerely, 
 
 Dr Jalesh N. Panicker 









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Urinary Symptom Profile - USP 
 
 
 
 
 
 
  Before starting the questionnaire, please fill in today’s date: 
 
/__/__/   /__/__/   /__/__/ 
     Day      Month   Year 
 
 
 
 
The following questions concern the intensity and frequency of urinary symptoms that you have had 
over the past 4 weeks. 
 
To answer the following questions, please tick the box which best applies to you. There are no “right” 
or “wrong” answers. If you are not quite sure how to answer, choose the answer which best applies  
to you. 
 
Please answer this questionnaire somewhere quiet and preferably on your own. Take as long as you 
need to fill it in. 
 
Once you have finished, put the questionnaire into the envelope provided and hand it to your doctor. 
 
Thank you for your cooperation. 
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You may sometimes experience urine leaks during physical effort. This effort could be strenuous (such 
as doing sport or having a violent coughing fit), moderate (climbing or coming down the stairs) or even 
light (walking or changing position).  
 
 
 
 
1. Over the past 4 weeks, please specify the number of times a week you have had leaks during 
physical effort:  
Please tick one box for each of the lines 1a, 1b and 1c. 
 
 No urine leaks Less than  
one urine  
leak a week 
Several urine 
leaks a week 
Several urine 
leaks a day 
1a. During strenuous 
physical effort  0 1 2 3 
1b. During moderate 
physical effort  0 1 2 3 
1c. During light physical 
effort  0 1 2 3 
 
 
 
For the doctor only: note the sum of items 1a + 1b + 1c on the scale below  
“STRESS URINARY INCONTINENCE” SCORE 
 
                                                                                                                                            
 
0 1 2 3 4 5 6 7 8 9 
 3 / 5 
 USP   2005 Association Française d’Urologie. All rights reserved  Confidential 
 
 
 
 
Over the past 4 weeks and under everyday conditions of social, professional or family life:  
 
 
 
2. How many times a week have you had to rush to the toilet to urinate because you urgently needed 
to go? 
 
0 1 2 3 
Never Less than once a week Several times a week Several times a day 
 
 
 
 
3. When you have had an urgent need to urinate, for how many minutes on average have you been 
able to hold on? 
 
0 1 2 3 
More than 15 minutes From 6 to 15 minutes From 1 to 5 minutes Less than 1 minute 
 
 
 
 
4. How many times a week have you experienced a urine leak preceded by an urgent need to urinate 
that you were unable to control? 
 
0 1 2 3 
Never Less than once a week Several times a week Several times a day 
 
 
 
 
4 a. In the above case, what kind of leaks did you have? 
 
0 1 2 3 
No leaks in this case A few drops Light leaks Heavy leaks 
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Over the past 4 weeks and under everyday conditions of social, professional or family life:  
 
 
 
 
5. During the day, in general, how long elapsed between urinating? 
 
0 1 2 3 
2 hours or more  Between 1 and 2 hours Between 30 minutes 
and 1 hour 
Less than 30 minutes 
 
 
 
 
6. How many times on average have you been woken up during the night by a need to urinate? 
 
0 1 2 3 
Never or Once Twice 3 or 4 times More than 4 times 
 
 
 
 
7. How many times a week have you had a urine leak while asleep or have you woken up wet? 
 
0 1 2 3 
Never Less than once a week Several times a week Several times a day 
 
 
For the doctor only: note the sum of items 2 + 3 + 4 + 4a + 5 + 6 + 7 on the scale 
below  
“OVERACTIVE BLADDER” SCORE 
 
                                                                                                                                                        
 
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 
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Over the past 4 weeks and under everyday conditions of social, professional or family life: 
 
 
 
8. How would you describe your usual urination over these past 4 weeks? 
 
0 1 2 3 
Normal Needed to push with abdominal 
(stomach) muscles or lean 
forward (or required a change  
of position) to urinate 
Needed to press on the 
lower stomach with my 
hands  
Used a catheter 
 
 
 
9. In general, how would you describe your urine flow? 
 
0 1 2 3 
Normal Weak  Drop by drop Used a catheter  
 
 
 
10. In general, how has your urination been? 
 
0 1 1 2 3 
Normal and quick  Difficult to start, 
then normal  
Easy at first but 
slow to finish 
Very slow from 
start to finish 
Used a catheter  
 
 
Please check that you have answered all the questions. 
 
Thank you for your cooperation 
For the doctor only: note the sum of items 8 + 9 + 10 on the scale below  
“LOW STREAM” SCORE  
 
                                                                                                                                             
 
0 1 2 3 4 5 6 7 8 9 


     







               
    


 
 
 

    

 
  
  
  
  
  
  
  
  
  
  
 
 
  

  


 
  
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       Bladder Diary    
    
Patients Name –  
Hospital Number –  
Date of Birth –  
 
Instructions 
Please complete this diary as accurately as possible. This will enable us to assess the 
severity of your bladder symptoms. 
Fill the diary columns each time you pass water. 
Date - Start the diary with the first time you pass water after you usually get out of the bed 
in the morning. Continue to record the volume and sensation each time you get up at night 
to pass water. 
Time - You can mention the time using am/pm or the hours (0000 - 2400) 
Voided Volume – You can use any measuring container to record the volume in milliliters 
(mL). 
Residual Volume - is measured if you self-catheterize, and is the volume that is drained 
using a catheter after you have voided when you had a desire to pass water. 
 
Sensation - What is the reason you went to urinate (pass water)? This can be graded as: 
Grade Definition 
0 Convenience (no urge) 
1 Mild urge (can hold more than 1 hour) 
2 Moderate urge (can hold for  10 to 60 minutes) 
3 Severe urge (can hold less than 10 minutes) 
4 Desperate urge (must go immediately) 
 
After completing, please return to: 
 
Department of Uro-neurology 
Internal Mail Box 71 
National Hospital for Neurology & Neurosurgery 
Queen Square London WC1N 3BG 
 Tel - 02078373611 ext 3418 
Fax - 02078134587 
 
 Day 1; date: 
 Time out of  bed -      Time to bed –  
 
Time 
Voided 
Volume mL 
Residual 
volume 
mL 
Urinary leakage 
(none, slight, 
moderate, heavy) 
Fluid 
intake 
Bladder 
sensation 
(0 to 4) 
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
        Day 2; date: 
       Time out of  bed -      Time to bed -  
 
Time 
Voided 
Volume mL 
Residual 
volume 
mL 
Urinary leakage 
(none, slight, 
moderate, heavy) 
Fluid 
intake 
Bladder 
sensation 
(0 to 4) 
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
         Day 3; date: 
 
       Time out of bed -      Time to bed –  
 
Time 
Voided 
Volume mL 
Residual 
volume 
mL 
Urinary leakage 
(none, slight, 
moderate, heavy) 
Fluid 
intake 
Bladder 
sensation 
(0 to 4) 
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
Patient Satisfaction Questionnaire 
 
Please complete the questions to describe your experience of using the device 
 
The device instructions are easy to understand 
 
Strongly Disagree---1------2------3------4-----5-----6------7---Strongly Agree 
 
The device is easy to attach and remove 
 
Strongly Disagree---1------2------3------4-----5-----6------7---Strongly Agree 
 
The device is easy to operate 
 
Strongly Disagree---1------2------3------4-----5-----6------7---Strongly Agree 
 
The device is comfortable to use 
 
Strongly Disagree---1------2------3------4-----5-----6------7---Strongly Agree 
 
I have full mobility when I am wearing the device 
 
Strongly Disagree---1------2------3------4-----5-----6------7---Strongly Agree 
 
The device improved my symptoms 
 
Strongly Disagree---1------2------3------4-----5-----6------7---Strongly Agree 
 
Overall I am satisfied with the device 
 
Strongly Disagree---1------2------3------4-----5-----6------7---Strongly Agree 
 
I would recommend the device to a friend for this use 
 
Strongly Disagree---1------2------3------4-----5-----6------7---Strongly Agree 
 
Global Response Assessment 
 
 
 
As compared to when you started the study [treatment], how would you rate your bladder symptoms 
now?"  
 
3 Markedly improved 
2 Moderately improved 
1 Slightly improved 
0 No change 
-1 Slightly worse 
-2 Moderately worse 
-3 Markedly worse 
